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1CHAPTER 1 
APPLICATION OF ORGANOCATALYSIS TO THE SYNTHESIS OF 
PHARMACEUTICALLY RELEVANT SCAFFOLDS: CHIRAL 
AZIRIDINES AND β-FLUOROAMINES 
1. 1.  General Access to Chiral N-Alkyl Terminal Aziridines via Organocatalysis 
1.1.1  Importance of Aziridines 
Aziridines are an important class of three-membered heterocycles containing one 
nitrogen atom with a rapidly expanding scope of applications in organic synthesis.1  
Aziridines are useful reactive substrates in synthetic chemistry, as they can undergo a 
variety of transformations involving ring opening.  This reactivity is attributed primarily 
to the Baeyer strain energy of approximately 27 kcal/mol for the 3-membered ring.2  
Release of this strain energy through nucleophilic ring opening allows for regio- and 
stereoselective installation of a wide range of functionalities in a 1,2 relationship to the 
nitrogen.3  In addition to being useful synthetic intermediates, aziridines can also be 
found in various biologically active natural products. As powerful akylating agents, 
aziridines have an inherent in vivo potency, often based on toxicity rather than specific 
activity.4  Aziridine-containing natural products, such as the mitomycins and 
azinomycins, have shown potent antitumor activity.  Structure-activity relationships have 
shown that the aziridine ring is essential for the anti-tumor activity (Figure 1.1.1.1).5   
2 
 
 
 
 
 
 
 
 
 
 
Figure 1.1.1.1  Aziridine-containing, biologically active natural products. 
 
Aziridines can be grouped into two main classes, the activated and non-activated 
aziridines. Activated aziridines have N-electron-withdrawing groups (typically a tosyl 
group), while non-activated aziridines are typically N-alkyl or N-aryl substituted.  The 
presence of the N-electron-withdrawing group in activated aziridines causes the ring to be 
susceptible to opening via nucleophilic attack.  Unactivated aziridines, on the other hand, 
require activation by quaternization, protonation, or Lewis-acid activation in order to 
achieve ring opening.6 
 
1.1.2  Reactivity of Aziridines 
 Similar to their cousin epoxides, aziridines undergo nucleophilic ring opening as 
their most widely-used transformation.4  There are numerous examples in the literature 
using carbon-based as well as heteroatom-based nucleophiles to open these highly 
strained ring systems.  For instance, primary amines attack aziridine-2-t-butyl carboxylate 
3 
 
at the least-hindered β-carbon to give diamino-propionic acid derivatives, which can be 
useful in the synthesis of cyclosporine analogs.7  Aziridine-2-carboxylate can be ring 
opened with higher-order cuprates via attack at the least hindered carbon to give 
protected amino acid derivatives (Scheme 1.1.2.1).8   
 
 
Scheme 1.1.2.1  Ring opening of activated aziridines by amine and carbon nucleophiles. 
 
 In the case of amino aziridines, the regioselectivity of the nucleophilic attack can 
be controlled simply by changing the reaction conditions.  Using a protic acid such as p-
toluenesulfonic acid leads to attack of water at the least hindered C-3 position.  Using an 
aprotic Lewis acid, such as boron trifluoride etherate, leads to anchimeric assistance from 
the neighboring amino substituent leading to activation and attack at C-2 (Scheme 
1.1.2.2).9 
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Scheme 1.1.2.2  Aziridine reactivity controlled by reaction conditions. 
 
The azide anion is often used as a nitrogen-nucleophile in aziridine ring opening 
to obtain 1,2-diamines following a reduction of the azido group.  For example, tosyl 
aziridines are readily transformed to azido amines upon treatment with NaN3 and 
CeCl3.10  Unactivated aziridines can also undergo similar azide opening in the presence of 
Lewis acids, such as AlCl3.11  Treatment of aziridinyl-propargylic alcohols with 
trimethylsilyl azide (TMSN3) affords amino alcohols, which upon further heating can 
undergo an intramolecular 1,3-cycloaddition between the azide and the alkyne (click 
chemistry) to form the corresponding bicyclic triazoles. (Scheme 1.1.2.3).12 
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Scheme 1.1.2.3  Ring-opening reaction by azide anion. 
 
 Ring-opening reactions can also be accomplished by attack of oxygen-, sulfur-, 
and halogen-based nucleophiles, as shown below in Scheme 1.1.2.4.  Facile ring cleavage 
of the asymmetrical bicyclic aziridine 1.22 with methanol in the presence of boron 
trifluoride etherate gives the product of attack at the more-substituted aziridine carbon.13  
Sulfur-based nucleophiles are equally suitable partners for ring-opening reactions, as 
shown by the reaction of p-chlorothiophenol with the functionalized sulfinylaziridine 
1.24 to give the corresponding sulfide in 80% yield.14  Indium trihalides are competent 
reagents in promoting the halide-mediated opening of aziridines, as demonstrated by the 
conversion of N-tosyl aziridine 1.26 to the iodo-amine derivative 1.27.15 
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Scheme 1.1.2.4  Ring-opening reaction by heteroatom nucleophiles. 
 
 Ring opening of aziridines and aziridinium ions has played an important role in 
the synthesis of pharmaceutical intermediates as well as in the total synthesis of natural 
products.  The current commercial production method of oseltamivir (Tamiflu), 
developed by Gilead Sciences and later modified by Hoffmann-La Roche, makes use of 
an aziridine ring opening by sodium azide in the presence of H2SO4 (Scheme 1.1.2.5). 16  
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Scheme 1.1.2.5  Commercial synthesis of Tamiflu. 
 
There have since been many improvements in the synthesis of oseltamivir including the 
Trost synthesis, which is the shortest synthesis to date (10 steps).  All of the improved 
routes make use of an aziridine ring opening as one of the key steps Figure 1.1.2.1.17-20 
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Figure 1.1.2.1  Improved syntheses of oseltamivir via aziridine ring opening. 
 
 Williams et. al. made use of an aziridinium ion in the total synthesis of the 
Stemona alkaloid (+)-croomine.  Treatment of secondary amine 1.41 with iodide allowed 
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for initial formation of the iodoamination intermediate, followed by nucleophilic 
anchimeric assistance by the vicinal tertiary amine to provide the intermediate 
aziridinium salt.  Capture of the salt by the proximate ester resulted in net retention of 
stereochemistry and afforded direct conversion to (+)-croomine (Scheme 1.1.2.6).21 
 
 
Scheme 1.1.2.6  Aziridinium ion in the total synthesis of (+)-croomine. 
 
1.1.3  Rearrangement Chemistry of Aziridines 
 In addition to ring-opening chemistry, aziridines can also undergo a variety of 
rearrangements both thermally and non-thermally. Ha and co-workers disclosed the 
synthesis of a substituted oxazolidinone from an aziridine (Scheme 1.1.3.1).  This ring 
expansion involves nucleophilic attack of the nitrogen center leading to formation of a 
short-lived bicyclic intermediate, which undergoes ring-opening via nucleophilic attack 
by chloride to give the oxazolidinone with retention of stereochemistry.22   
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Scheme 1.1.3.1  Nonthermal rearrangement of aziridines. 
 
 Heating an N-alkenyl aziridine to 135 oC affords the imine as a result of a thermal 
1,5 hydrogen shift.  When heating the same aziridine in the presence of dimethyl 
acetylenedicarboxylate (DMAD), a formal [3+2] cycloaddition occurs, giving a mixture 
of two regioisomers depending on which carbon center of the aziridine participates in the 
cyclization (Scheme 1.1.3.2).23  Other known rearrangements of aziridines include [3+3] 
annulation reactions, ring expansion (with heterocumulenes, isocyanates, nitriles and 
carbonylative ring expansion) and radical reactions.3 
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Scheme 1.1.3.2  Thermal rearrangement of aziridines. 
 
1.1.4  Synthesis of Aziridines 
 In 1888, the first synthesis of aziridines was reported by Gabriel.  His synthesis of 
the parent aziridine was accomplished via nucleophilic ring closure of vic-haloamines 
(Scheme 1.1.4.1).24  
 
 
Scheme 1.1.4.1  Gabriel synthesis of aziridines. 
 
A similar approach was later developed by Wenker in 1935.25  His approach involved 
treatment of vic-aminoalcohols with sulfuric acid at high temperatures to form the 
sulfonate salt followed by treatment with base to obtain the aziridine (Scheme 1.1.4.2).  
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Scheme 1.1.4.2  Wenker synthesis of aziridines. 
 
 Since the classic work of Gabriel and Wenker, the synthetic scope of aziridines 
has broadened tremendously and more mild conditions for aziridine formation have been 
developed. Using modern methods, aziridines can be made from addition to olefins 
(nitrene transfer to alkenes and addition/elimination sequences), addition to imines 
(carbene methodology, aza-Darzens approaches, and ylide-mediated strategies), and 
intramolecular nucleophilic substitution (Figure 1.1.4.1).4 
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Figure 1.1.4.1  Synthetic approaches toward aziridines. 
 
1.1.5  Aziridine Formation via Nitrene Addition to Alkenes 
Nitrene addition to olefins is one of the most common approaches to the 
formation of aziridines but requires a reagent to facilitate the nitrene transfer.  Several 
metal-based reagents (copper, manganese, rhodium) have been developed to generate the 
nitrene source which, in the presence of chiral ligands, provides a route for catalytic 
asymmetric aziridination. In 1993, Evans26 and Jacobsen27 were the first to report 
catalytic asymmetric synthesis of aziridines utilizing copper-(I)-complexes generated 
from chiral bisoxazoline (BOX) or diimine ligands (Scheme 1.1.5.1).   
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Scheme 1.1.5.1  Asymmetric aziridination via copper-catalyzed nitrene. 
 
Che and co-workers reported the asymmetric synthesis of an aziridine via a 
copper-bisoxazoline complex and nitrene precursor generated from a hypervalent iodine 
reagent and sulfonamides.28  Dauban and co-workers later reported an intramolecular 
copper-catalyzed aziridination using the same chiral bisoxazoline ligand. The sulfamates 
were subjected to iodosylbenzene and [Cu(MeCN)4]PF6 to give the corresponding 
aziridines in good yields and enantioselectivities (Scheme 1.1.5.2).29 
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Scheme 1.1.5.2  Aziridination of alkenes mediated by bisoxazoline ligand. 
 
Another aziridination method utilizing the approach of addition to olefins is 
aziridination through an addition–elimination sequence. Dodd and co-workers utilized a 
Michael-type addition-elimination sequence in the total synthesis of the non-natural 
enantiomer of polyoxamic acid (Scheme 1.1.5.3).30 
 
 
Scheme 1.1.5.3  Synthesis of (-)-polyoxamic acid via addition-elimination sequence. 
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Decomposition of organic azides can also be used as a method in the aziridination 
of olefins. Using a ruthenium salen complex, Katsuki and coworkers reported an 
improvement in the scope of olefins that can be used to form aziridines. The nitrene 
addition occurred in moderate to excellent yield with enantiomeric excess (ee) up to 98% 
(Scheme 1.1.5.4).31 
 
 
Scheme 1.1.5.4  Aziridination via organyl azides using ruthenium salen complex. 
 
1.1.6  Aziridines via Addition to Imines 
Aziridine formation from imines can be subdivided into three major areas:  
carbene methodology, α-haloenolates (aza-Darzens), and ylide chemistry. The addition of 
carbenes, generated from diazo compounds, to imines is well known and is an attractive 
route to aziridines due to generally good yields and high stereoselectivities.  The 
Jacobsen group has been active in the area of asymmetric aziridine synthesis using 
carbenoid transfer to imines employing copper salts and the BOX ligands.  This reaction 
proceeds through the addition of a metallocarbene derived from ethyl diazoacetate and 
copper(I)hexafluorophosphate adding to N-arylaldimines (Scheme 1.1.6.1).32   
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Scheme 1.1.6.1  Aziridine synthesis via carbenoid transfer to imines. 
 
 
 Akiyama and co-workers have developed a route towards chiral CF3-substituted 
aziridines utilizing Lewis acid mediated aziridination of aldimines with chiral 
diazoacetates (Scheme 1.1.6.2).33   
 
 
 
 
 
 
Scheme 1.1.6.2  Aziridination of aldimines with chiral diazoacetates. 
 
A strategy which is analogous to the carbene methods is the reaction of sulfur and 
iodine ylides with imines to generate the desired aziridines.  These ylides react with 
imines to give β-sulfonium or β-iodonium amide anions, which undergo nucleophilic ring 
closure to give aziridines.  Aggarwal and co-workers have been active in this area, 
utilizing chiral sulfides to access trans-disubstituted aziridines (Scheme 1.1.6.3).34   
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Scheme 1.1.6.3 Chiral aziridines from sulfur ylides. 
 
The aza-Darzens is a common, efficient approach in the synthesis of aziridines. 
This approach is similar to the Darzens synthesis of epoxides but uses imines rather than 
aldehydes or ketones.  An enolate is often generated using a lithium base, with the 
reaction proceeding through a Zimmerman-Traxler transition state.  Davis and co-
workers reported the asymmetric synthesis of cis-N-sulfinylaziridine-2-phosphonate as a 
single diastereomer in good yield. The asymmetric aza-Darzens reaction involves the 
addition of an iodophosphonate anion to a chiral sulfinimine (Scheme 1.1.6.4).35  
 
 
 
 
 
 
Scheme 1.1.6.4  Aza-Darzens reaction of a chiral imine. 
 
In 2003, Johnston and co-workers reported a Brønsted acid-catalyzed direct aza-
Darzens synthesis of N-alkyl-cis-aziridines.36  This method facilitates construction of 
more Lewis basic and functionally diverse N-alkyl aziridines under mild conditions, with 
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no by-products forming as a result of acid-promoted aziridine ring-opening (Scheme 
1.1.6.5).  This method has also been applied in the stereoselective synthesis of polycyclic 
aziridines en route towards the total synthesis of mitomycin C (Scheme 1.1.6.6).37  
 
 
 
 
 
Scheme 1.1.6.5  Brønsted-acid-catalyzed aza-Darzens synthesis of aziridines. 
 
 
Scheme 1.1.6.6  Brønsted-acid-catalyzed aza-Darzens towards synthesis of mitomycin C. 
 
1.1.7  Aziridination via Intramolecular Substitution 
Since the first example reported by Gabriel in 1888, the nucleophilic ring closure 
of an amine with a vicinal leaving group has been one of the most utilized routes to 
aziridines.  Intramolecular displacement can be achieved using 1,2-amino alcohols, 1,2-
azido alcohols, 1,2-amino halides, 1,2-amino sulfides, 1,2-amino selenides, or epoxides.1 
However, in order to use this route to obtain enantiopure azirdines, non-racemic starting 
materials are required.  
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In recent years, there have been several reports describing the synthesis of simple 
chiral aziridines starting from 1,2-amino alcohols.  For example, Badia and co-workers 
reported a simple procedure for the preparation of chiral N-tosyl-2-alkyl aziridines in a 
single step involving a sequential one-pot N-tosylation and O-tosylation followed by an 
intramolecular substitution to afford chiral aziridines.38  Similarly, the synthesis of 
enantiopure pyrrole-aziridines was reported by Savoia and co-workers. The treatment of 
enantiopure β-hydroxyamines derived from (S)-phenylglycinol bearing a pyrrole moiety 
with triphenylphosphine and diethylazodicarboxylate (DEAD) proceeds through an 
intramolecular Mitsonobu reaction, leading to enantiopure pyrrole-aziridines in excellent 
yields (Scheme 1.1.7.1).39 
 
 
Scheme 1.1.7.1  Synthesis of aziridines from 1,2-amino alcohols. 
 
Davis and co-workers have reported the synthesis of N-sulfinylaziridine-2-
phosphonates, in high yields and enantioselectivities, via a base induced cyclization of β-
amino-α-chlorophosphonates (Scheme 1.1.7.2).40 
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Scheme 1.1.7.2  Synthesis of N-sulfinylaziridine-2-phosphonates. 
 
In 2007, Cordova and co-workers reported an organocatalytic aziridination of α,-
unsaturated aldehydes with acylated hydroxycarbamates. Utilizing a chiral silyl-protected 
pyrrolidine alcohol, 2-formylaziridines were achieved in moderate yields with moderate 
to high diastereoselectivities and enantioselectivities (Scheme 1.1.7.3).41  
 
 
 
 
 
 
 
Scheme 1.1.7.3  Organocatalytic aziridination of α,β-unsaturated aldehydes. 
 
Many of the classical methods for aziridine synthesis incorporate a p-
toluenesulfonyl moiety or some other electron withdrawing group as the N-substituent.  
Despite the usefulness and prevalence of aziridines, synthetic routes to the non-activated 
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class are limited in terms of generality and diversity of the N-substituent. The synthesis of 
enantiopure, unactivated, terminal aziridines with diversity at the N-substituent is 
extremely rare.1  One recent example was reported by Kocovsky and co-workers for the 
synthesis of terminal diarylaziridines by organocatalytic enantioselective reductive 
amination of α-chloroketones followed by base-induced intramolecular cyclization of the 
corresponding α-chloroamines (Scheme 1.1.7.4).20  However, this method lacks 
generality and substrate scope as only N-arylaziridines can be formed. 
 
 
Scheme 1.1.7.4  Synthesis of 1,2-diaryl aziridines. 
 
Since there are few synthetic methods in the literature for the preparation of 
enantiopure N-alkylziridines, and due to their utility as synthetic intermediates,43 we set 
out to develop a methodology that would allow for the rapid enantioselective synthesis of 
N-alkyl terminal aziridines. 
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1.1.8  General Access to N-Alkyl Terminal Aziridines 
Previously, Jørgensen44 and MacMillan45 reported the use of various pyrrolidine-
based catalysts for the direct α-chlorination of aldehydes with excellent asymmetric 
induction (Scheme 1.1.8.1).  
 
 
 
Scheme 1.1.8.1  Organocatalytic enantioselective α-chlorination of aldehydes. 
 
Based on this work and previous work in our lab towards the asymmetric 
synthesis of enantiopure β-fluoroamines by way of selective fluorination using a proline-
based catalyst followed by reductive amination,46 we reasoned that an analogous α-
chlorination/reductive amination sequence to give enantioenriched β-chloroamines would 
represent an attractive approach to chiral N-alkyl aziridines (Scheme 1.1.8.2).  
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Scheme 1.1.8.2  Organocatalytic approach to chiral β-fluoroamines and envisioned route 
to chiral N-alkyl terminal aziridines. 
 
 
 
For a one-pot protocol involving a reductive amination step, we could not use the 
MacMillan α-chlorination chemistry, as that route employs a chloroquinone as the 
chlorinating agent and acetone as the solvent. The Jørgensen route was an attractive 
starting point, as N-chlorosuccinimide (NCS) is the chlorinating agent and the optimized 
solvent is 1,2-dichloroethane (DCE).  We first set out to determine if this proposal would 
allow access to a broad range of racemic N-alkyl terminal aziridines.  DL-proline-
catalyzed chlorination of aldehydes with NCS, followed by reductive amination with 
primary amines and subsequent base-induced neighboring group displacement with KOH 
in THF/H2O at 65 °C proved to be the ideal conditions to provide racemic aziridines  in 
up to 70% yield for the three step, one-pot protocol (average of 90% per step). 
Importantly, KOH was the only base screened that provided 100% conversion to the 
aziridine.  A screen of other organic (ie. Et3N, pyridine, DBU, KOt-Bu) and inorganic 
25 
 
(ie.,NaH, K2CO3) bases provided less than 50% conversion to the desired aziridine, and 
in many cases resulted in elimination of the chloride (Table 1.1.8.1). 
 
Table 1.1.8.1  Screening of bases for aziridine ring closure. 
 
 
Our efforts then focused on developing an enantioselective one-pot protocol. To 
ensure we had optimal conditions for the enantioselective chlorination of aldehydes, we 
elected to survey a set of organocatalysts employing NCS as the chlorinating agent 
(Table 1.1.8.2).  This study demonstrated that the Jørgensen catalyst 
(diphenylpyrrolidine) was optimal (>97% conversion and 95% ee).  In order to determine 
the degree of enantioselectivity by chiral HPLC, the aldehydes were reduced to the 
corresponding β-chloroalcohols.  Organocatalysts 1.120, 1.121, 1.22, and 1.123 had 
never before been employed for this transformation and provided moderate 
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enantioselectivities and comparable conversions (>95%), but lower enantioselectivity 
(56-90% ee). 
 
Table 1.1.8.2  Screening of organocatalysts for α-chlorination. 
 
 
As summarized in Table 1.1.8.2, Jorgensen’s diphenylpyrrolidine organocatalyst 
and the tetrazole catalyst gave excellent conversion.  Surprisingly, only 5 mol% of the 
tetrazole catalyst was needed to provide the desired β-chloroalcohol in excellent yield and 
moderate enantioselectivity.  It should be mentioned that multiple solvents were also 
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screened, but only dichloromethane (CH2Cl2) and tetrahydrofuran (THF) gave acceptable 
yields.   
 With optimal chlorination conditions in hand, we attempted the three-step, one-
pot protocol to deliver the aziridine enantioselectively. Utilizing the protocol shown in 
Table 1.1.8.1, but replacing DL-proline with the 2,5-diphenylpyrrolidine catalyst, we 
were disappointed to find that this approach afforded the aziridine in comparable yield, 
but in less than 40% ee.  We investigated the most probable source of epimerization in 
the sequence: the room-temperature reductive amination step. Molecular sieves proved 
essential, and we found a direct correlation between enantioselectivity and temperature. 
As shown in Table 1.1.8.3, reducing the temperature for the reductive amination step to   
-78 °C resulted in the enantioselective synthesis of the aziridine in 71% yield for the three 
steps (∼90% per step) and 94% ee.  
 
Table 1.1.8.3  Optimization of reductive amination step. 
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 In order to determine the scope of this methodology, we prepared several N-alkyl 
terminal aziridines from different readily available aldehydes and primary amines.  As 
shown in Table 1.1.8.4, the reaction is very general and provides chiral aziridines in 
overall yields of 40-65% (74-87% per step) and, in most cases, >90% ee for the three-
step, one-pot protocol.   
 
Table 1.1.8.4  Scope of one-pot aziridine formation. 
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 Finally, modest improvements in yield and comparable enantioselectivty were 
observed if a workup was performed after the chlorination step. The addition of pentane 
to the crude reaction mixture precipitated both the succinimide and organocatalyst. 
Removal of the pentane, resupsension in CH2Cl2, and proceeding with the reductive 
amination and base-induced cyclization steps provided N-alkyl terminal aziridines in 51-
75% yield and >90% ee for the two-pot protocol (Scheme 1.1.8.3). 
 
 
Scheme 1.1.8.3  Two-pot procedure to chiral aziridines. 
 
 In summary, we have developed a three-step, one-pot protocol for the general 
enantioselective synthesis of terminal N-alkyl aziridines via organocatalysis.47  Previous 
approaches to these useful moieties required long multi-step syntheses, had a lack of 
generality and substrate scope, and required starting materials that were not readily 
available. This study has led to the development of a powerful extension of the 
organocatalyzed enantioselective synthesis of α-chloroaldehydes for the general 
enantioselective synthesis of N-alkyl terminal aziridines in very high yields and ee.  This 
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new methodology provides access to aziridines utilizing aldehydes and primary amines, 
thousands of which are commercially available. 
 
1.2:  Highly Diastereoselective and General Synthesis of Primary β-Fluoroamines 
 
 
 
1.2.1  Fluorine in Pharmaceuticals 
 
Increasingly in recent years, researchers have utilized the unique and desirable 
characteristics of the fluorine atom in the creation of new drugs that have impacted the 
quality of life for many individuals.  No other substituent has single-handedly captured 
the imagination of medicinal chemists to the extent that fluorine has.  With its small 
atomic radius and ability to be both electron-withdrawing and lipophilic while 
maintaining the ability to accept hydrogen bonds and block metabolic liabilities, fluorine 
has become an essential tool in the medicinal chemist’s arsenal.48-50  
 Until 1957, no fluorine-containing drug had been developed.  This relatively 
recent trend of fluorinating compounds began its expansion in the 1970’s.  It is now 
estimated that as many as 30-40% of agrochemicals and 20% of pharmaceuticals on the 
market contain fluorine, including 9 of the 31 newly-licensed drugs in 2002 and half of 
the top 10 drugs sold in 2005.  It is estimated that roughly 25% of drugs in the 
pharmaceutical pipeline contain at least one fluorine atom.48-50   Shown in Figure 1.2.1.1 
are a few examples of fluorinated drugs on the market, including the current top-selling 
drug, Pfizer’s cholesterol lowering medicine atorvastatin (Lipitor);51 the inhaled 
corticosteroid fluticasone (Advair, Flonase, GSK); the atypical antipsychotic risperidone 
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(Risperdal, Janssen-Cilag); and the proton-pump inhibitor lansoprazole (Prevacid, 
Novartis). 
 
Figure 1.2.1.1  Examples of pharmaceuticals containing fluorine. 
  
1.2.2  Effects of the Fluorine Substituent 
The reasoning behind a fluorine substitution in a molecule is based on the unique 
characteristics of the fluorine atom, especially its small size and high electronegativity. 
The small size of the fluorine atom is a distinctive characteristic; with a van der Waals 
radius similar to that of hydrogen and oxygen (Table 1.2.2.1), a fluorine atom is a 
reasonable substitution for a hydrogen atom or hydroxyl group in a bioactive compound 
with respect to steric requirements at receptor binding sites.50  
Fluorine is also the most electronegative element on the periodic table.  As a 
consequence of this electronegativity, fluorine makes a very strong bond with carbon 
(Table 1.2.1), and it is often introduced into a target compound in order to improve the 
metabolic stability by blocking sites that are prone to metabolism such as oxidation by 
cytochrome P450s (CYP450s).  As a result of these unique electronic properties, fluorine 
may modulate the physicochemical properties of a molecule such as acidity and basicity, 
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lipophilicity, hydrogen bonding ability, and even the overall conformation of the 
molecule.48,52 
 
 Table 1.2.2.1  Physiochemical properties of the carbon-fluorine bond. 
 
 
1.2.3  Metabolic Stability of Fluorinated Compounds 
 In order for an orally administered drug to be effective, it must be able to 
withstand the physiological pH in the stomach long enough to enter the blood stream and 
be transported in sufficient quantity to the site of action.  It must then perform its desired 
task efficiently and be metabolized at an appropriate rate into non-toxic materials.  
Metabolic stability is one of the most crucial factors in determining the bioavailability of 
a drug molecule.  Low metabolic stability due to CYP450-mediated oxidation processes 
is a common problem in drug discovery.  The incorporation of fluorine has been widely 
used to alter the pharmacokinetic properties of compounds and block metabolically labile 
sites.  Metabolism can be affected by addition of fluorine either directly at or adjacent to 
the metabolic site.  In the lead optimization studies of the cholesterol inhibitor ezetimibe 
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(Schering-Plough), the first generation of the drug produced a complex metabolic mixture 
in the bile of rats, which proved to be more potent than the drug itself.  The primary 
metabolism pathways were found to be dealkylation of the N-1 and C-4 methoxyphenyl 
groups, para hydroxylation of the C-3 side chain phenyl group, and benzylic oxidation.  
The benzylic (S)-hydroxy group and C-4 hydroxy groups proved to be beneficial and led 
to an increase in potency.  The non-productive metabolism was blocked by incorporation 
of fluorine at the remaining metabolically labile sites.  The result was a second-
generation drug which was found to be 400 times more potent and required lower, less 
frequent dosing due to the improved metabolic stability in vivo (Figure 1.2.3.1).53 
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Figure 1.2.3.1  Effect of fluorine on drug metabolism. 
                 
1.2.4  Acidity and Basicity Effects from Fluorine 
 As an incredibly electronegative substituent, fluorine has strong effects on the 
acidity (and basicity) of neighboring functional groups.48-50 For instance, the inductive 
effects of a single β-fluorine atom are pronounced, lowering the pKa of a linear aliphatic 
amine (non-fluorinated pKa ~10.7) to pKa ~9.0.  These effects are additive, with a β,β-
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difluoro substitution lowering the pKa to ~7.3 and a β-CF3 moiety lowering the pKa to 
~5.7 (Figure 1.2.4.1).48-50  These changes can also have important consequences 
pharmacokinetic properties of a drug; quite often, a change in the pKa has a strong effect 
on the distribution and absorption of a drug in the body.  
 
 
Figure 1.2.4.1  The effect of fluorine substitution on pKa. 
 
For example, incorporation of fluorine into a series of 3-piperdinylindole compounds 
synthesized for migraine treatment (5-HT1D antagonists) led to significantly improved 
pharmacokinetic profiles of the compounds by lowering the pKa of the piperidine 
nitrogen (Figure 1.2.4.2).54 
 
36 
 
 
Figure 1.2.4.2  Effects of pKa values on the bioavailability and receptor binding. 
 
1.2.5  Mitigation of Off-Target Effects 
 In addition to improving the pharmacokinetic profiles of compounds, the 
incorporation of fluorine into a drug can also diminish off-target activity.  The human 
ether a-go-go–related gene (hERG) codes for a protein that contributes to the electrical 
activity of the heart and helps to coordinate the heart's beating. Activity at the hERG ion 
channel is a major cause of toxicity in many drug molecules. Several drug candidates 
have failed in clinical trials due to activity at the hERG ion channel.  It is estimated that 
about 25-40% of all lead compounds will show some hERG activity.  Drug activity at 
hERG results in prolonged electrocardiographic QT intervals, which can give rise to long 
QT syndrome.  These episodes may lead to palpitations, fainting, and sudden death due to 
ventricular fibrillation.55 Due to toxicity from drug-hERG interactions, the Food and 
Drug Administration (FDA) and the European Medicines Agency now require a thorough 
screening of new drugs to check for any hERG activity.56  
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 Evidence has linked T-type Ca2+ channels to several CNS disorders, including 
epilepsy.  Piperidine 1.146 was identified as a potent T-type calcium channel inhibitor 
with good selectivity against hERG and L-type channels.  By reducing the basicity of the 
piperidine nitrogen through the addition of an electron-withdrawing β-fluorine at the 3-
position of the piperidine ring, a threefold reduction in hERG activity was observed in 
addition to a twofold increase in potency (Figure 1.2.5.1).57 
 
 
Figure 1.2.5.1  Modulation of hERG activity following fluorine substitution. 
 
1.2.6  Sources of Fluorine 
Organofluorine compounds are generally formed using prepared or commercially 
available nucleophilic, electrophilic, and radical fluorine reagents.  Some common 
examples of nucleophilic fluorine reagents include DAST, DFI, and Deoxofluor (Figure 
1.2.6.1). 
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Figure 1.2.6.1  Common nucleophilic fluorine reagents. 
 
Common examples of electrophilic fluorine reagents include Selectfluor, NFSI, 
N-fluorocamphor sultam, and N-fluoropyridinium salt (Figure 1.2.6.2). Many methods for 
the synthesis of enantioenriched organofluoro compounds have been reported. 
Enantioselective fluorination is usually accomplished through substrate-controlled, 
reagent-controlled, or asymmetric catalytic conditions.  
 
 
Figure 1.2.6.2  Common electrophilic sources of fluorine. 
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1.2.7  Current Methods Towards β-Fluoroamines 
Despite the importance of the β-fluoroamine moiety, there	 are few synthetic 
methods in the literature for its preparation.48-50,58 Two common methods, the ring 
opening of aziridines with nucleophilic fluoride sources59 and the hydrofluorination of 
olefins,60 deliver β-fluoroamines but lack generality, require starting materials that are not 
readily available, and/or do not provide access to enantiopure β-fluoroamines (Scheme 
1.2.7.1). 
 
 
Scheme 1.2.7.1  Common approaches to β-fluoroamines. 
. 
The route most utilized involves the treatment of ketones or secondary alcohols 
with DAST to provide β,β-difluoroamines and β-fluoroamines (with inversion of 
stereochemistry), respectively.48-50,58-62 However, this method requires preparation of 
enantiopure secondary alcohols and can suffer from the formation of rearranged and 
dehydrated products, which in many cases greatly diminishes yields of the desired β-
fluoroamines.24   
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Cossy and co-workers utilized DAST to achieve an enantiospecific and 
regioselective rearrangement of N,N-dialkyl-β-amino alcohols to give optically active β-
fluoroamines (Scheme 1.2.7.2).63  
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Scheme 1.2.7.2  Synthesis of β-fluoroamines using DAST. 
 
Hu and co-workers reported a highly stereoselective, nucleophilic 
monofluoromethylation of chiral imines with fluoromethyl phenyl sulfone to afford α-
monofluoromethylamines and α-monofluoromethylated cyclic amines (Scheme 
1.2.7.3).64   
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Scheme 1.2.7.3  Stereoselective nucleophilic monofluoromethylation of chiral imines. 
 
 
 
In 2009, Liu and co-workers developed a novel palladium-catalyzed 
intermolecular and intramolecular oxidative aminofluorination of unactivated alkenes to 
yield acyclic and cyclic β-fluoroamines (Scheme 1.2.7.4).65 
 
 
Scheme 1.2.7.4  Palladium-catalyzed oxidative aminofluorination. 
 
 Lu and co-workers developed a novel tryptophan-based bifunctional thiourea 
catalyst that was effective in promoting the asymmetric Mannich reaction of an α-fluoro-
β-ketoester with N-Boc imines to afford α-fluoro-β-amino acids in good to excellent 
yields, diastereoselectivity, and enantioselectivity (Scheme 1.2.7.5).66 Brenner-Moyer 
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and co-workers reported an organocatalytic asymmetric olefin aminofluorination 
reaction. Enantiopure α-fluoro-β-amino alcohols were generated from achiral α,β-
unsaturated aldehydes in low to moderate yields and excellent enantioselectivity (Scheme 
1.2.7.5).67 
 
 
Scheme 1.2.7.5  Organocatalyzed synthesis of enantiopure β-fluoroamines. 
 
The first organocatalytic enantioselective fluorobisphenylsulfonylmethylation was 
developed by Toru and co-workers.  Imines from α-amino sulfones, generated in situ, 
underwent a Mannich-type reaction with 1-fluorobis(phenylsulfonyl)methane to give α-
fluorobisphenylsulfonyl amines in excellent yield and enantioselectivity. Further 
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reductive desulfonylation under Mg/MeOH conditions gave monofluoromethylated 
amines in high yields with retained enantiopurity (Scheme 1.2.7.6).68 
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Scheme 1.2.7.6  Cinchona alkaloid-catalyzed enantioselective monofluoromethylation. 
 
Early methods for the preparation of enantiopure organofluorine compounds 
relied on substrate-controlled fluorinations. This approach was commonly accomplished 
through enolate trapping of chiral auxiliaries, such as Evan’s oxazolidinones, with an 
electrophilic fluorinating reagent to afford chiral α-fluorocarbonyl compounds (Scheme 
1.2.7.7).69 Enantioselective fluorinations can also be under reagent control, which utilizes 
stoichiometric amounts of electrophilic fluorinating reagents. Chiral N-fluorinating 
reagents such as N-fluorosultams, N-fluorosulfonamides, and N-fluoroammonium salts of 
cinchona alkaloids have been used for the enantioselective fluorination of various 
enolizable substrates.70 
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Scheme 1.2.7.7  Substrate-controlled enantioselective fluorination. 
 
In 1988, Differding and Lang developed N-fluorocamphorsultams as the first 
enantioselective fluorinating reagents. Subjecting various achiral metal enolates 
generated from ketoesters led to fluorinated ketoesters in low to moderate 
enantioselectivities (Scheme 1.2.7.8); these results demonstrated the possibility of 
reagent-controlled asymmetric fluorination using a chiral electrophilic fluorine atom.71   
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Scheme 1.2.7.8  Enantioselective fluorination using N-fluorocamphorsultams. 
 
One of the most remarkable demonstrations of the effectiveness of [N-F]+ 
reagents was reported by Cahard and co-workers. A new N-fluoroammonium salt F-
2NaphtQN-BF4 was developed and applied to the enantioselective synthesis of BMS-
204352 (MaxiPost), a potent agonist of maxi-K channels, which is being evaluated in a 
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phase III clinical trial for treatment of acute ischemic stroke. Cahard and co-workers 
reacted an oxindole with the N-fluoroammonium salt F-2NaphtQN-BF4 in the presence 
of 1,4-diazabicyclo[2.2.2]octane (DABCO) to yield the fluorinated product (S)-BMS-
204352 in excellent yield and high enantioselectivity (Scheme 1.2.7.9).72 
 
 
Scheme 1.2.7.9  Enantioselective synthesis of BMS-204352. 
 
1.2.8  Catalytic Enantioselective Fluorination 
In 2000, Togni and co-workers reported the first catalytic enantioselective 
fluorination reaction.  β-ketoesters were subjected to catalytic transition-metal complex 
TiCl2(R,R)-TADDOL, which acted as a Lewis acid to activate the β-keto group in the 
presence of Selectfluor to give α-fluoro-β-ketoesters in good yields and moderate 
enantioselectivity (Scheme 1.2.8.1).73  
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Scheme 1.2.8.1  TADDOL-titanium catalyzed asymmetric fluorination. 
 
1.2.9  Enantioselective α-Fluorination of Aldehydes 
 Recently, Jørgensen,74 Barbas,75 and MacMillan76 concurrently reported their 
findings on the use of various pyrrolidines and imidazolines as catalysts for the direct α-
fluorination of aldehydes with excellent asymmetric induction. Their approaches to direct 
enantioselective α-fluorination of aldehydes used NFSI as the electrophilic source of 
fluorine (Scheme 1.2.9.1).  We envisioned applying this methodology towards the 
preparation of chiral β-fluoroamines. 
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Scheme 1.2.9.1  Organocatalytic enantioselective α-fluorination of aldehydes. 
 
1.2.10  Studies Towards Organocatalyzed Synthesis of β-Fluoroamines 
` Recently, our lab reported a one-pot protocol to provide pharmaceutically relevant 
chiral β-fluoroamines via organocatalysis (Scheme 1.2.10.1).46   
 
 
 
Scheme 1.2.10.1  Previous work towards chiral β-fluoroamines. 
 
 
One limitation of this methodology was the inability to generate primary amines 
with a fluorine at the β-position.  We envisioned a route to access these primary β-
fluoroamines using the same organocatalytic enantioselective α-fluorination of 
aldehydes76 followed by condensation with a chiral sulfinamide77-81 to afford α-fluoro-N-
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sulfinyl imines.  Organometalllic additions82-86 into the imine with subsequent 
deprotection of the amine would afford the chiral, primary β-fluoroamine.  This 
methodology would allow for complete control of the two contiguous stereogenic centers, 
based on the chirality of the organocatalyst and sulfimine employed and on the transiton 
state (metal-chelate versus nonmetal-chelate transition states, MCTS and NMCTS, 
respectively) that the organometallic species adopts (Scheme 1.2.10.2). 
 
 
Scheme 1.2.10.2  Envisioned route towards primary β-fluoroamines. 
   
 
 
 One major issue to be addressed during enantioselective fluorination of aldehydes 
is the need to avoid racemization of the enantioenriched fluorinated compound.  Due to 
the instability of the fluoroaldehydes, these products were originally isolated more often 
as the corresponding α-fluoroalcohols after reduction with hydride sources.  Key to the 
success of our approach was the ability to trap the incipient chiral fluoroaldehyde with 
the Ellman tert-butanesulfonamide to form the corresponding (R)-fluoro-N-
sulfinylaldimine in high diastereomeric ratio (dr).  A number of conditions were surveyed 
(time, desiccant, equivalents of NFSI) for the conversion of hydrocinnamaldehyde to the 
β-fluoro-N-sulfinylaldimine. Ultimately, we found that 5.0 equiv of NFSI, 20 mol% (5R)-
(+)-2,2,3-trimethyl-5-benzyl-4-imidazolidinone dichloroacetic acid 1.193, Ti(OEt)4 as 
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desiccant with (R)-tert-butanesulfinamide, and a 5 h reaction time were optimal to deliver 
the desired products in >20:1 dr (as judged by 19F NMR). With these conditions, a variety 
of diverse aldehydes could be converted into their corresponding β-fluoro-N-
sulfinylaldimines in good isolated yield (67-75%) for the two steps and with up to >20:1 
dr (Scheme 1.2.10.3). Here, substrates with handles for further elaboration were tolerated, 
such as the phthalimide congener, a progenitor for basic amine analogues, the olefin for 
subsequent manipulations, and a benzyl protected alcohol congener.  
 
 
 
Scheme 1.2.10.3  Preparation of α-fluoro-N-sulfinyl aldimines. 
 
 
 
 With (R)-fluoro-N-sulfinylaldimines in hand, we examined the addition of a 
number of organometallic nucleophiles to add unprecedented diversity to the primary β-
fluoroamine scaffold and access derivatives which were previously unavailable.  We first 
explored Grignard reagents (Scheme 1.2.10.4) and found that a wide range of diverse R 
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groups were tolerated, affording the sulfinamide-protected primary β-fluoroamines in 
good isolated yields (72-92%) and >20:1 dr (as determined by 19F NMR).45  The anti-
diastereomer of the β-fluoroamine formed predominantly, as expected, due to the known 
metal-chelated transition state (see inset under arrow) for 1.203 and 1.204. The syn-
diastereomer was formed in the case of 1.205, as a result of additional coordination to the 
acetal oxygen, in accordance with the work of Ellman.82,83 
 
 
 
Scheme 1.2.10.4  Scope of Grignard addition. 
 
 
 
 Due to the extensive diversity and availability of functionalized boronic acids, we 
next explored boronic acid additions. Under Batey’s mild Rh(I) catalysis protocol,84 a 
diverse group of aryl boronic acids (electron-rich, biaryl, and heterocyclic congeners) 
smoothly afforded the target adducts in 65-91% yield and all in >20:1 dr (Scheme 
1.2.10.5). In this instance, the syn-diastereomers of the β-fluoroamines are formed based 
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on the known addition of the aryl rhodium species through a nonmetal-chelated transition 
state.84 
 
 
 
 
Scheme 1.2.10.5  Scope of boronic acid addition. 
 
 
 
 Lin and co-workers previously demonstrated that indium-mediated allylations 
(In(0), allyl bromide in aqueous NaBr) of (R)-N-tert-butanesulfinylimines provide the 
(S)-adducts as confirmed by single X-ray crystallography.85  To further add structural 
diversity to the primary β-fluoroamine scaffolds accessible through our approach, we 
employed Lin’s protocol with our β-fluoro-N-sulfinylaldimine (Scheme 1.2.10.6). As 
expected, anti-diastereomers of the sulfinamide-protected β-fluoroamine products were 
produced in good yields (66-90%) and up to 9:1 dr. Here, we could install additional 
stereogenic centers and allene moieties. 
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Scheme 1.2.10.6  Scope of In-mediated allylation. 
 
 
 
 We also hoped to expand this protocol to include β-amino alcohols. Following the 
work of Xu and Lin,86  the SmI2-induced reductive aldehyde cross-coupling with our β-
fluoro-N-sulfinylaldimine (Scheme 1.2.10.7) produced the target sulfinamide-protected 
primary β-fluoro-β’-amino alcohols in excellent yields (80-87%) and with high dr 
(>20:1). 
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Scheme 1.2.10.7  Scope of SmI2-induced reductive aldehyde coupling. 
 
 
 An attractive feature of the Ellman sulfonamide-protected primary amines is the 
generality and ease of deprotection.77-86  Treatment of a representative example with HCl 
in dioxane at room temperature smoothly affords the desired primary β-fluoroamine 
congener in greater than 90% yield and without any loss of stereochemical integrity 
(Scheme 1.2.10.8). In our drug discovery efforts, we have deprotected numerous 
congeners of and have never encountered problems with stereochemical integrity or clean 
deprotections. 
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Scheme 1.2.10.8  Deprotection to afford 1o β-fluoroamines. 
 
 
 
 Finally, we wanted to apply this methodology to cyclic primary β-fluoroamines, 
as this pharmacophore has proven to be an important component of therapeutic agents, 
such as BACE inhibitors.87,88  Classically, cyclic, racemic trans-primary β-fluoroamines 
have been prepared by the ring opening of aziridines with nucleophilic fluoride, followed 
by deprotection.59,87,88  Cyclic, racemic cis-primary β-fluoroamines can be prepared by 
fluorination of a silyl enol ether, followed by reductive amination and deprotection 
(Figure 1.2.10.9).87,88  Overall, yields are modest to low (average 12% overall) for the 
production of racemic, cyclic primary β-fluoroamines via these routes, which all contain 
multiple steps. In order to access enantiopure derivatives, chiral chromatography is 
performed on either the free amine or, more likely, a protected form that introduces a 
chromophore, followed by deprotection. Ultimately, pure enantiomers of trans- and cis- 
are arrived at in typically less than 3% overall yield. 
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Scheme 1.2.10.9  Standard route to trans- and cis- cyclic primary β-fluoroamines.  
 
 In contrast, our methodology can provide rapid, high-yielding access to either cis- 
or trans-cyclic primary β-fluoroamines with high enantioselectivity based on the chirality 
of the organocatalyst and the sulfinylamine employed. For example, an indium-mediated 
allylation with allyl bromide gives 1.227 in 90% yield and 9:1 dr (if allyl Grignard 
employed, the yield is comparable, but with improved dr of >20:1) (Scheme 1.2.10.10). 
Ring-closing metathesis with Grubbs II affords cyclohexene 1.228 in 85% yield. 
Hydrogenation and standard acid-mediated deprotection provide the chiral cyclic primary 
β-fluoroamine in 70% overall yield for the four-step sequence, a notable improvement 
over the classical route. The relative stereochemistry was confirmed by correlation with 
previously reported 19F NMR shifts for cis- and trans-cyclic β-fluoroamines (-197 and-
180 ppm respectively), wherein 1.230 displayed a singlet at -198 ppm.89 
 
56 
 
 
Scheme 1.2.10.10  Access to chiral, cyclic 1o β-fluoroamines. 
 
 
 
 In summary, we have developed a highly diastereoselective and general synthesis 
of primary β-fluoroamines using a combination of organocatalysis and Ellman N-
sulfinylaldimine technology to enable the preparation of all possible stereoisomers in 
high isolated yields.90  Importantly, this methodology provides access to primary β-
fluoramine chemotypes that are generally not accessible, or difficult to prepare, through 
classic routes, as well as providing a significant improvement in the synthesis of cyclic 
primary β-fluoroamines. 
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Experimental for N-Alkyl Terminal Aziridines  
 
General Experimental 
All reagents were purchased from Sigma-Aldrich Corp., TCI America, and Rieke Metals, 
Inc. and were used without purification.  All polymer-supported reagents were purchased 
from Biotage, Inc.  Analytical thin-layer chromatography (TLC) was performed on 250 
μm silica gel plates from Sorbent Technologies.  Visualization was accomplished via UV 
light and/or the use of ninhydrin and potassium permanganate solutions followed by 
application of heat.  Chromatography was performed using Silica Gel 60 (230-400 mesh) 
from Sorbent Technologies or Silica RediSep Rf flash columns on a CombiFlash Rf 
automated flash chromatography system.  All 1H and 13C NMR spectra were recorded on 
a Bruker AV-400 (400 MHz) instrument.  Chemical shifts are reported in ppm relative to 
residual solvent peaks as an internal standard set to δ 7.26 and δ 77.16 (CDCl3).  Data are 
reported as follows:  chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = 
quartet, p = pentet, br = broad, m = multiplet), coupling constant (J, in Hz), integration.  
Low resolution mass spectra (LCMS) were obtained on an Agilent 1200 LCMS with 
electrospray ionization.  High resolution mass spectra (HRMS) were recorded on a 
Waters Qtof-API-US Plus Acquity system with ES as the ion source.  Analytical high 
performance liquid chromatography (HPLC) was performed on an Agilent 1200 
analytical LCMS with UV detection at 214 nm and 254 nm along with ELSD detection.  
Chiral separations were performed on an Agilient 1200 series HPLC and a Thar 
Investigator II supercritical fluid chromatograph  (SFC) utilizing Chiralcel® OD, OD-Cl, 
OJ, and Chiralpak® IA columns.  Optical rotations were acquired on a Jasco P-2000 
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polarimeter at 23 oC and 589nm.  The specific rotations were calculated according to the 
equation [α]ଶଷ஽  = 
ଵ଴଴ఈ
௟	௫	௖  where l is the path length in decimeters and c is the concentration in 
g/100mL.  
 
One-Pot Procedure for Chiral Aziridine Synthesis 
 
 
 
To a solution of aldehyde (1.0 eq) and catalyst (2R,5R)-2,5-diphenylpyrrolidine (0.1 
eq) in CH2Cl2 was added N-chlorosuccinimide (1.3 eq) at -78 oC.  The reaction 
mixture warmed to rt and continued stirring over a period of 1.5-2.0 h after which 
ground molecular sieves were added.  The reaction mixture was cooled to -78 oC and a 
solution of amine (1.0 eq) in 2 mL of CH2Cl2 at -78 oC was added.  This solution 
stirred at -78 oC for an additional 1.5-2.0 h followed by addition of sodium 
triacetoxyborohydride (1.2 eq) and stirring overnight at -78 oC.  The reaction mixture 
was filtered through a pad of Celite eluting with CH2Cl2 and concentrated in vacuo, 
resulting in a crude oil which was then dissolved in 1:1 THF/H2O along with KOH 
(6.5 eq) and stirred overnight at 65 oC.  The reaction mixture was extracted with 
EtOAc (5x), dried over MgSO4, and concentrated under vacuum to give the crude 
product.  Purification by flash column chromatography afforded the title compounds.  
The enantiomeric excess was determined either by chiral HPLC or SFC analysis.  The 
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diastereomeric ratio was determined by NMR experiments using chiral solvating 
agents. 
 
Two-Pot Procedure for Chiral Aziridine Synthesis 
 
 
 
To a solution of aldehyde (1.0 eq) and catalyst (2R,5R)-2,5-diphenylpyrrolidine (0.1 eq) 
in CH2Cl2 was added N-chlorosuccinimide (1.3 eq) at -78 oC.  This mixture was allowed 
to stir and warm to room temperature over a period of 1.5-2.0 h.  The reaction was 
quenched by addition of excess pentane followed by filtration and concentration of the 
filtrate in vacuo.  The crude product was redissolved in CH2Cl2 and ground molecular 
sieves were added.  The reaction mixture was then cooled to -78 oC and a solution of 
amine (1.0 eq) in 2 mL of CH2Cl2 at -78 oC was added.  This solution stirred at -78 oC for 
an additional 1.5-2.0 h followed by addition of sodium triacetoxyborohydride (1.2 eq) 
with stirring overnight at -78 oC.  The reaction mixture was filtered through a pad of 
Celite eluting with CH2Cl2 and concentrated in vacuo, resulting in a crude oil which was 
then dissolved in 1:1 THF/H2O along with KOH (6.5 eq) and stirred overnight at 65 oC.  
The reaction mixture was extracted with EtOAc (5x), dried over MgSO4, and 
concentrated under vacuum to give the crude product.  Purification by flash column 
chromatography afforded the title compounds.  The enantiomeric excess was determined 
either by chiral HPLC or SFC analysis. 
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(R)-1,2-dibenzylaziridine (1.109) 
The product was prepared according to the two-pot procedure and purified by silica 
chromatography (4:1 EtOAc/hexane) to afford the product as a clear, yellow oil (167.5 
mg, 75%), which was determined to have an ee of 94% by chiral HPLC analysis 
(Chiralcel® OD, Isocratic 2% IPA/hexane, tR (major) = 7.8 min, tR (minor) = 6.8 min).  
1H NMR (400.1 MHz, CDCl3) δ (ppm):  7.29-7.25 (m, 3H); 7.24-7.18 (m, 4H); 7.18-7.13 
(m, 3H); 3.40 (d, J = 1.65 Hz, 2H); 2.81 (dd, J1 = 5.88 Hz, J2 = 14.64 Hz, 1H); 2.60 (dd, 
J1 = 5.84 Hz, J2 = 14.64 Hz, 1H); 1.76-1.68 (m, 2H); 1.43 (d, J = 6.10 Hz, 1H).  13C 
NMR (100.6 MHz, CDCl3) δ (ppm):  139.75, 139.35, 128.81, 128.47, 128.22, 127.11, 
126.30, 64.90, 40.82, 39.48, 33.95.  HRMS (TOF, ES+) C16H17N [M+H]+ calc. mass 
224.1439, found 224.1432.  Specific rotation [α]మయವ  = +32.96° (c = 4.733, CHCl3). 
 
 
 
 
 
(R)-tert-butyl 4-(2-benzylaziridin-1-yl) piperidine-1-carboxylate (1.124) 
The product was prepared according to the one-pot procedure and purified by silica 
chromatography (1:1 EtOAc/hexane with 1% Et3N) to afford the product as a clear 
yellow oil (145.6 mg, 46%), which was determined to have an ee of 91% by chiral HPLC 
analysis (Chiralpak® IA, Isocratic 60:40 pH 9, 20mM NH4HCO3(aq) /acetonitrile, tR 
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(major) = 27.3 min, tR (minor) = 30.4 min).  1H NMR (400.1 MHz, CDCl3) δ (ppm):  
7.31 (m, 2H); 7.24 (m, 3H); 3.92 (br d, J = 31.2 Hz, 2H); 2.84-2.56 (m, 4H); 1.72 (m, 
2H); 1.59 (m, 1H); 1.45 (m, 1H); 1.45 (s, 9H); 1.35 (d, J = 6.4 Hz, 2H); 1.24 (m, 2H).  
13C NMR (100.6 MHz, CDCl3) δ (ppm):  154.98, 139.93, 128.92, 128.50, 126.40, 79.49, 
66.75, 40.35, 39.86, 32.67, 31.89, 31.44, 28.56.  HRMS (TOF, ES+) C19H29N2O2 [M+H]+ 
calc. mass 317.2229, found 317.2233. Specific rotation [α]మయವ  = +21.82° (c = 5.133, 
CHCl3). 
 
 
 
 
(R)-2-benzyl-1-(2,3-dihydro-1H-inden-2-yl) aziridine (1.125) 
The product was prepared according to the two-pot procedure and purified by silica 
chromatography (4:1 EtOAc/hexane) to afford the product as a dark brown oil (127.1 mg, 
51%), which had an ee of 90% by chiral HPLC analysis (Chiralcel® OD, Isocratic 2% 
IPA/hexane, tR (major) = 7.8 min, tR (minor) = 6.2 min). 1H NMR (400.1 MHz, CDCl3) δ 
(ppm): 7.31-7.25 (m, 2H); 7.24-7.13 (m, 4H); 7.12-7.04 (m, 3H); 3.02-2.90 (m, 2H); 2.80 
(dd, J1 = 6.70 Hz, J2 = 15.93 Hz, 1H); 2.68 (dd, J1 = 5.51 Hz, J2 = 14.14 Hz, 1H); 2.63-
2.54 (m, 2H); 2.24 (p, J = 5.51 Hz, 1H); 1.70 (d, J = 3.27, 1H); 1.66-1.59 (m, 1H); 1.39 
(d, J = 6.31 Hz, 1H). 13C NMR (100.6 MHz, CDCl3) δ (ppm): 141.98, 141.66, 140.05, 
128.94, 128.45, 126.39, 126.33, 124.89, 124.64, 70.92, 40.86, 39.67, 39.60, 39.35, 33.51. 
HRMS (TOF, ES+) C17H19N [M+H]+ calc. mass 250.1596, found 250.1596.  Specific 
rotation [α]మయವ  = +32.96° (c = 4.733, CHCl3).  Specific rotation [α]మయವ  = +7.19° (c = 4.867, 
CHCl3). 
N
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(R)-2-benzyl-1-((S)-1-phenylethyl) aziridine (1.126) 
The product was prepared according to the one-pot procedure and purified by silica 
chromatography (4:1 EtOAc/hexane) to afford the product as a clear yellow oil (151.9 
mg, 64%), which was determined to have a dr of >10:1 by NMR with the chiral solvating 
agent (R)(-)-1-(9-anthryl)-2,2,2-trifluoroethanol (Pirkle alcohol).  1H NMR (400.1 MHz, 
CDCl3) δ (ppm):  7.33-7.24 (m, 8H); 7.21-7.15 (m, 2H); 2.78 (dd, J1 = 6.51 Hz, J2 = 
14.15 Hz, 1H); 2.67 (dd, J1 = 6.06 Hz, J2 = 14.14 Hz, 1H); 2.34 (q, J = 6.59 Hz, 1H); 
1.66 (dq, J1 = 3.51 Hz, J2 = 6.34 Hz, 1H); 1.57 (d, J = 3.51 Hz, 1H); 1.28 (d, J = 6.35 Hz, 
1H); 1.21 (d, J = 6.63 Hz, 3H).  13C NMR (100.6 MHz, CDCl3) δ (ppm):  144.73, 139.98, 
129.01, 128.44, 128.38, 127.02, 126.93, 126.34, 69.98, 41.80, 39.89, 33.60, 23.39.  
HRMS (TOF, ES+) C17H19N [M+H]+ calc. mass 238.1596, found 238.1596.  Specific 
rotation [α]మయವ  = -32.67° (c = 8.600, CHCl3). 
 
 
 
(R)-2-benzyl-1-((S)-1-(naphthalen-2-yl)ethyl) aziridine (1.127) 
The product was prepared according to the one-pot procedure and purified by silica 
chromatography (4:1 EtOAc/hexane) to afford the product as a clear orange oil (163.8 
mg, 57%), which was determined to have a dr of >10:1 by NMR with the chiral solvating 
agent (R)(-)-1-(9-anthryl)-2,2,2-trifluoroethanol (Pirkle alcohol).  1H NMR (400.1 MHz, 
CDCl3) δ (ppm):  7.76-7.70 (m, 4H); 7.45-7.41 (m, 1H); 7.36 (m, 2H); 7.26 (d, J = 4.32 
N
N
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Hz, 3H); 7.20-7.13 (m, 2H); 2.79 (dd, J1 = 6.50 Hz, J2 = 14.15 Hz, 1H); 2.67 (dd, J1 = 
6.09 Hz, J2 = 14.15, 1H); 2.47 (q, J = 6.59 Hz, 1H); 1.69 (dq, J1 = 3.58 Hz, J2 = 6.31 Hz, 
1H); 1.58 (d, J = 3.58 Hz, 1H); 1.29 (d, J = 6.31 Hz, 1H); 1.25 (d, J = 6.59 Hz, 3H).  13C 
NMR (100.6 MHz, CDCl3) δ (ppm):  142.27, 140.01, 133.54, 132.85, 129.05, 128.50, 
128.06, 127.97, 127.75, 126.40, 126.03, 125.60, 125.51, 125.28, 70.21, 42.00, 39.94, 
33.73, 23.47.  HRMS (TOF, ES+) C21H21N [M+H]+ calc. mass 288.1752, found 
288.1746.  Specific rotation [α]మయವ  = -23.72° (c = 4.933, CHCl3). 
 
 
 
 
(R)-1-benzyl-2-(cyclopentylmethyl) aziridine (1.128) 
The product was prepared according to the two-pot procedure and purified by silica 
chromatography (4:1 EtOAc/hexane) to afford the product as a clear yellow oil (116.3 
mg, 54%), which was determined to have an ee of 95% by chiral HPLC analysis 
(Chiralcel® OD, Isocratic 2% IPA/hexane, tR (major) = 5.2 min, tR (minor) = 4.6 min).  
1H NMR (400.1 MHz, CDCl3) δ (ppm):  7.37-7.29 (m, 4H); 7.28-7.22 (m, 1H); 3.47 (d, J 
= 13.20 Hz, 1H); 3.36 (d, J = 13.20 Hz, 1H); 1.85-1.75 (m, 1H); 1.75-1.62 (m, 2H); 1.60 
(d, J = 3.15 Hz, 1H); 1.59-1.52 (m, 2H); 1.51-1.40 (m, 4H); 1.39 (d, J = 6.00 Hz, 1H); 
1.33 (q, J = 7.90 Hz, 1H); 1.15-1.00 (m, 2H).  13C NMR (100.6 MHz, CDCl3) δ (ppm):  
139.64, 128.43, 128.36, 127.10, 65.18, 39.42, 39.28, 38.87, 34.43, 32.85, 32.53, 25.24, 
25.12.  HRMS (TOF, ES+) C15H22N [M+H]+ calc. mass 216.1752, found 216.1752.  
Specific rotation [α]మయವ  = +6.29° (c = 7.000, CHCl3). 
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(R)-1-benzyl-2-decylaziridine (1.129) 
The product was prepared according to the one-pot procedure and purified by silica 
chromatography (4:1 EtOAc/hexane) to afford the product as a clear yellow oil (177.7 
mg, 65%), which was determined to have an ee of 94% by chiral HPLC analysis 
(Chiralcel® OD, Isocratic 2% IPA/hexane, tR (major) = 4.5 min, tR (minor) = 4.1 min).  
1H NMR (400.1 MHz, CDCl3) δ (ppm):  7.37-7.29 (m, 4H); 7.28-7.22 (m, 1H); 3.50 (d, J 
= 13.25 Hz, 1H); 3.32 (d, J = 13.25 Hz, 1H); 1.61 (d, J = 3.23 Hz, 1H); 1.49-1.16 (m, 
20H); 0.88 (t, J = 6.67 Hz, 3H).  13C NMR (100.6 MHz, CDCl3) δ (ppm):  139.64, 
128.43, 128.32, 127.09, 65.20, 39.98, 34.24, 33.19, 32.07, 29.76, 29.73, 29.53, 29.49, 
27.60, 22.84, 14.27.  HRMS (TOF, ES+) C19H31N [M+H]+ calc. mass 274.2535, found 
274.2527.  Specific rotation [α]మయವ  = +7.42° (c = 6.467, CHCl3). 
 
 
 
 
(R)-tert-butyl 4-((2-benzylaziridin-1-yl)methyl) piperidine-1-carboxylate (1.130) 
The product was prepared according to the one-pot procedure and purified by silica 
chromatography (1:1 EtOAc/hexane with 1% Et3N) to afford the product as a clear 
yellow oil (177.7 mg, 65%), which was determined to have an ee of 86% by SFC analysis 
(Chiralcel® OJ, 5% IPA/CO2, tR (major) = 3.2 min, tR (minor) = 3.7 min).  1H NMR 
(400.1 MHz, CDCl3) δ (ppm):  7.34-7.17 (m, 5H); 4.15-3.95 (br, 2H); 2.73 (dd, J1 = 5.60 
Hz, J2 = 14.25 Hz, 1H); 2.64 (dd, J1 = 7.00 Hz, J2 = 14.25 Hz, 1H); 2.60-2.46 (m, 2H); 
N
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2.28 (dd, J1 = 7.81 Hz, J2 = 11.76 Hz, 1H); 1.91 (dd, J1 = 5.70 Hz, J2 = 11.76 Hz, 1H); 
1.76 (d, J = 12.82 Hz, 1H); 1.71 (d, J = 3.34, 1H); 1.57-1.48 (m, 3H); 1.46 (s, 9H); 1.30 
(d, J = 6.25, 1H); 1.06 (pd, J1 = 4.15 Hz, J2 = 12.27 Hz, 2H).  13C NMR (100.6 MHz, 
CDCl3) δ (ppm):  154.96, 139.92, 128.86, 128.49, 126.38, 79.29, 67.36, 40.97, 39.64, 
37.23, 34.32, 30.67, 30.54, 28.58.  HRMS (TOF, ES+) C20H30N2O2 [M+H]+ calc. mass 
331.2386, found 331.2387.  Specific rotation [α]మయವ  = +32.15° (c = 0.933, CHCl3). 
 
 
 
(R,Z)-1-benzyl-2-(oct-5-en-1-yl) aziridine (1.131) 
The compound was prepared according to the two-pot procedure and purified by silica 
chromatography (4:1 EtOAc/hexane) to afford the product as a clear yellow oil (146.0 
mg, 60%), which was determined to have an ee of 96% by chiral HPLC analysis using 
the (2R,5R)-2,5-diphenylpyrrolidine catalyst (Chiralcel® OD, Isocratic 2% IPA/hexane, 
tR (major) = 5.2 min, tR (minor) = 4.7 min).  When the compound was prepared using the 
(2S,5S)-2,5-diphenylpyrrolidine catalyst, the product had an ee of 94% (Chiralcel® OD, 
Isocratic 2% IPA/hexane, tR (major) = 4.7 min, tR (minor) = 5.3 min).  1H NMR (400.1 
MHz, CDCl3) δ (ppm):  7.37-7.29 (m, 4H); 7.28-7.23 (m, 1H); 5.39-5.23 (m, 2H); 3.49 
(d, J = 13.25, 1H); 3.32 (d, J = 13.25, 1H); 2.06-1.93 (m, 4H); 1.61 (d, J = 3.06 Hz, 1H); 
1.49-1.24 (m, 8H); 0.94 (t, J = 7.54 Hz, 3H).  13C NMR (100.6 MHz, CDCl3) δ (ppm):  
139.61, 131.79, 129.23, 128.44, 128.31, 127.10, 65.19, 39.88, 34.26, 33.09, 29.62, 27.22, 
27.18, 20.64, 14.53.  HRMS (TOF, ES+) C17H25N [M+H]+ calc. mass 244.2065, found 
244.2055.  Specific rotation [α]మయವ  = -18.19° (c = 7.200, CHCl3). 
N
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(R)-tert-butyl 4-(2-(3-phenylpropyl)aziridin-1-yl)piperidine-1-carboxylate (1.132) 
The product was prepared according to the one-pot procedure and purified by silica 
chromatography (1:1 EtOAc/hexane with 1% Et3N) to afford the product as a clear 
yellow oil (179.1 mg, 52%), which was determined to have an ee of 90% by chiral HPLC 
analysis (Chiralpak® IA, Isocratic 60:40 pH 9, 20mM NH4HCO3(aq) /acetonitrile, tR 
(major) = 68.8 min, tR (minor) = 81.4 min).  1H NMR (400.1 MHz, CDCl3) δ (ppm):  
7.31-7.24 (m, 2H); 7.21-7.14 (m, 3H); 4.12-3.91 (br, 2H); 2.80-2.68 (m, 2H); 2.64 (t, J = 
7.87 Hz, 2H); 1.89-1.59 (m, 5H); 1.59-1.50 (m, 3H); 1.45 (s, 9H); 1.38-1.17 (m, 4H).  13C 
NMR (100.6 MHz, CDCl3) δ (ppm):  155.03, 142.49, 128.54, 128.46, 125.88, 79.54, 
66.95, 38.55, 36.01, 33.09, 32.71, 32.18, 31.61, 29.89, 28.58.  HRMS (TOF, ES+) 
C21H32N2O2 [M+H]+ calc. mass 345.2542, found 345.2537.  Specific rotation [α]మయವ  = 
+3.08° (c = 7.467, CHCl3). 
 
 
 
 
 
(R)-1-(2,3-dihydro-1H-inden-2-yl)-2-(3-phenylpropyl) aziridine (1.133) 
 
The product was prepared according to the one-pot procedure and purified by silica 
chromatography (4:1 EtOAc/hexane) to afford the product as a dark brown oil (155.3 mg, 
56%), which was determined to have an ee of 92% by chiral HPLC analysis (Chiralcel® 
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OD-Cl (Cellulose-2),  4% EtOH/hexane, tR (major) = 6.0 min, tR (minor) = 5.3 min).  1H 
NMR (400.1 MHz, CDCl3) δ (ppm):  7.31-7.24 (m, 2H); 7.22-7.15 (m, 5H); 7.15-7.09 
(m, 2H); 3.11-2.94 (m, 4H); 2.65 (t, J = 7.97 Hz, 2H); 2.32 (p, J = 6.12 Hz, 1H); 1.92-
1.68 (m, 2H); 1.56 (d, J = 3.32 Hz, 1H); 1.54-1.40 (m, 2H); 1.39-1.28 (m, 2H).  13C NMR 
(100.6 MHz, CDCl3) δ (ppm):  142.58, 141.87, 141.84, 128.58, 128.46, 126.54, 126.50, 
125.87, 124.92, 124.75, 71.21, 39.88, 39.38, 35.99, 33.44, 32.95, 29.87.  HRMS (TOF, 
ES+) C20H23N [M+H]+ calc. mass 278.1909, found 278.1906.  Specific rotation [α]మయವ  = 
+0.42° (c = 7.067, CHCl3). 
 
 
 
 
 
tert-butyl 3-((R)-1-(2-(pyridin-2-yl)ethyl)aziridin-2-yl) piperidine-1-carboxylate 
(1.134) 
 
The product was prepared according to the one-pot procedure and purified by silica 
chromatography (1:1 EtOAc/hexane with 1% Et3N followed by 1:1 MeOH/CH2Cl2 with 
0.1% Et3N) to afford the product as an orange oil (175.7 mg, 53%), which was 
determined to have an ee of 77% by chiral HPLC analysis using the (2R,5R)-2,5-
diphenylpyrrolidine catalyst (Chiralcel® OD, Isocratic 5% IPA/hexane, tR (major) = 15.1 
min, tR (minor) = 23.0 min).  When the compound was prepared using the (2S,5S)-2,5-
diphenylpyrrolidine catalyst, the product had an ee of 74% (Chiralcel® OD, Isocratic 2% 
IPA/hexane, tR (major) = 15.7 min, tR (minor) = 21.9 min).  1H NMR (400.1 MHz, 
CDCl3) δ (ppm):  8.50 (d, J = 4.63 Hz, 1H); 7.58 (td, J1 = 1.66 Hz, J2 = 7.68 Hz, 1H); 
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7.19 (d, J = 7.83 Hz, 1H); 7.10 (m, 1H); 4.23-3.96 (br, 2H); 3.10-2.94 (m, 2H); 2.82-2.72 
(m, 1H); 2.71-2.55 (br, 2H); 2.53-2.43 (m, 1H); 1.81 (d, J = 12.69, 1H); 1.64-1.54 (m, 
2H); 1.45 (s, 9H); 1.31-1.14 (m, 4H); 1.08-0.96 (m, 1H).  13C NMR (100.6 MHz, CDCl3) 
δ (ppm):  159.93, 155.01, 149.42, 136.50, 123.45, 121.42, 79.42, 61.14, 44.36, 39.72, 
38.89, 32.97, 30.39, 29.46, 28.60.  HRMS (TOF, ES+) C19H29N3O2 [M+H]+ calc. mass 
332.2338, found 332.2336 [M+H-Boc]+ calc. mass 232.1814, found 232.1808.  (R)-
enantiomer specific rotation [α]మయವ  = -9.58° (c = 5.533, CHCl3).  (S)-enantiomer specific 
rotation [α]మయವ  = +8.24° (c = 6.800, CHCl3). 
 
 
 
 
(S)-2-((benzyloxy)methyl)-1-(cyclohexylmethyl) aziridine (1.135) 
The product was prepared according to the one-pot procedure using (S)-5-(pyrrolidin-2-
yl)-1H-tetrazole as the catalyst and purified by silica chromatography (4:1 
EtOAc/hexane) to afford the product as a clear yellow oil (103.8 mg, 56%), which was 
determined to have an ee of 56% by SFC analysis (Chiralpak® IA, 15% IPA/CO2, tR 
(major) = 1.5 min, tR (minor) = 1.3 min).  1H NMR (400.1 MHz, CDCl3) δ (ppm):  7.28-
7.22 (m, 4H); 7.21-7.16 (m, 1H); 4.47 (q, J = 11.94 Hz, 2H); 3.40 (dd, J1 = 5.18 Hz, J2 = 
10.73 Hz, 1H); 3.34 (dd, J1 = 6.04 Hz, J2 = 10.36 Hz, 1H); 2.08 (dd, J1 = 7.44 Hz, J2 = 
11.80 Hz, 1H); 1.97 (dd, J1 = 6.16 Hz, J2 = 11.71 Hz, 1H); 1.85-1.77 (m, 1H); 1.75-1.67 
(m, 1H); 1.66-1.44 (m, 6H); 1.23-1.03 (m, 4H); 0.92-0.78 (m, 2H).  13C NMR (100.6 
MHz, CDCl3) δ (ppm):  138.48, 128.45, 127.74, 127.65, 73.11, 72.87, 68.16, 38.85, 
38.30, 32.02, 31.71, 31.68, 26.73, 26.18.  HRMS (TOF, ES+) C17H25NO [M+H]+ calc. 
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mass 260.2014, found 260.2014.  Specific rotation [α]మయವ  = +32.96° (c = 4.733, CHCl3).  
Specific rotation [α]మయವ  = +8.27° (c = 6.533, CHCl3). 
 
 
 
 
 
 
(R)-tert-butyl 4-(2-(4-methoxybenzyl)aziridin-1-yl) piperidine-1-carboxylate (1.136) 
The product was prepared according to the one-pot procedure and purified by silica 
chromatography (1:1 EtOAc/hexane) to afford the product as a clear, yellow oil (180.1 
mg, 52%), which was determined to have an ee of 92% by chiral HPLC analysis 
(Chiralpak® IA, Isocratic 60:40 pH 9, 20mM NH4HCO3(aq) /acetonitrile, tR (major) = 28.1 
min, tR (minor) = 31.8 min).  1H NMR (400.1 MHz, CDCl3) δ (ppm):  7.17 (d, J = 8.48 
Hz, 2H); 6.85 (d, J = 8.48 Hz, 2H); 4.05-3.85 (br, 2H); 3.80 (s, 3H); 2.84-2.72 (m, 1H); 
2.68 (dd, J1 = 5.15 Hz, J2 = 14.21 Hz, 2H); 2.53 (dd, J1 = 7.34 Hz, J2 = 14.21 Hz, 1H); 
1.77-1.69 (m, 1H); 1.67 (d, J = 3.36 Hz, 1H); 1.58-1.40 (m. 3H); 1.45 (s, 9H); 1.33 (d, J 
= 6.34 Hz, 2H); 1.25-1.17 (m, 1H).  13C NMR (100.6 MHz, CDCl3) δ (ppm):  158.25, 
155.02, 132.08, 129.86, 113.90, 79.50, 66.83, 55.38, 40.58, 38.98, 32.61, 31.98, 31.48, 
28.58.  HRMS (TOF, ES+) C20H30N2O3 [M+H]+ calc. mass 347.2335, found 347.2325.  
Specific rotation [α]మయವ  = +33.20° (c = 3.133, CHCl3). 
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(R)-tert-butyl 4-(2-(3-chlorobenzyl)aziridin-1-yl) piperidine-1-carboxylate (1.137) 
The product was prepared according to the one-pot procedure and purified by silica 
chromatography (1:1 EtOAc/hexane) to afford the product as a clear, orange oil (171.9 
mg, 49%), which was determined to have an ee of 95% by chiral HPLC analysis 
(Chiralpak® IA, Isocratic 60:40 pH 9, 20mM NH4HCO3(aq) /acetonitrile, tR (major) = 45.4 
min, tR (minor) = 49.4 min).  1H NMR (400.1 MHz, CDCl3) δ (ppm):  7.28-7.18 (m, 3H); 
7.15-7.11 (m, 1H); 4.04-3.79 (br, 2H); 2.87-2.66 (m, 3H); 2.55 (dd, J1 = 7.37 Hz, J2 = 
14.08 Hz, 1H); 1.76-1.69 (m, 1H); 1.68 (d, J = 3.38 Hz, 1H); 1.62-1.52 (m, 1H); 1.52-
1.38 (m, 2H); 1.45 (s, 9H); 1.36 (d, J = 6.37 Hz, 1H); 1.34-1.27 (m, 1H); 1.27-1.18 (m, 
1H).  13C NMR (100.6 MHz, CDCl3) δ (ppm):  154.99, 141.93, 134.20, 129.75, 129.01, 
127.17, 126.61, 79.51, 66.67, 39.96, 39.47, 32.65, 31.87, 31.42, 28.56.  HRMS (TOF, 
ES+) C19H28N2O2Cl [M+H]+ calc. mass 351.1839, found 351.1832.  Specific rotation 
[α]మయವ  = +13.26° (c = 21.867, CHCl3). 
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Experimental for Primary β-Fluoroamines 
 
General Experimental 
All reagents were purchased from commercial suppliers and purified as needed according 
to the procedures of Armarego and Chai.1  Analytical thin-layer chromatography (TLC) 
was performed on 250 μm silica gel plates from Sorbent Technologies.  Visualization 
was accomplished via UV light and/or the use of ninhydrin and potassium permanganate 
solutions followed by application of heat.  Chromatography was performed using Silica 
Gel 60 (230-400 mesh) from Sorbent Technologies or Silica RediSep Rf flash columns 
on a CombiFlash Rf automated flash chromatography system.  All 1H and 13C NMR 
spectra were recorded on a Bruker AV-400 (400 MHz and 100 MHz respectively).  All 
19F NMR spectra were recorded on a Bruker DPX-300 (282 MHz).  All 1H and 13C 
chemical shifts are reported in ppm relative to residual solvent peaks as an internal 
standard set to δ 7.26 and δ 77.16 (CDCl3).  All 19F chemical shifts are reported in ppm 
relative to CCl3F as an internal standard set to δ 0.00.  Data are reported as follows:  
chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, br = broad, m 
= multiplet), coupling constant (J, in Hz), integration.  Low resolution mass spectra 
(LCMS) were obtained on an Agilent 1200 LCMS with electrospray ionization.  High 
resolution mass spectra (HRMS) were recorded on a Waters Qtof-API-US plus Acquity 
system with ES as the ion source.   
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 General Procedure for the Synthesis of β-Fluoro-N-Sulfinyl Aldimines 
 
 
 
The enantioselective α-fluorination of aldehydes was accomplished using the 
procedure established by MacMillan and co-workers.2  To a vial equipped with a stir 
bar was added (R)-5-benzyl-2,2,3-trimethylimidazolidin-4-one dichloroacetic acid salt 
(0.40 mmol, 0.2 eq) and N-fluorobenzenesulfonimide (10.0 mmol, 5.0 eq) followed by 
THF (9.0 mL) and iPrOH (1.0 mL).  This solution was allowed to stir at rt until 
homogeneous then cooled to -20 oC.  The aldehyde (2.0 mmol, 1.0 eq) was added and 
the reaction stirred at -20 oC for 12 h.  The solution was then cooled to -78 oC, diluted 
with 10 mL Et2O, and filtered through a plug of Davisil® Silica Gel, eluting with ether 
at -78 oC.  5.0 mL of SMe2 was then added to the filtrate, resulting in a white 
precipitate.  The resulting suspension was washed with sat NaHCO3 (3x) and brine 
(1x), and dried over MgSO4, filtered, and concentrated in vacuo.  The resulting α-
fluoroaldehyde was dissolved in THF (5 mL), and Ti(OEt)4 (4.0 mmol, 2.0 eq) was 
added followed by (R)-(+)-2-methyl-2-propanesulfinamide (2.0 mmol, 1.0 eq).  The 
mixture was stirred at rt for 5 h.  The reaction was then quenched by addition of an 
equal volume of sat NaHCO3.  The resulting mixture was filtered through a pad of 
Celite® and the filter cake rinsed with EtOAc.  The filtrate was extracted with EtOAc, 
dried over MgSO4, and concentrated.  The α-fluorosulfinimines were purified by flash 
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column chromatography and their diastereomeric ratio determined by 19F NMR 
experiments.   
 
 
(R)-N-((R)-2-fluoro-3-phenylpropylidene)-2-methylpropane-2-sulfinamide (1.198) 
The product was prepared according to the general procedure and purified by silica 
chromatography (3:1 hexanes/EtOAc) to afford the product as a clear oil (72%), which 
was determined to have a dr of >20:1 by 19F NMR.  1H NMR (400 MHz, CDCl3) δ 
(ppm):  8.17 (dd, J1 = 3.5 Hz, J2 = 9.4 Hz, 1H); 7.38-7.25 (m, 5H); 5.53-5.35 (dm, 1H); 
3.25-3.14 (m, 2H); 1.18 (s, 9H).  13C NMR (100 MHz, CDCl3) δ (ppm):  166.37 (d, J = 
30.1 Hz); 135.36 (d, J = 3.2 Hz); 129.71; 129.02; 127.49; 93.41 (d, J = 177.5 Hz); 57.53; 
39.57 (d, J = 21.6 Hz); 22.64.  19F NMR (282 MHz, CDCl3) δ (ppm):  -188.11 (s).  
HRMS (TOF, ES+) C13H18NOFS [M+H]+ calc. mass 256.1171, found 256.1173. 
 
 
 
(R)-N-((R)-4-(1,3-dioxoisoindolin-2-yl)-2-fluorobutylidene)-2-methylpropane-2-
sulfinamide (1.199) 
 
The product was prepared according to the general procedure and purified by silica 
chromatography (3:1 hexanes/EtOAc) to afford the product as a clear oil (67%), which 
80 
 
was determined to have a dr of >9:1 by 19F NMR.  1H NMR (400 MHz, CDCl3) δ (ppm):  
8.10 (dd, J1 = 3.1 Hz, J2 = 9.8 Hz, 1H); 7.85 (m, 2H); 7.72 (m, 2H); 5.30 (dm, 1H); 3.94 
(m, 2H); 2.27 (m, 2H); 1.18 (s, 9H).  13C NMR (100 MHz, CDCl3) δ (ppm):  168.45; 
166.05 (d, J = 30.1 Hz); 134.44; 132.32; 123.71; 91.36 (d, J = 175.3 Hz); 57.71; 34.21 (d, 
J = 3.8 Hz); 32.03 (d, J = 20.8 Hz); 22.68.  19F NMR (282 MHz, CDCl3) δ (ppm):  -
190.92 (s).  HRMS (TOF, ES+) C16H19N2O3FS [M+H]+ calc. mass 339.1179, found 
339.1178. 
 
 
 
(R)-N-((R)-2-fluoropent-4-en-1-ylidene)-2-methylpropane-2-sulfinamide (1.200) 
The product was prepared according to the general procedure and purified by silica 
chromatography (3:1 hexanes/EtOAc) to afford the product as a clear oil (68%), which 
was determined to have a dr of >20:1 by 19F NMR.  1H NMR (400 MHz, CDCl3) δ 
(ppm):  8.09 (dd, J1 = 3.2 Hz, J2 = 10.3 Hz, 1H); 5.84 (m, 1H); 5.39-4.98 (m, 3H); 2.75-
2.56 (m, 2H); 1.22 (s, 9H).  13C NMR (100 MHz, CDCl3) δ (ppm):  166.32 (d, J = 28.5 
Hz); 131.30 (d, J = 4.7 Hz); 119.86; 92.28 (d, J = 177.7 Hz); 57.64; 37.62 (d, J = 21.5 
Hz); 22.76.  19F NMR (282 MHz, CDCl3) δ (ppm):  -189.48 (s).  HRMS (TOF, ES+) 
C9H16NOFS [M+H]+ calc. mass 206.1015, found 206.1017. 
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(R)-N-((R)-5-(benzyloxy)-2-fluoropentylidene)-2-methylpropane-2-sulfinamide 
(1.201) 
 
The product was prepared according to the general procedure and purified by silica 
chromatography (2:1 hexanes/EtOAc) to afford the product as a clear yellow oil (75%), 
which was determined to have a dr of >9:1 by 19F NMR.    1H NMR (400 MHz, CDCl3) δ 
(ppm):  8.02 (dd, J1 = 3.35 Hz, J2 = 10.33 Hz, 1H); 7.30-7.19 (m, 5H); 5.16 (dm, 1H); 
4.44 (s, 2H); 3.45 (m, 2H); 2.04-1.68 (m, 4H); 1.15 (s, 9H).  13C NMR (125 MHz, 
CDCl3) δ (ppm):  199.87 (d, J = 33.9 Hz); 166.51 (d, J = 28.6 Hz); 138.37; 128.42; 
127.64; 92.77 (d, J = 175.0 Hz); 72.93; 69.34; 57.26; 29.92 (d, J = 20.6 Hz); 24.78; 
22.40.  19F NMR (282 MHz, CDCl3) δ (ppm):  -187.88 (s).  HRMS (TOF, ES+) 
C16H24NO2FS [M+H]+ calc. mass 314.1590, found 314.1590. 
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General Procedure for Grignard Addition 
 
 
 
Grignard additions were done according to the general procedure by Ellman and co-
workers.3  To a solution of the N-tert-butanesulfinyl aldimine at -48 oC was added the 
Grignard reagent in either Et2O or THF.  The reaction stirred at -48 oC for 5 h and was 
then warmed to rt and stirred overnight.  The reaction was quenched by the addition of 
sat NH4Cl and extracted with EtOAc (3x).  The combined organic layers were dried over 
MgSO4, concentrated, and purified by flash column chromatography.  The diastereomeric 
ratio of the sulfinamide-protected primary β-fluoroamines was determined by 19F NMR 
experiments. 
 
 
 
(R)-N-((2R,3S)-2-fluoro-1-phenylheptan-3-yl)-2-methylpropane-2-sulfinamide 
(1.203) 
 
The product was prepared according to the general procedure and purified by silica 
chromatography (4:1–1:1 gradient EtOAc/hexane) to afford the product as a clear oil 
(92%), which was determined to have a dr of >20:1 by 19F NMR.  1H NMR (400 MHz, 
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CDCl3) δ (ppm):  7.37-7.22 (m, 5H); 5.05 (dm, 1H); 3.57 (d, J = 9.2 Hz, 1H); 3.33 (m, 
1H); 3.08 (td, J1 = 8.6 Hz, J2 = 14.8 Hz, 1H); 2.89 (ddd, J1 = 4.7 Hz, J2 = 14.5 Hz, J3 = 
31.2 Hz, 1H); 1.74-1.58 (m, 2H); 1.42-1.27 (m, 4H); 1.25 (s, 9H); 0.93 (t, J = 7.1 Hz, 
3H).  13C NMR (100 MHz, CDCl3) δ (ppm):  136.95 (d, J = 4.7 Hz); 129.48; 128.95; 
127.09; 97.43 (d, J = 175.1 Hz); 59.86 (d, J = 20.1 Hz); 56.62; 38.13 (d, J = 21.5 Hz); 
58.07 (d, J = 4.5 Hz); 28.32; 23.04; 22.68; 14.31.  19F NMR (282 MHz, CDCl3) δ (ppm):   
-188.11 (s).  HRMS (TOF, ES+) C17H28NOFS [M+H]+ calc. mass 314.1876, found 
314.1876. 
 
 
 
(R)-N-((1S,2R)-2-fluoro-1,3-diphenylpropyl)-2-methylpropane-2-sulfinamide (1.204) 
The product was prepared according to the general procedure and purified by silica 
chromatography (2:1 hexanes/EtOAc) to afford the product as a clear oil (89%) with a dr 
of >20:1 by 19F NMR. 1H NMR (400 MHz, CDCl3) δ (ppm): 7.46-7.35 (m, 4H); 7.35-
7.22 (m, 4H); 7.21-7.13 (d, J1 = 7.24 Hz, 2H); 5.11 (dm, 1H); 4.51 (dm, 1H); 3.81 (d, J = 
5.4 Hz, 1H); 2.87-2.69 (m, 2H); 1.26 (s, 9H). 13C NMR (100 MHz, CDCl3) δ (ppm):  
137.56; 136.80 (d, J = 3.1 Hz); 129.30, 128.90; 128.71; 128.65; 126.94; 95.15 (d, J = 
182.3 Hz); 61.72 (d, J = 19.2 Hz); 56.53; 38.30; 29.83; 22.68. 19F NMR (282 MHz, 
CDCl3) δ (ppm): -188.11 (s).  HRMS (TOF, ES+) C19H24NOFS [M+H]+ calc. mass 
334.1641, found 334.1639. 
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(R)-N-((2R,3R)-5-(1,3-dioxan-2-yl)-2-fluoro-1-phenylpentan-3-yl)-2-methylpropane-
2-sulfinamide (1.205) 
 
The product was prepared according to the general procedure and purified by silica 
chromatography (2:1 hexanes/EtOAc) to afford the product as a white solid (81%) with a 
dr of >9:1 by 19F NMR.  1H NMR (400 MHz, CDCl3) δ (ppm):  7.33-7.20 (m, 5H); 5.03 
(dm, J = 47.6 Hz, 1H); 4.54 (t, J = 4.3 Hz, 1H); 4.16-4.02 (m, 4H); 3.22-3.00 (m, 2H); 
2.94-2.79 (m, 1H); 2.17-1.56 (m, 6H); 1.22 (s, 9H).  13C NMR (100 MHz, CDCl3) δ 
(ppm):  129.71; 129.32; 128.74; 126.85 (d, J = 8.6 Hz); 101.85 (d, J = 6.8 Hz); 97.23 (d, 
J = 175.9 Hz); 67.03 (d, J = 5.6 Hz); 59.73 (d, J = 7.6 Hz); 38.04 (d, J = 22.6 Hz); 31.54 
(d, J = 5.70 Hz); 28.03; 25.89 (d, J = 3.9 Hz); 23.51; 22.88.  19F NMR (282 MHz, CDCl3) 
δ (ppm):  -188.11. HRMS (TOF, ES+) C19H30NO3FS [M+H]+ calc. mass 372.2009, found 
372.2006. 
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General Procedure for Boronic Acid Addition 
 
 
 
Addition of boronic acids to β-fluorosulfinimines was achieved using the methods shown 
by Batey and co-workers.4  To a vial containing sulfinimine (0.25 mmol, 1.0 eq), 
[Rh(COD)(MeCN)2]BF4 (0.0125 mmol, 0.05 eq), and boronic acid (0.50 mmol, 2.0 eq) in 
dioxane (0.6 mL) was added Et3N (0.50 mmol, 2.0 eq) and H2O (1.2 mL).  The resulting 
mixture was stirred at rt for 2 h.  The aqueous layer was then extracted with EtOAc (3x).  
The combined organic layers were washed with brine, dried over MgSO4, filtered, and 
concentrated in vacuo to give a crude oil.  The products were purified using flash column 
chromatography.  The diastereomeric ratio of the sulfinamide-protected primary β-
fluoroamines was determined by 19F NMR experiments. 
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(R)-N-((1R,2R)-2-fluoro-1-(4-methoxyphenyl)-3-phenylpropyl)-2-methylpropane-2-
sulfinamide (1.207) 
 
The product was prepared according to the general procedure and purified by silica 
chromatography (2:1 hexanes/EtOAc) to afford the product as a yellow solid (80%), 
which was determined to have a dr of >20:1 by 19F NMR.  1H NMR (400 MHz, CDCl3) δ 
(ppm):  7.35-7.20 (m, 5H); 7.19-7.10 (m, 2H); 6.95 (d, J = 8.60 Hz, 2H); 5.04 (dm, 1H); 
4.55-4.49 (m, 1H); 3.95 (d, J = 4.1 Hz, 1H); 3.86 (s, 3H); 2.85-2.69 (m, 2H); 1.21 (s, 9H).  
13C NMR (100 MHz, CDCl3) δ (ppm):  159.64 (d, J = 32.2 Hz); 136.35; 129.97 (d, J = 
22.47 Hz); 129.20 (d, J = 14.2 Hz); 128.51; 126.69 (d, J = 7.49 Hz); 114.23; 113.83; 
96.45 (d, J = 180.6 Hz); 61.07 (d, J = 19.3 Hz); 58.34; 55.49 (d, J = 63.8 Hz); 37.60 (d, J 
= 21.0 Hz); 29.62; 22.47.  19F NMR (282 MHz, CDCl3) δ (ppm):   -184.63 (s).  HRMS 
(TOF, ES+) C20H26NO2FS [M+H]+ calc. mass 364.1747, found 364.1748. 
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(R)-N-((1R,2R)-1-([1,1'-biphenyl]-3-yl)-2-fluoro-3-phenylpropyl)-2-methylpropane-
2-sulfinamide (1.208) 
 
The product was prepared according to the general procedure and purified by silica 
chromatography (2:1 hexanes/EtOAc) to afford the product as a clear oil (87%), which 
was determined to have a dr of >20:1 by 19F NMR.  1H NMR (400 MHz, CDCl3) δ 
(ppm):  7.65-7.56 (m, 4H); 7.52-7.45 (m, 3H); 7.43-7.22 (m, 5H); 7.17-7.13 (m, 2H); 
4.90 (dm, 1H); 4.64 (m, 1H); 4.20 (s, 1H); 2.91 (d, J = 5.8 Hz, 1H); 2.88-2.82 (m, 1H); 
1.24 (s, 9H).  13C NMR (100 MHz, CDCl3) δ (ppm):  141.99; 140.66; 137.88 (d, J = 5.80 
Hz); 136.42; 129.50; 129.47; 129.01; 128.62; 127.75; 127.68; 127.65; 127.60; 127.25; 
126.94; 97.12 (d, J = 180.0 Hz); 61.75 (d, J = 18.5 Hz); 55.84; 37.96 (d, J = 20.0 Hz); 
22.68.  19F NMR (282 MHz, CDCl3) δ (ppm):   -185.00 (s).  HRMS (TOF, ES+) 
C25H28NOFS [M+H]+ calc. mass 410.1954, found 410.1953. 
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(R)-N-((1R,2R)-2-fluoro-1-(1-methyl-1H-indol-5-yl)-3-phenylpropyl)-2-
methylpropane-2-sulfinamide (1.209) 
 
The product was prepared according to the general procedure and purified by silica 
chromatography (2:1 hexanes/EtOAc) to afford the product as a dark brown oil (65%), 
which was determined to have a dr of >20:1 by 19F NMR.  1H NMR (400 MHz, CDCl3) δ 
(ppm):  7.65 (s, 1H); 7.40-7.08 (m, 8H); 6.53 (d, J = 3.1 Hz, 1H); 4.91 (dm, J = 49.3 Hz, 
1H); 4.68 (t, J = 8.7 Hz, 1H); 3.84 (s, 3H); 2.86-2.68 (m, 2H); 1.21 (s, 9H).  13C NMR 
(100 MHz, CDCl3) δ (ppm):  136.74; 129.53; 129.29; 129.15; 128.56; 128.43; 128.35; 
128.26; 126.52; 121.78; 109.68; 101.19; 97.49 (d, J = 177.1 Hz); 61.89 (d, J = 18.3 Hz); 
55.29; 37.73 (d, J = 20.3 Hz); 32.87; 22.50.  19F NMR (282 MHz, CDCl3) δ (ppm):   -
184.26 (s).  HRMS (TOF, ES+) C22H27N2OFS [M+H]+ calc. mass 387.1906, found 
387.1908. 
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General Procedure for In-Mediated Allylation 
 
 
 
In-mediated allylation was done according to procedures published by Lin and co-
workers.5  To a vial containing sulfinimine (0.25 mmol, 1.0 eq) and indium powder (1.0 
mmol, 4.0 eq) was added saturated aqueous NaBr solution (5 mL) followed by the allylic 
bromide (1.0 mmol, 4.0 eq).  The resulting suspension stirred at rt for 12 h.  The reaction 
was quenched by the addition of 15 mL of sat aqueous NaHCO3.  The aqueous layer was 
extracted with EtOAc (3x), dried over MgSO4, filtered, concentrated in vacuo, and 
purified by flash column chromatography to afford the allylation product.  The 
diastereomeric ratio of the sulfinamide-protected primary β-fluoroamines was determined 
by 19F NMR experiments. 
 
 
 
(R)-N-((2R,3S)-2-fluoro-1-phenylhex-5-en-3-yl)-2-methylpropane-2-sulfinamide 
(1.211) 
 
The product was prepared according to the general procedure and purified by silica 
chromatography (2:1 hexanes/EtOAc) to afford the product as a clear oil (90%), which 
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was determined to have a dr of >9:1 by 19F NMR.  1H NMR (400 MHz, CDCl3) δ (ppm):  
7.32 (s, 2H); 7.31 (s, 2H); 7.27-7.21 (m, 1H); 5.79-5.67 (m, 1H); 5.11 (s, 1H); 5.07 (d, J 
= 2.96 Hz, 1H); 4.76 (dtd, J1 = 2.60 Hz, J2 = 6.9 Hz, J3 = 46.5 Hz, 1H); 3.66 (d, J = 7.5 
Hz, 1H); 3.47-3.33 (m, 1H); 3.21-3.13 (m, 1H); 3.11 (d, J = 6.9 Hz, 1H); 2.50-2.31 (m, 
2H); 1.24 (s, 9H).  13C NMR (100 MHz, CDCl3) δ (ppm):  136.68; 133.97; 129.67; 
128.77; 126.87; 118.54; 95.14 (d, J = 175.8 Hz); 57.83 (d, J = 19.2 Hz); 56.57; 38.21 (d, 
J = 2.5 Hz); 37.78 (d, J = 21.6 Hz); 22.93.  19F NMR (282 MHz, CDCl3) δ (ppm):  -
188.35 (s).  HRMS (TOF, ES+) C16H24NOFS [M+H]+ calc. mass 298.1641, found 
298.1642. 
 
 
 
(R)-N-((2R,3S,4R)-2-fluoro-4-methyl-1-phenylhex-5-en-3-yl)-2-methylpropane-2-
sulfinamide (1.212) 
 
The product was prepared according to the general procedure and purified by silica 
chromatography (2:1 hexanes/EtOAc) to afford the product as a clear oil (82%), which 
was determined to have a dr of >20:1 by 19F NMR.  1H NMR (400 MHz, CDCl3) δ 
(ppm):  7.35-7.15 (m, 5H); 5.97-5.86 (m, 1H); 5.85-5.55 (m, 1H); 5.09-4.98 (m, 1H); 
4.62-4.43 (dm, J = 47.7 Hz, 1H); 3.52-2.78 (m, 4H); 1.29 (s, 9H); 1.05 (dd, J1 = 4.2 Hz, 
J2 = 6.9 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ (ppm):  138.24; 137.48; 129.42; 
128.68; 126.88; 118.14; 94.96 (d, J = 178.7 Hz); 62.23 (d, J = 22.9 Hz); 60.35; 38.24 (d, 
J = 20.8 Hz); 36.62 (d, J = 4.4 Hz); 23.04; 16.40.  19F NMR (282 MHz, CDCl3) δ (ppm):  
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-184.09 (s).  HRMS (TOF, ES+) C17H26NOFS [M+H]+ calc. mass 312.1797, found 
312.1798. 
 
 
 
(R)-N-((2R,3S)-2-fluoro-1-phenylhexa-4,5-dien-3-yl)-2-methylpropane-2-sulfinamide 
(1.213) 
 
The product was prepared according to the general procedure and purified by silica 
chromatography (2:1 hexanes/EtOAc) to afford the product as a yellow oil (78%), which 
was determined to have a dr of >20:1 by 19F NMR.  1H NMR (400 MHz, CDCl3) δ 
(ppm):  7.38-7.18 (m, 5H); 5.48-5.31 (m, 1H); 5.05-4.97 (m, 2H); 4.82-4.63 (dm, J = 
47.2 Hz, 1H); 3.86 (d, J =  9.06 Hz,1H); 3.25-3.08 (m, 1H); 3.02-2.86 (m,1H); 1.30 (s, 
9H).  13C NMR (100 MHz, CDCl3) δ (ppm):  208.62; 136.62; 129.35; 128.47; 126.76; 
93.15 (d, J = 179.0 Hz); 88.32 (d, J = 7.1 Hz); 72.31; 57.47; 56.29 (d, J = 25.7 Hz); 37.68 
(d, J = 20.4 Hz); 22.62.  19F NMR (282 MHz, CDCl3) δ (ppm):  -187.09 (s).  HRMS 
(TOF, ES+) C16H22NOFS [M+H]+ calc. mass 296.1484, found 296.1483. 
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General Procedure for the SmI2-Induced Reductive Aldehyde Coupling 
 
 
 
Reductive coupling of aldehydes was accomplished using the procedure established by 
Lu and Xin.6 To a flame-dried flask under an argon atmosphere was added a solution of 
0.1M SmI2 in THF (1.0 mmol, 2.0 eq).  The solution was cooled to -78 oC and a mixture 
of sulfinimine (0.5 mmol, 1.0 eq), t-butyl alcohol (1.0 mmol, 2.0 eq), and aldehyde (0.75 
mmol, 1.5 eq) in 6 mL of THF was added dropwise.  The reaction was stirred at -78 oC 
for 4-6 h.  The reaction was quenched with the addition of 5 mL of sat aq Na2S2O3 
followed by extraction with EtOAc (3x) and purification by reverse-phase column 
chromatography to afford the product.  The diastereomeric ratio of the sulfinamide-
protected primary β-fluoroamines was determined by 19F NMR experiments. 
 
 
 
(R)-N-((1R,2R,3R)-1-cyclopropyl-3-fluoro-1-hydroxy-4-phenylbutan-2-yl)-2-
methylpropane-2-sulfinamide (1.215) 
 
The product was prepared according to the general procedure and purified by silica 
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chromatography (2:1 hexanes/EtOAc) to afford the product as a clear oil (87%), which 
was determined to have a dr of >20:1 by 19F NMR.  1H NMR (400 MHz, CDCl3) δ 
(ppm):  7.38-7.17 (m, 5H); 5.19 (dm, J = 46.7 Hz, 1H); 4.07 (dd, J1 = 1.8 Hz, J2 = 8.2 Hz, 
1H); 3.44-3.02 (m, 5H); 1.32 (s, 9H); 0.62-0.28 (m, 4H).  13C NMR (100 MHz, CDCl3) δ 
(ppm):  136.65 (d, J = 7.32 Hz); 129.69; 128.75; 126.86; 93.22 (d, J = 175.6 Hz); 62.23 
(d, J = 16.8 Hz); 56.72; 38.3; 22.99; 14.68; 3.81; 21.2.  19F NMR (282 MHz, CDCl3) δ 
(ppm):  -194.35 (s).  HRMS (TOF, ES+) C17H26NO2FS [M+H]+ calc. mass 328.1747, 
found 328.1749. 
 
 
 
(R)-N-((2S,3R,4R)-1-(benzyloxy)-4-fluoro-2-hydroxy-5-phenylpentan-3-yl)-2-
methylpropane-2-sulfinamide (1.216) 
 
The product was prepared according to the general procedure and purified by silica 
chromatography (2:1 hexanes/EtOAc) to afford the product as a clear oil (83%), which 
was determined to have a dr of >20:1 by 19F NMR.  1H NMR (400 MHz, CDCl3) δ 
(ppm):  7.44-7.27 (m, 10H); 4.63 (dm, 1H); 4.55 (s, 2H); 3.97-3.93 (m, 2H); 3.54 (m, 
1H); 2.97-2.60 (m, 3H); 1.55 (s, 9H).  13C NMR (100 MHz, CDCl3) δ (ppm):  138.58; 
137.72; 129.29; 129.19; 128.47 (d, J = 3.2 Hz); 127.83; 127.75; 126.57; 93.54 (d, J = 
169.7 Hz); 73.43; 71.53; 70.81; 55.90 (d, J = 21.7 Hz); 55.52; 55.33; 38.18 (d, J = 22.0 
Hz); 21.7.  19F NMR (282 MHz, CDCl3) δ (ppm):  -189.07 (s).  HRMS (TOF, ES+) 
C13H19NOFS [M+H]+ calc. mass 408.1930, found 408.1931. 
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tert-butyl-4-((2R,3R,4R)-3-((R)-1,1-dimethylethylsulfinamido)-4-fluoro-2-hydroxy-5-
phenylpentyl)piperidine-1-carboxylate (1.217) 
 
The product was prepared according to the general procedure and purified by silica 
chromatography (2:1 hexanes/EtOAc) to afford the product as a clear oil (80%), which 
was determined to have a dr of >20:1 by 19F NMR.  1H NMR (400 MHz, CDCl3) δ 
(ppm):  7.35-7.16 (m, 5H); 4.84 (dm, J = 47.9 Hz, 1H); 4.07 (br, 1H); 3.67 (m, 1H); 3.16-
2.85 (m, 3H); 2.77-2.58 (m, 4H); 1.83-1.51 (m, 5H); 1.45 (s, 18H).  13C NMR (100 MHz, 
CDCl3) δ (ppm):  154.81; 136.63; 129.18; 128.58; 126.75; 94.14 (d, J = 173.0 Hz); 79.17; 
64.23 (d, J = 22.1 Hz); 62.57; 57.43; 39.57; 38.44 (d, J = 20.1 Hz); 33.25; 32.32; 31.19; 
28.39.  19F NMR (282 MHz, CDCl3) δ (ppm):  -188.40 (s).    HRMS (TOF, ES+) 
C25H41N2O4FS [M+H]+ calc. mass 485.2771, found 485.2771. 
 
 
 
(1S,2R)-2-fluoro-1,3-diphenylpropan-1-amine (1.218) 
The product was prepared by treatment of (R)-N-((1S,2R)-2-fluoro-1,3-diphenylpropyl)-
2-methylpropane-2-sulfinamide with excess HCl in dioxane to afford analytically pure 
product as a yellow solid (92%) which was determined to have a dr of >20:1 by 19F 
NMR.  1H NMR (400 MHz, CDCl3) δ (ppm):  7.42-7.11 (m, 10H); 4.91 (dm, J = 47.7 
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Hz, 1H); 4.14 (d, J = 15.7 Hz, 1H); 2.97-2.67 (m, 2H).  13C NMR (150 MHz, CDCl3) δ 
(ppm):  140.80; 137.42 (d, J = 2.2 Hz); 129.38; 128.75; 128.59; 127.92; 127.71; 126.70; 
97.49 (d, J = 177.8 Hz); 58.59 (d, J = 20.9 Hz); 37.21 (d, J = 21.2 Hz).  19F NMR (282 
MHz, CDCl3) δ (ppm):  -186.59 (s).  HRMS (TOF, ES+) C15H16NF [M+H]+ calc. mass 
230.1345, found 230.1346. 
 
 
 
(R)-N-((4S,5R)-5-fluoroocta-1,7-dien-4-yl)-2-methylpropane-2-sulfinamide (1.227) 
The product was prepared according to the general procedure and purified by silica 
chromatography (4:1–1:1 gradient EtOAc/hexane) to afford the product as a clear oil 
(90%), which was determined to have a dr of >20:1 by 19F NMR.  1H NMR (400 MHz, 
CDCl3) δ (ppm):  5.90-5.77 (m, 2H); 5.27-5.11 (m, 4H); 4.54-4.36 (dm, 1H); 3.54-3.38 
(m, 2H); 2.53-2.38 (m, 4H); 1.21 (s, 9H).  13C NMR (100 MHz, CDCl3) δ (ppm):  133.51; 
133.08 (d, J = 4.6 Hz); 120.49; 118.71; 93.97 (d, J = 177.7 Hz); 57.25 (d, J = 23.2 Hz); 
56.52; 36.18 (d, J = 21.5 Hz); 35.57 (d, J = 4.6 Hz); 22.95.  19F NMR (282 MHz, CDCl3) 
δ (ppm):  -189.74 (s).  HRMS (TOF, ES+) C12H22NOFS [M+H]+ calc. mass 248.1484, 
found 248.1483. 
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(R)-N-((1S,6R)-6-fluorocyclohex-3-en-1-yl)-2-methylpropane-2-sulfinamide (1.228) 
The product was prepared by treatment of (R)-N-((4S,5R)-5-fluoroocta-1,7-dien-4-yl)-2-
methylpropane-2-sulfinamide with Grubbs 2nd generation catalyst to afford the cyclized 
product in 85% yield as an off-white solid.   1H NMR (400 MHz, CDCl3) δ (ppm):  5.67 
(m, 1H); 5.57 (m, 1H); 4.84 (dm, 1H); 3.54 (m, 1H); 3.36 (d, J = 8.52 Hz, 1H); 2.61-2.25 
(m, 4H); 1.23 (s, 9H).  13C NMR (100 MHz, CDCl3) δ (ppm):  124.83; 122.48; 90.37 (d, J 
= 174.13 Hz); 56.18; 54.54 (d, J = 19.17 Hz); 30.91 (d, J = 22.10 Hz); 30.41 (d, J = 6.03 
Hz); 22.71.  19F NMR (282 MHz, CDCl3) δ (ppm):  -193.57 (s).  HRMS (TOF, ES+) 
C10H18NOFS [M+H]+ calc. mass 220.1171, found 220.1171. 
 
 
 
(R)-N-((1S,2R)-2-fluorocyclohexyl)-2-methylpropane-2-sulfinamide (1.229) 
The product was prepared by treatment of (R)-N-((1S,6R)-6-fluorocyclohex-3-en-1-yl)-2-
methylpropane-2-sulfinamide with 10% Pd/C in a H2 atmosphere to afford the product as 
an off-white solid (95% yield).  1H NMR (500 MHz, CDCl3) δ (ppm):  4.29 (dm, J = 49.2 
Hz); 3.33-3.22 (m, 2H); 2.20-2.07 (m, 2H); 1.83-1.65 (m, 2H); 1.57-1.37 (m, 2H); 1.36-
1.26 (m, 2H); 1.24 (s, 9H).  13C NMR (100 MHz, CDCl3) δ (ppm):  95.19 (d, J = 177.7 
Hz); 59.45 (d, J = 17.0 Hz); 56.11; 32.32; 31.25 (d, J = 17.2 Hz); 24.33; 23.38 (d, J = 
10.8 Hz); 22.65.  19F NMR (282 MHz, CDCl3) δ (ppm):  -175.84 (s)  HRMS (TOF, ES+) 
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C10H20NOFS [M+H]+ calc. mass 222.1328, found 222.1326. 
 
 
(1S,2R)-2-fluorocyclohexanamine hydrochloride (1.230) 
The product was prepared by treatment of (R)-N-((1S,2R)-2-fluorocyclohexyl)-2-
methylpropane-2-sulfinamide with excess HCl in dioxane to afford analytically pure 
product as an off-white solid (98%) which was determined to have a dr of >20:1 by 19F 
NMR.  1H NMR (500 MHz, CDCl3) δ (ppm):  4.78 (br s, 1H); 3.83-3.61 (m, 1H); 3.56–
3.07 (br s, 1H); 2.68-0.70 (m, 9H).  13C NMR (125 MHz, CDCl3) δ (ppm):  55.39; 30.78; 
29.60; 28.71; 23.52; 22.91.  19F NMR (282 MHz, CDCl3) δ (ppm):  -175.98 (br s).  
HRMS (TOF, ES+) C6H12NF [M+H]+ calc. mass 118.0954, found 118.0954. 
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CHAPTER 2 
   
RAPID GENERAL ACCESS TO AZABICYCLIC RING SYSTEMS AND THE 
TOTAL SYNTHESIS OF STEMAPHYLLINE 
2.1  Introduction 
Azabicyclic ring systems are common structural subunits present in many classes 
of natural products and serve as important scaffolds in many biologically active 
compounds.1-8 Pyrrolizidine, indolizidine, pyrrolo[1,2-α]azepine, and pyrrolo[1,2-
α]azocine are examples of compounds containing an azabicyclic ring system (Figure 
2.1.1).  In general, synthetic approaches to azabicyclic ring systems are limited.  The 
existing strategies for their construction rely on Staudinger-aza-Wittig,9 7-exo-tet-
cyclizations,10,11 [5+2], [4+2], and [2+2+2] cycloadditions,12 ring-closing metathesis,13
Mitsunobu,14 and rearrangement chemistry15,16.  For the larger azabicyclic ring systems, 
routes are rare and those reported lack stereocontrol.8,17  Due to the importance of 
azabicyclic skeletons, the synthesis of these ring systems constitutes an area of current 
interest among synthetic chemists.  
Figure 2.1.1  Azabicylic ring systems. 
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2.2  Stemona Alkaloids 
Plants in the family Stemonaceae, which includes the genera Stemona, Croomia, 
Stichoneuron, and Pentastemona, are known in the Thai, Chinese, and Vietnamese 
vernacular as “Non Tai yak”, “Bai Bu”, and “Bach Bo” respectively and are often sold in 
local markets and herb shops for medicinal purposes.18  There are many species within 
this family under multiple genera, but all are commonly referred to by the same common 
names, which has led to many far-reaching conclusions about their biological activity in 
the chemical and pharmaceutical literature.  The extracts of these plants, found primarily 
in Asia, Malaysia, and northern Australia, have been used in traditional folk medicine in 
East Asia for centuries.19  Many secondary metabolites from plants in this family possess 
significant biological activities and extracts from their roots have been used to treat 
respiratory diseases (pulmonary tuberculosis, bronchitis), parasitic infections, and as 
domestic insecticides.8g   
In the period from 1975-1998, there were thirty-five known unique Stemona 
alkaloids reported in the literature.1g  Today, the Stemona alkaloids represent a class of 
approximately 140 biogenetically intriguing and structurally unique natural products 
(Figure 2.2.1).1h  
 
 
Figure 2.2.1  Selected examples of Stemona alkaloids. 
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The Stemona alkaloids are all polycyclic and most of them possess a central 
pyrrolo[1,2-a]azepine core while a few contain a pyrido[1,2-α]azepine core. Pilli and co-
workers have classified the Stemona alkaloids into 8 major groups based on common 
structural motifs and named for the most representative member within each group.  
These groups, shown in figure 2.2.2, include the stenine, stemoamide, 
tuberostemospirone, stemonamine, stemofoline, stemocurtisine, and parvistemoline 
groups, as well as a miscellaneous group, which includes some Stemona alkaloids with a 
cleaved pyrrolo[1,2-a]azepine ring system.1h   
 
 
Figure 2.2.2  Stemona alkaloid groups and their characteristic structural features. 
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 In 2006, Greger and co-workers proposed a different classification system for the 
Stemona alkaloids based on structural considerations and their various distributions in 
different species.  The three skeletal types include the stichoneurine- (also known as 
tuberostemonine-), protostemonine-, and croomine-type alkaloids.  As shown in Figure 
2.2.3, the three types can be distinguished by the different carbon chains attached to C-9 
of the pyrroloazepine core.19   
 
 
Figure 2.2.3  Greger classification of Stemona alkaloids. 
102 
 
 In the stichoneurine- and protostemonine-types the C-9 chains usually contain 
eight carbon atoms forming a terminal lactone ring, but differ from each other in the 
branching pattern.  In the croomine-type, the chain consists of only four carbons forming 
a lactone ring directly attached to C-9 in a spiro system.  The first two types contain the 
majority of compounds.  Due to their unique structural motifs, stereochemical 
arrangements and interesting biological activities, the synthesis of Stemona alkaloids has 
attracted considerable interest from the synthetic community. 
 
2.3  Biosynthesis of Stemona Alkaloids 
 The biosynthetic origin of the Stemona alkaloids is presently not well understood. 
In addition to the characteristic pyrrolo[1,2-α]azepine core, Stemona alkaloids typically 
feature an eight-carbon unit attached at C-9 (as described above) and, in most cases, a 
further substituent at C-3.  The substituent at C-9 of the azabicyclic core shows many 
variations which originate from cleaving and forming bonds to different types of 
polycyclic A/B ring systems including a series of spiro compounds, which includes the 
tuberostemospirone class of Stemona alkaloids.  In 2004, Seger and co-workers proposed 
that the common branching at C-9 and C-3 could be of terpenoid origin, leaving C3NC4 
as an additionally required unit to construct the pyrroloazepine system (Figure 2.3.1).1i  
The broad variability at C-9 can be explained by the typical Wagner-Meerwein-type 
carbon skeleton rearrangements common in terpenoid compounds. 
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Figure 2.3.1  Terpene origin of Stemona alkaloid substituents. 
 
 The formation of the core could follow a pathway similar to that of the 
pyrrolizidine alkaloids, which utilize a homospermidine (C4NC4) precursor.  In the 
biosynthesis of pyrrolizidines, the required C4NC4 building block originates from 
spermidine (C3NC4) and putrescine (NC4N) via homospermidine synthase.  Spermidine is 
biosynthesized from putrescine (which is derived from ornithine) and a C3 unit supplied 
by S-adenosyl-L-methionine.  The first step in cyclization to a pyrrolizidine system takes 
place through an oxidative deamination of the terminal CH2NH2 groups to terminal 
aldehydes.  The resulting aldehydes cyclize to the monocyclic iminium ion, followed by 
formation of the hexahydropyrrolizidine-1-carbaldehyde (Figure 2.3.2).1i 
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Figure 2.3.2  Biosynthetic origin of pyrrolizidine alkaloids 
 
 An analogous biosynthesis can be formulated for the pyrrolo[1,2-α]azepine 
system.  This is shown in the proposed biosynthesis of stemofoline.  The first cyclization 
to the iminium ion would be similar to that in the pyrrolizidine biosynthesis.  The second 
cyclization would involve nucleophilic addition of a C10 geranyl unit to the iminium ion 
resulting in the 7,5-azabicyclic ring system.  Attachment of further isoprene units 
followed by ring closures and oxidations results in the structure of stemofoline (Figure 
2.3.3).1i  However, there have been no adequate precursors found within the Stemonaceae 
family to support this proposed synthesis.20 
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Figure 2.3.3  Proposed biosynthesis of the Stemona alkaloid stemofoline. 
 
 In 2009, Greger and co-workers isolated a series of alkaloids, previously found 
only in members of the related Pandanus genus, from Stichoneuron calcicola of the 
family Stemonaceae.  Pandanamine was shown to be the precursor to series of 
pyrrolidine-type alkaloids, pandamarilactones A-D, which were also isolated from S. 
calcicola.  Additionally, pandanamine can be regarded as a precursor of the Stemona 
alkaloid croomine isolated from the genus Croomia, which is thought to be closely 
related to Stichoneuron.  Croomine-like alkaloids have been found to be widespread in 
different Stemona species.  This co-occurrence of pandanamines, croomine, and 
stichoneurin in the family Stemonaceae represents a new argument in the biogenetic 
origin of Stemona alkaloids. It was proposed that pandanamines, which originate from 
leucine and glutamate, are a biosynthetic precursor to croomine and stichoneurine 
(Scheme 2.3.4).1j 
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Figure 2.3.4 Possible biosynthetic origin of Stemona alkaloids.   
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2.4  Synthetic Approaches to Stemona Alkaloids 
In 1989 Williams and co-workers completed the first total synthesis of a Stemona 
alkaloid. In their pioneering work, the total synthesis of (+)-croomine was accomplished 
in a 24-step linear sequence from (2S)-3-(hydroxymethyl) propionate. Their strategy 
makes use of an azidoaldehyde in a Staudinger-aza-Wittig reaction to generate the 
azepine ring. The pyrrolidino-butyrolactone unit of croomine was achieved in a single 
step involving iodoamination, followed by nucleophilic anchimeric assistance by the 
vicinal tertiary amine to provide the intermediate aziridinium salt.  Capture of the salt by 
the proximate ester resulted in net retention of stereochemistry and afforded direct 
conversion to (+)-croomine (Scheme 2.4.1).9a 
 
 
Scheme 2.4.1  Staudinger-aza-Wittig approach for the synthesis of (+)-croomine. 
 
 Similar to the approach used in the total synthesis of croomine, Williams and co-
workers also accomplished the total synthesis of (-)-stemospironine and (-)-stemonine via 
a Staudinger-aza-Wittig reaction and iodine-induced double cyclization process (Scheme 
2.4.2).9b,c 
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Scheme 2.4.2 Synthesis of stemospironine and stemonine. 
 
In 1990 Hart and co-workers described a Diels-Alder approach in the first total 
synthesis of the Stemona alkaloid stenine.  The key features of the synthesis include an 
intramolecular Diels-Alder, Curtius rearrangement, an Eschenmoser-Claisen 
rearrangement, and stereoselective free-radical allylation (Scheme 2.4.3).21 
 
 
Scheme 2.4.3  Total synthesis of stenine. 
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Hart’s synthesis of stenine set the precedent for utilizing a Diels-Alder approach 
to this target.  Since the original synthesis, many other groups have embarked on a total 
synthesis of this natural product with nearly all of them making use of a Diels-Alder 
reaction as the key step to form the fused cyclohexane ring.  Of all the completed 
syntheses to date, only the route used by Wipf does not employ a Diels-Alder approach.  
Instead his synthesis utilizes a selective reduction of a π-allyl palladium complex 
(Scheme 2.4.4).22 
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Scheme 2.4.4  Other approaches to stenine. 
 
111 
 
The Diels-Alder approach has been extended to other Stemona alkaloids as well.  
Jacobi and Lee made use of an intramolecular Diels-Alder/retro-Diels-Alder reaction in 
the rapid total synthesis of (±)-stemoamide, which was obtained in 7 steps and 20% 
overall yield (Scheme 2.4.5).  The key transformation allowed for the construction of the 
entire tricyclic carbon skeleton in a single step.23 
 
 
Scheme 2.4.5  Jacobi and Lee Synthesis of (±)-stemoamide. 
  
 In several syntheses of the Stemona alkaloids, a ring-closing metathesis (RCM) is 
used to form the azepine ring.  The pioneering work in the use of RCM was that of Mori 
and co-workers.  The key step in their approach was an enyne intramolecular metathesis 
reaction.  The use of RCM for the formation of the azepine ring of (-)-stemoamide has 
been accomplished by several groups using the RCM approach, as shown in Scheme 
2.4.6.24 
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Scheme 2.4.6  Strategies toward stemoamide using an RCM approach. 
 
 In 2002, Wipf reported the total synthesis of the Stemona alkaloid (-)-
tuberostemonine in 24 steps and 1.4% overall yield. The synthesis utilizes the same 
lynchpin bicyclic system used in his previous total synthesis of stenine, which is obtained 
in three steps from L-tyrosine.  The scaffold allows for installation of nine of the ten 
stereogenic carbons of tuberostemonine, including the western fused lactone which is 
113 
 
obtained by a Claisen rearrangement and halolactonization.  This synthesis also features 
installation of the azepane ring using RCM (Scheme 2.4.7).25  
 
 
Scheme 2.4.7  Wipf’s total synthesis of (-)-tuberostemonine. 
 
2.5  Isolation of Stemaphylline and Stemaphylline-N-Oxide  
In 2009, stemaphylline and stemaphylline-N-oxide (Figure 2.5.1) were isolated 
from root extracts of Stemona aphylla plants that were collected at Mae Hong Son, 
Thailand, by Mungkornasawakul and co-workers.26  The structures were elucidated by 
extensive NMR analysis and correlation to other previously known natural products 
isolated en masse.   
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Figure 2.5.1  Stemaphylline and stemaphylline-N-oxide. 
 
The authors suggested that stemaphylline was an extensively reduced product of 
neostemonine and suggested a possible mechanism for the conversion of neostemonine to 
stemaphylline (Scheme 2.5.1).26 
 
 
Scheme 2.5.1  Proposed biosynthetic origin of stemaphylline. 
 
Biological assays of stemaphylline showed moderate acetylcholinesterase (AChE) 
inhibitory activity, moderate insecticidal activity (LC50 1,824 g/mL), and weak 
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antimicrobial activity against Escherichia coli, Staphylococcus aureus, Pseudomonas 
aeruginosa, and Candida albicans (MIC 62.5-125 μg/mL).26 
To date, there have been no reported synthetic efforts directed toward the total 
synthesis of stemaphylline and stemaphylline-N-oxide.  
 
2.6  Previous Work Towards the Total Synthesis of Stemaphylline 
Due to the unique properties of azabicyclic-containing natural products, our lab 
became interested in the development of a general and asymmetric synthesis for the 
construction of azabicyclic ring systems and its application towards the total synthesis of 
stemaphylline and other biologically interesting natural products. Relying on our 
previously developed work on the enantioslective synthesis of N-alkyl aziridines,27 we 
envisioned a Lewis acid mediated aziridine ring opening followed by a reductive 
amination/RCM sequence to access various ring sizes of the azabicylic skeleton (Scheme 
2.6.1).  
 
 
Scheme 2.6.1  Azabicyclic ring skeleton via N-alkyl aziridines. 
 
Based on the proposed approach to azabicyclic ring systems, we then developed a 
retrosynthesis for stemaphylline. The retrosynthetic analysis is outlined in Scheme 2.6.2. 
The lactone and 7-membered azepine rings could be installed via RCM. The pyrrolidine 
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ring would be constructed by ring opening of the aziridine and subsequent reductive 
amination. 
 
 
Scheme 2.6.2  Retrosynthetic analysis of stemaphylline. 
 
Previous attempts at the synthesis of stemaphylline in our lab began with the 
preparation of the desired N-alkyl terminal aziridine (Scheme 2.6.2).  Starting from 4-
(benzyloxy)butanoic acid, acylation of pseudoephedrine with the mixed anhydride of the 
carboxylic acid derived from pivaloyl chloride followed by auxiliary-controlled 
asymmetric α-alkylation gave the desired alkylated product in 96% yield.  A two-step 
protocol involving reduction with lithium amidotrihydroborate (LiH2NBH3, LAB) 
followed by Swern oxidation proceeded to give the aldehyde in 96% yield (Scheme 
2.6.3).26  
 
  
Scheme 2.6.3  Synthesis of aldehyde 2.92. 
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 The aldehyde was subjected to a Horner-Wadsworth-Emmons reaction28 with a 
chiral imide prepared from Evan’s oxazolidinone (Scheme 2.6.4)29 to give the E-enone in 
97% yield.30 1,4-Conjugate addition with allyl cuprate afforded the desired addition 
product in 95% yield (dr=10:1).31  Reductive cleavage of the oxazolidinone with LiBH4 
gave the desired primary alcohol in 98% yield, followed by a Swern oxidation of the 
alcohol to give the required aldehyde in 92% yield. Application of the three-step, one-pot 
aziridine protocol provided the 4-epi-aziridine in 27% yield (3:1 dr) (Scheme 2.6.4).  
 
 
Scheme 2.6.4  Synthesis of 4-epi-aziridine 2.95. 
 
Encouraged by the progress in the synthesis of the key 4-epi-aziridine precursor, 
members of our lab attempted to advance model system aziridines to their corresponding 
azabicyclic frameworks.  Regrettably, every attempt to ring-open the aziridines to the 
corresponding amines led to complex mixtures. Additionally, using various Lewis acid 
catalysts failed to give the desired product (Scheme 2.6.5). Since the aziridine route 
proved to be problematic, it was decided to switch to an alternate route. 
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Scheme 2.6.5  Failed aziridine ring opening. 
 
2.7  Approach to Azabicyclic Ring Systems via Chiral Sulfinamides  
Our new route was inspired by Ellman’s synthesis of chiral 2-substituted 
pyrrolidines (Scheme 2.7.1).  In his work, it was observed that the addition of (2-(1,3-
dioxan-2-yl)ethyl)magnesium bromide proceeded with the opposite sense of induction 
typically observed for Grignard additions to sulfinyl aldimines.32,33   
 
 
Scheme 2.7.1  Synthesis of chiral 2-substituted pyrrolidines. 
 
We envisioned using a newly developed protocol involving asymmetric Grignard 
addition or indium-mediated allylation to the N-sulfinyl aldimine followed by N-
alkylation, RCM, and finally an intramolecular reductive amination or cyclization to 
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afford enantiopure azabicyclic ring skeleton. Our new approach to azabicyclic rings is 
outlined in Scheme 2.7.2.  
 
 
 
Scheme 2.7.2  Enantioenriched azabicyclic rings via chiral sulfinamides. 
 
To test the viability of the above strategy, an azepine skeleton was prepared in 
excellent enantiopurity starting from 4-propenal (Scheme 2.7.2). The N-sulfinyl 
aldimines were prepared by condensation of the aldehydes in the presence of Ti(OEt)4.  
Addition of Grignard reagent into the N-sulfinyl aldimine gave the desired sulfinamide in 
88% yield and high diastereoselectivity (9:1 dr). The sulfinamide was isolated as a single 
diastereomer using silica-gel column chromatography. N-alkylation with allyl bromide 
yielded acetal 2.106 as single diastereomer. As previously noted by Ellman, the addition 
of the acetal Grignard reagent to the N-sulfinyl aldimine proceeded with the opposite 
sense of induction compared to that observed for other Grignard reagents.  This was later 
confirmed through an X-ray crystal structure in the synthetic efforts towards the natural 
product (+)-amabiline in our lab.34  RCM followed by acidic deprotection of the 
sulfinamide protecting group and acetal cleavage effected the cyclization, which upon 
reduction of the resulting iminium ion with triethyl silane gave the desired azepine ring in 
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86% yield (Scheme 2.7.2).  This methodology was further developed in our lab and 
applied towards the general synthesis of azabicyclic ring systems and the application 
towards the total synthesis of several other natural products.35,36 
 
2.8  Progress Towards the Total Synthesis of Stemaphylline via Chiral Sulfinamides 
With the model ring systems in place, we went on to apply this new methodology 
to the total synthesis of stemaphylline.  Outlined in Scheme 2.8.1 is our new 
retrosynthetic analysis of stemaphylline.  
 
 
 
Scheme 2.8.1  Retrosynthetic analysis of stemaphylline using chiral sulfinamides. 
 
In the new approach, the azepane ring and the western lactone could be installed 
through a tandem ring-closing metathesis reaction.  The 5-membered ring of the 
azabicycle would be installed via asymmetric Grignard addition and an acid mediated 
global deprotection/intramolecular reductive amination protocol.  The sulfinamide would 
be obtained from diene 2.109, while the C-10 and C-9 stereochemistry would be installed 
by asymmetric 1,4-conjugate addition and allylation of commercially available chiral 
camphor sultam (Scheme 2.8.1). 
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Conjugate addition of allyl cuprate into the acylated Oppolzer sultam in the 
presence of lithium chloride and chlorotrimethylsilane provided olefin 2.111 in 91% yield 
and 97:3 dr.  Cross metathesis with bis-silyl diol 2.112 in the presence of Grubbs second 
generation catalyst gave exclusively the isomerized product 2.113 in 75% yield (Scheme 
2.8.2).  
Recently, Grubbs and co-workers reported that using 10 mol% 1,4-benzoquinone 
as an additive prevents olefin isomerization of a number of allylic ethers and long-chain 
aliphatic alkenes during olefin metathesis reactions with ruthenium catalysts.37 
Accordingly, performing the reaction in the presence of 10 mol% 1,4-benzoquinone gave 
the desired cross metathesis product, which was subsequently subjected to stereoselective 
α-allylation with potassium bis(trimethylsilyl)amide (KHMDS) and 
hexamethylphosphoramide (HMPA) to give diene 2.114 in 78% yield for 2 steps 
(Scheme 2.8.2). 
 
 
Scheme 2.8.2  Synthesis of sultam. 
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The sultam was reductively cleaved with LAH and oxidation of the resulting 
primary alcohol via Ley oxidation furnished the desired aldehyde in 71% over 2 steps. 
The N-sulfinyl aldimine was cleanly prepared by condensation with (S)-tert-
butanesulfinamide in the presence of Ti(OEt)4 in 86% yield (Scheme 2.8.3).   
 
 
Scheme 2.8.3  Synthesis of sulfinimine 2.116. 
 
Addition of (2-(1,3-dioxan-2-yl)ethyl)magnesium bromide to the chiral aldimine 
afforded the addition product in 75% yield but, unfortunately, in 1:1 dr.  By switching to 
the opposite (R)-tert-butanesulfinamide, the product could be obtained in comparable 
yields but in 9:1 dr in favor of the undesired diastereomer (Scheme 2.8.4). 
 
 
Scheme 2.8.4  Grignard addition to chiral aldimine. 
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This match/mismatch reactivity can be explained through the transition state for 
the Grignard addition.  Several early studies revealed the effects of solvent, metal, and 
additives on the selectivity in additions of organometallic additions to unfunctionalized 
N-tert-butanesulfinyl aldimines.33,38  Based on these studies, Ellman and co-workers 
proposed two transition state models to explain the stereochemical outcome of these 
reactions (Scheme 2.8.5).  
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Scheme 2.8.5  Transition states for addition to aldimines. 
 
 A standard Grignard addition proceeds with “Ellman control” in a 6-membered-
chelate transition state.  In cases where the imine or Grignard reagent contains a 
heteroatom that can coordinate the magnesium, the chelate transition is disrupted and the 
reaction proceeds through the open transition state (Scheme 2.8.5).  It is known that the 
(2-(1,3-dioxan-2-yl)ethyl)magnesium bromide adds with “Anti-Ellman” control.  This 
can be explained through an intramolecular, 5-membered chelation of the magnesium by 
the oxygen atoms of the acetal.  This coordination disrupts the ability of the magnesium 
to coordinate to the sulfinamine causing the addition to proceed through the open 
transition state.   
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Beginning with substrate 2.116 using the (S)-tert-butanesulfinamide, and 
proceeding through the open transition state, attack from the re face of the imine is 
blocked by the tert-butyl group of the sulfinimine.  However, attack from the si face of 
the imine is also hindered by the alpha-allyl group, and an attack from this face results in 
anti-Felkin addition product. The directing effect of the chiral tert-butanesulfinamide 
auxiliary is mismatched with the directing effects of substrate 2.116 and results in the 
observed poor selectivity.  When (R)-tert-butanesulfinamide is used, a matched case is 
observed.  The re face is accessible since the allyl and tert-butyl groups are both blocking 
the si face between the control of the chiral auxiliary and Felkin-Ahn control. This results 
in good selectivity for the undesired diastereomer (Scheme 2.8.6). 
 
 
Scheme 2.8.6  Stereochemical outcome of Grignard addition to aldimine. 
 
Despite the poor selectivity for the Grignard addition, the diastereomers were 
separable by column chromatography.  Therefore, we elected to move forward to the 
epoxidation/Appel/ring-opening sequence to obtain the desired secondary allylic alcohol.  
Following TBAF deprotection of the allylic alcohol, the desired diastereomer of the 
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resulting allylic alcohol was subjected to Sharpless epoxidation conditions.  The desired 
epoxide was cleanly formed in 95% yield.  Unfortunately, attempts at the Appel reaction 
and subsequent elimination/ring-opening of the epoxide resulted in complex mixtures of 
products (Scheme 2.8.7).   
 
 
 
Scheme 2.8.7  Failed completion of stemaphylline via chiral sulfinamides. 
 
With poor selectivity in the Grignard addition and no reaction in the subsequent 
epoxidation, we decided to explore a new route to the natural product. 
 
 2.9  Progress Towards Stemaphylline Via Indium-Mediated Allylation 
 Our new route was inspired by the work of Lin and co-workers on indium-
mediated allylations in aqueous sodium bromide and our previous application of this 
methodology in the preparation of chiral β-fluoroamines.39,40   
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Scheme 2.9.1  Indium-mediated allylation. 
 
 Based on this work, we designed a route to stemaphylline making use of a 
complex allylic bromide to install the stereochemistry at C-9 and C-9a.  Outlined in 
Scheme 2.9.2 is our new retrosynthetic analysis of stemaphylline. 
 
 
Scheme 2.9.2  Retrosynthetic analysis of stemaphylline via indium-mediated allylation. 
  
To test the viability of the above strategy, a model azabicyclic skeleton was 
prepared in excellent enantiopurity starting from 6-chloro-1-hexanal (Scheme 2.9.3).      
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Scheme 2.9.3  Rapid, general synthesis of azabicyclic ring systems 
 
The chloroalkyl N-(tert-butanesulfinyl)aldimine was easily prepared in 94% yield 
by condensing the corresponding chloroaldehyde with the Ellman (S)-tert-
butanesulfinamide.  A subsequent indium-mediated allylation reaction afforded the 
anticipated product in >9:1 diastereoselectivity and 86% yield.  Acid-mediated liberation 
of the primary amine followed by base-induced, microwave-assisted cyclization and 
alkylation with allyl bromide smoothly afforded the chiral N-alkyl azepane in 65% yield 
for the three-step, one-pot reaction sequence.   A survey of the literature regarding RCM 
methods with tertiary amines suggested that protection of the amine by in situ generation 
of ammonium salts enabled facile ring-closing.41  Thus, treatment of diene 2.137 with 
trifluoroacetic acid (TFA) in toluene, followed by the addition of  Grubbs II and 
microwave heating for 1 hour at 100 oC,  provided the unsaturated pyrido[1,2-α]azepine 
ring system in 68% isolated yield and 35% overall yield from commercially available 
starting materials. 
Previous efforts in our lab towards the enantioselective synthesis of azabicyclic 
ring systems provided a notable advance over current literature but did have some 
128 
 
significant drawbacks, including the need for different transformations depending on the 
desired ring size, inconsistencies in alkylation of the tert-butanesulfinyl nitrogen, and the 
lack of ability to access multiple rings from a single lynchpin intermediate.  Encouraged 
by the results of our model system, we opted to develop this into a general methodology 
that would allow rapid access to diverse small to large azabicyclic ring systems (Scheme 
2.9.4). 
 
 
 
Scheme 2.9.4  Envisioned route to access diverse 1-azabicyclo[m.n.0]alkane cores. 
  
  Following the same method described above for the model system, the 
chloroalkyl N-(tert-butanesulfinyl)aldimines were easily prepared in 92-94% yields by 
condensing the corresponding chloroaldehydes with the Ellman (S)-tert-
butanesulfinamide.  A subsequent indium-mediated allylation reaction afforded the 
anticipated (R)-anti-adducts in >9:1 diastereoselectivity and 85-86% yield.  Acid-
mediated deprotection and base-induced, microwave-assisted cyclization and alkylation 
with the required allyl, butenyl and pentenyl bromides smoothly afforded the chiral N-
alkyl ring systems in 63-83% yields for the three-step, one-pot reaction sequence 
(Scheme 2.9.5). 
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Scheme 2.9.5  Enantioselective synthesis of N-alkyl rings. 
 
Yields for the RCM reaction averaged 70% for all the substrates, providing high-yielding, 
enantioselective access to each of the  1-azabicyclo[m.n.0]alkane systems.  Overall yields 
from the commercial chloroaldehydes ranged from 29-59%. This work provides a general 
route to access these important azabicyclic ring systems with an embedded olefin handle 
for further functionalization (Figure 2.9.1).42 
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Figure 2.9.1  Mono-unsaturated 1-azabicyclo[m.n.0]alkane ring systems. 
 
 
 Once the conditions for the methodology were optimized, we moved on to its 
application in the total synthesis of stemaphylline.  The required chloroalkyl N-(tert-
butanesulfinyl)aldimine was easily prepared from the corresponding alcohol in 93% yield 
(Scheme 2.9.5).  We then shifted our focus towards the synthesis of the required complex 
allylic bromide for the indium-mediated allylation. 
 The synthesis of the allylic bromide emanated from a Myers alkylation of 
(1R,2R)-(−)-pseudoephedrinepropionamide with TBDPS protected iodoethanol which 
proceeded in 83% yield.  Reductive cleavage of the chiral auxiliary and subsequent Ley 
oxidation to the corresponding aldehyde gave the chiral, α-methyl aldehyde in 65% yield 
over two steps.  The aldehyde was subjected to a Horner-Wadsworth-Emmons olefination 
with triethyl phosphonoacetate to give the α,β-unsaturated ester in 81% yield.  Reduction 
of the ester to the allylic alcohol with diisobutylaluminum hydride (DIBAL) followed by 
an Appel reaction afforded the allylic bromide in 89% yield over two steps (Scheme 
2.9.7). 
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Scheme 2.9.6  Synthesis of allylic bromide. 
 
 With the allylic bromide in hand we attempted the indium-mediated allylation on 
the chloroalkyl imine.  Regrettably, the allylation resulted in only starting material after 
stirring for 3 days at room temperature, and only about 5% conversion to product by 
LCMS after heating for an additional 3 days with no isolatable product (Scheme 2.9.8).   
 
 
Scheme 2.9.7  Attempted indium-mediated allylation in route to stemaphylline. 
 
 Based on these results, we decided to perform a screen of allylic bromides to test 
the limits of the indium-mediated allylation.  Using crotyl bromide, we found that the 
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indium-mediated allylation smoothly provided the allylated product in 91% yield.  When 
1-bromo-4-methylpent-2-ene was used, the allylated product was obtained in only 6% 
isolated yield.  This indicated that when branching is introduced into the allylic bromide 
at the 4-position the reactivity is greatly reduced (Scheme 2.9.9).   Based on these results 
we chose to explore a new way to intercept the same intermediates from the indium route. 
 
 
Scheme 2.9.8  Effect of olefin substitution on indium-mediated allylation. 
 
2.10  Stemaphylline Via Tandem [2,3]-Wittig/Oxy-Cope Rearrangement 
 After the unsuccessful indium addition, we explored ways to access intermediate 
2.132 using different chemistry, as we felt that the later steps in that route were feasible.  
This led us to start from the chiral pool using L-proline, eliminating the need to 
synthesize the pyrrolidine ring of the pyrrolo[1,2-α]azepine core and allowing us to start 
with the stereocenter at C-9a already set.  Greeves and co-workers have shown that bis-
allylic ethers can undergo a stereoconvergent, one-pot tandem [2,3]-Wittig/anionic oxy-
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Cope rearrangement to give δ,ε-unsaturated aldehydes.43  Based on this precedent, we 
designed a route to stemaphylline using this tandem rearrangement starting from L-
prolinol to access the aldehyde intermediate 2.176.  Outlined in Scheme 2.10.1 is our new 
retrosynthetic analysis of stemaphylline using this method. 
       
 
Scheme 2.10.1  Retrosynthetic analysis of stemaphylline via tandem rearrangement. 
 
 We began our synthesis from commercially available Z-L-prolinol.  Oxidation of 
the alcohol to the aldehyde via Swern oxidation proceeded smoothly in 99% yield.  
Addition of vinyl Grignard followed by alkylation of the resulting allylic alcohol with 
crotyl bromide generated the requisite bis-allylic ether needed for the tandem 
rearrangement in 57% yield over two steps (Scheme 2.10.2). 
 
 
Scheme 2.10.2  Synthesis of bis-allylic ether. 
 
134 
 
 After successfully preparing the bis-allylic ether, we attempted the tandem 
rearrangement sequence.  Disappointingly, after screening multiple sets of conditions 
(bases, solvents, temperatures, N-protecting groups), we were unable to achieve the 
rearrangement and observed only decomposition of starting material (Scheme 2.10.3). 
 
 
 
Scheme 2.10.3  Tandem rearrangement in route to stemaphylline. 
 
 After very briefly exploring other routes, we chose to go back to our most 
successful route to date using chiral sulfonamides and try to solve the problems with 
setting the stereochemistry at the allylic alcohol and amine stereocenter. 
 
2.11  Total Synthesis of Stemaphylline Via Chiral Sulfonamides, Revisited 
 In order to solve some of the problems we encountered in the previous 
sulfonamide route, we wanted to design a synthesis of stemaphylline in which the 
stereocenter at C-12 was set early in the synthesis.  Due to the reversal in selectivity of 
the Grignard addition using (2-(1,3-dioxan-2-yl)ethyl)magnesium bromide, we preferred 
to use a Grignard that would proceed through normal “Ellman” selectivity. 
 In the new approach, the azabicyclic ring system could be closed through a 
tandem reductive amination in conjunction with a lactol ring closure.  The required tris-
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aldehyde intermediate could be generated from a hydroformylation reaction on the 
corresponding triolefin.44  The remaining C-9 and C-10 stereocenters could be set 
through an oxazolidinone-controlled α-alkylation and conjugate addition respectively 
while C-12 could be installed through a Nagao-type acetate aldol reaction (Scheme 
2.11.1).45-47 
 
 
 
Scheme 2.11.1  Retrosynthetic analysis of stemaphylline using hydroformylation. 
 
To test the feasibility of the hydroformylation reaction, a model system was 
constructed to form a simple azabicyclic ring system.  Starting from 4-pentenal, 
condensation with (S)-tert-butanesulfinamide followed by addition of vinyl Grignard and 
deprotection of the amine afforded the chiral dienamine 2.186 in 73% yield and 4:1 dr.  
Treatment of the amine with Rh(acac)(CO)2 and biphephos under 1000 psi of 1:1 H2/CO 
(syngas) at 80 oC for 24 hours cleanly gave the saturated pyrrolo[1,2-α] azepine ring 
system in 26% yield for the six-step, one-pot sequence (Scheme 2.11.2).  Studies towards 
further development of this methodology are ongoing in our lab. 
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Scheme 2.11.2  Hydroaminomethylation model system. 
 
 With encouraging results in the model system, we proceeded with the application 
of this methodology towards the synthesis of stemaphylline.  Starting from (4R)-3-acetyl-
4-isopropyl-1,3-thiazolidine-2-thione, an acetate aldol reaction with acrolein gave the 
aldol product in 90% yield and 5:1 dr.47  The desired diastereomer can be separated via 
silica chromatography in up to 75% yield.  Protection of the secondary alcohol as the tert-
butyldiphenylsilyl (TBDPS) ether proceeded in 95% yield.  Reductive cleavage of the 
auxiliary with LiBH4 afforded the chiral 1,3-diol 2.189 in 93% yield (Scheme 2.11.3) 
 
 
Scheme 2.11.3  Synthesis of 1,3-diol 2.189. 
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 Swern oxidation of the primary alcohol 2.189 afforded the aldehyde in 98% yield, 
which was then subjected to mild Horner-Wadsworth-Emmons olefination conditions 
with triethyl phosphonoacetate and DBU to give the α,β-unsaturated ether ester in 90% 
yield.  Hydrolysis of the ester with LiOH to carboxylic acid 2.191 proceeded in up to 
90% yield (81% over 2 steps) (Scheme 2.11.4).   
 
 
Scheme 2.11.4  Synthesis of α,β-unsaturated carboxylic acid 2.191. 
 
 Coupling of the Evans (R)-4-phenyl-2-oxazolidinone auxiliary to the acid 
followed by conjugate addition using  Li[MeCuI]/TMSI, (obtained from MeLi and CuI-
0.75DMS) gave the anti-s-cis conformation of the methyl group in 90% yield and 17:1 
dr.46  Directed installation of the alpha allyl group by the same auxiliary proceeded in 
87% yield and 15:1 dr (Scheme 2.11.5).45   
 
 
Scheme 2.11.5  Installation of C-9 and C-10 stereocenters. 
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 Attempts at reductive cleavage of the auxiliary using LiBH4 afforded the desired 
alcohol in only 30% yield (Scheme 2.11.6).   
 
 
Scheme 2.11.6  Cleavage of oxazolidinone auxiliary. 
 
  In order to more efficiently make use of our material at this stage, we opted to use 
a two-step removal of the oxazolidinone in an attempt to obtain the alcohol in better 
yields.  Hydrolysis of the oxazolidinone to the carboxylic acid with LiOH and H2O2 
followed by reduction of the acid with LAH afforded the desired alcohol in 80% yield 
over two steps, a drastic improvement over the single step reduction.  Oxidation of the 
alcohol using Ley oxidation conditions provided the aldehyde in 85% yield.  Condensation 
with (R)-tert-butanesulfinamide provided the chiral imine in 81% yield (69% over two 
steps) (Scheme 2.11.7). 
 
 
Scheme 2.11.7  Synthesis of chiral imine 2.195. 
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 Addition of vinyl Grignard to the imine proceeded in a moderate 65% yield and 
1:1 diastereoselectivity with the diastereomers separable by column chromatography 
(Scheme 2.11.8).   
 
 
Scheme 2.11.8 Grignard addition to sulfinimine. 
 
 In an attempt to improve the selectivity for the desired diastereomer, we 
investigated other ways to set the amine stereocenter.  Attempts at preparation of the 
Weinreb amide directly from oxazolidinone 2.193 through a transamination reaction with 
AlMe3 resulted in production of the 1,2-amino alcohol formed as a result of ring opening 
of the oxazolidinone, rather than the desired Weinreb amide (Scheme 2.11.9).  
 
 
 
Scheme 2.11.9  Ring opening of oxazolidinone. 
 
 This unexpected result, however, proved to be beneficial.  The amino alcohol 
could be crystallized from MeCN/H2O to yield X-ray suitable crystals. Crystals were 
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obtained as thin, colorless needles. Due to significant positional disorder in the structure, 
diffraction quality was poor at high angles requiring the use of a rotating-anode to obtain 
sufficient completeness for determination of the absolute structure. The molecule 
crystallized in the orthorhombic space group P212121 with 2 molecules in the asymmetric 
unit. The absolute configuration was determined with a Flack parameter of -0.0032, with 
an e.s.d. of 0.0383. (Figure 2.11.1). 
 
 
Figure 2.11.1  X-ray crystal structure of amino alcohol 2.195. 
 
 
 We successfully synthesized the Weinreb amide from carboxylic acid 2.197 in 
85% yield.  Addition of vinyl Grignard to the Weinreb amide cleanly afforded the 
terminal vinyl ketone 2.198 in 77% yield.  Condensation with (R)-tert-butanesulfinamide 
yielded the chiral ketimine in poor yields, up to 24%.  Attempted reduction of the 
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ketimine with L-selectride resulted in 1,4-reduction of the terminal olefin, followed by 
1,2-reduction of the imine (Scheme 2.11.10). 
 
 
Scheme 2.11.10  Attempted selective ketimine reduction. 
 
 In order to test the key hydroformylation step, the material was carried forward 
with the 1:1 selectivity observed with addition of vinyl Grignard to the sulfinimine as 
shown in Scheme 2.11.8.  Deprotection of the alcohol with TBAF cleanly afforded the 
allylic alcohol in 91% yield.  All attempts to liberate the amine under standard acidic 
conditions resulted in elimination of the allylic alcohol.  All efforts to deprotect the amine 
with the alcohol protected as the TBDPS silyl ether also resulted in complex mixtures of 
products with the primary product being a result of elimination (Scheme 2.11.11). 
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Scheme 2.11.11  Attempted global deprotection 
 
 In an attempt to improve the selectivity at the amine stereocenter and eliminate 
the need for an acidic deprotection of the amine, vinyl Grignard was added through 
Felkin-Ahn control to aldehyde 2.203 to give the allylic alcohol 2.204 in 87% yield and 
7:1 dr (Scheme 2.11.12). 
 
 
Scheme 2.11.12  Felkin-Ahn controlled addition to aldehyde 2.203. 
 
 We then explored ways to convert the alcohol to a leaving group and displace it 
with an amine nucleophile.  Unfortunately, after converting the alcohol to the tosylate, 
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mesylate, and triflate derivatives, only SN2' products were recovered upon treatment with 
a number of amine nucleophiles (Scheme 2.11.13).   
 
 
Scheme 2.11.13  Attempted SN2 displacement of allylic alcohol 2.204. 
 
Treatment of alcohol 2.204 under Mitsunobu conditions, using phthalimide as the 
nucleophilic functional group, resulted in a low yield of the desired amine product.  This 
reaction proved to be unreliable, as product was not always obtained and yields were 
inconsistent and low (Scheme 2.11.14). 
 
OHTBDPSO NTBDPSON
N
O
R
O
R
PPh3, THF
R = Et
i-Pr
Pip
2.204 2.206
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OO
up to 25% yield
7:1 dr  
Scheme 2.11.14  Attempted amine incorporation via Mitsunobu conditions. 
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 Treatment of alcohol 2.204 under the same Mitsunobu conditions using 
diphenylphosphoryl azide (DPPA) resulted in an 85% yield of a product with the correct 
mass by LCMS.  NMR analysis revealed the presence of only 8 vinylic protons, 
suggesting that once the azide was incorporated, it underwent a [3,3]-sigmatropic 
rearrangement to give the terminal allylic azide (Scheme 2.11.15). 
 
 
Scheme 2.11.15  [3,3]-sigmatropic rearrangement of allylic azide 
 
Encouraged by the selectivity in the Grignard addition to the aldehyde, we sought 
to eliminate the possibility of the SN2' addition product. Therefore, we abandoned the 
hydroformylation approach by returning to the use of (2-(1,3-dioxan-2-
yl)ethyl)magnesium bromide as a nucleophile and subsequent acid mediated ring closure 
of the pyrrolidine ring.  Felkin-Ahn-controlled addition to the aldehyde proceeded in 84% 
yield and >20:1 dr.  Displacement of the alcohol under Mitsunobu conditions using 
diphenylphosphoryl azide (DPPA) afforded the secondary azide in only 26% yield.  
TBAF deprotection of the allylic alcohol followed by acylation with methacrylic 
anhydride gave the α,β-unsaturated ester in 71% yield over two steps (Scheme 2.11.16). 
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Scheme 2.11.16  Mitsunobu installation of the azide. 
 
 Initial attempts at reducing the azide through Staudinger reduction conditions 
resulted in only starting material.  A survey of other known azide reduction conditions 
resulted in either recovery of starting material or complex mixtures of products.48  A 
reduction of the azide using sodium-mercury amalgam in refluxing ethanol resulted in 
only trace amounts of the amine after heating for 24 hours (Table 2.11.1).49 
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Table 2.11.1  Survey of azide reduction conditions. 
 
 
 With poor, inconsistent yields in the azide installation and slow progress in its 
reduction, we opted to return to the original installation of the amine stereocenter through 
Grignard addition to the Ellman sulfinimine.  Even with 1:1 selectivity, the ability to 
separate the diastereomers would afford more of the desired amine product than the 
multi-step azide installation/reduction sequence.   
 Addition of (2-(1,3-dioxan-2-yl)ethyl)magnesium bromide proceeded in good 
yield (84%) and 1:1 dr.  Upon further investigation, we found that Ellman and co-workers 
had reported some success in improving their diastereoselectivity in Grignard additions to 
sulfinimines by forming the Grignard reagents in Et2O rather than THF in order to reduce 
the chelating ability of the solvent.33  Unfortunately, we found that (2-(1,3-dioxan-2-
yl)ethyl)magnesium bromide does not readily form in Et2O.  Instead of using Et2O, we 
sought to reduce the amount of THF in the reaction by forming the Grignard at 3.0 M 
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concentration, a three-fold increase from the 1.0 M concentration used previously.  While 
the Grignard reagent will form at this high concentration, it was observed to partially 
precipitate out of solution.  Addition of the 3.0 M Grignard to a solution of sulfinylimine 
in CH2Cl2 (0.2 M) resulted in a slight increase in diastereoselectivity (1.5:1); however, 
this selectivity was in favor of the undesired diastereomer.  We subsequently found that 
the Grignard reagent could form cleanly in 2-methyltetrahydrofuran at a concentration of 
3.0 M, resulting in a further increase in selectivity for the undesired diastereomer to 2.5:1.  
Additional dilution of the sulfinylimine in CH2Cl2 to 0.1 M resulted in an 86% overall 
yield with 4:1 selectivity in favor of the undesired diastereomer.  These results suggest 
that non-coordinating solvents may deteriorate or reverse the selectivity of the Ellman 
chiral auxiliary in this case (Table 2.11.2).   
 
Table 2.11.2  Grignard addition to sulfinimine. 
 
 
 Unable to improve the selectivity for the desired Grignard addition product, we 
moved forward with our effort toward the total synthesis of stemaphylline.  Silyl 
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deprotection of the allylic alcohol with TBAF followed by acylation with methacrylic 
anhydride gave the α,β-unsaturated ester in 80% yield over two steps (Scheme 2.11.17).  
We then focused on a one-pot sequence involving global deprotection/cyclization of the 
amine and the acetal, reductive amination, and alkylation to give the N-allyl pyrrolidine 
ring.  Treatment with 95:5 TFA/H2O at room temperature for 5 min followed by removal 
of the solvent in vacuo gave the crude imine.  Resuspension in 1,2-dichloroethane (DCE) 
followed by addition of polymer-supported triacetoxyborohydride (PS-BH(OAc)3) and 
rotation for 3 hours gave the saturated pyrrolidine ring.  After filtration (to remove the 
polymer supported reagent) and concentration, the crude pyrrolidine was resuspended in 
DMF, followed by addition of allyl iodide and K2CO3.  After stirring for an additional 3 
hours, the reaction was quenched and purified to give the N-allyl pyrrolidine in 47% yield 
for the 5-step, one-pot sequence (Scheme 2.11.17).  The corresponding stereoisomer 
bearing the opposite amine stereocenter was also synthesized in an analogous fashion 
with similar yields (Scheme 2.11.18). 
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Scheme 2.11.17  Synthesis of tandem-RCM precursor. 
 
 
Scheme 2.11.18  Synthesis of C-9a epimeric tandem-RCM precursor. 
 
150 
 
 With the allyl-pyrrolidine in hand, we were ready to attempt the tandem ring-
closing metathesis reaction to close the 7-membered ring of the azabicyclic core and the 
α,β-unsaturated gamma lactone.  Having larger quantities of the undesired pyrrolidine 
from our studies on the asymmetric Grignard addition, we chose to first explore the 
tandem ring closing metathesis with this substrate.  It is well established in the literature 
that compounds containing basic nitrogen atoms are problematic substrates for olefin 
metathesis.  It is assumed that the basic nitrogen can coordinate to the metal center and 
interfere with catalytic activity.  In our previous work on the formation of azabicyclic 
ring systems, we circumvented this by forming the TFA salt of our tertiary amines.42  
This allowed for the successful closure of rings of varying sizes using Grubbs second 
generation catalyst.  Initial attempts using 1.0 eq of TFA and 10 mol% of Grubbs II at   
40 oC overnight resulted in a single ring closure observable by LCMS.  An additional 10 
mol% was added and the reaction was heated to 80 oC, after which the major product was 
still from the mono-ring closure with only a hint of a bis-closure product visible by 
LCMS.  Unfortunately, attempts to isolate this bis ring closure product by reverse-phase 
chromatography were unsuccessful.   
 Grela and co-workers reported a catalyst, related to that of Hoveyda, with 
improved reactivity and mild reaction conditions for challenging ring closing metathesis 
reactions, including a protected nitrogen-containing azepane ring and a trisubstituted α,β-
unsaturated δ lactone.  This catalyst was easily obtained in a three-step synthesis (Scheme 
2.11.19) and was shown to operate under very mild conditions (0 oC to room 
temperature).50   
 
151 
 
 
Scheme 2.11.19  Synthesis of Grela catalyst. 
 
Encouraged by these findings, we prepared this catalyst and applied it in our tandem ring 
closing metathesis.   
 We found that 15 mol% of the Grela catalyst in toluene at room temperature was 
optimal to obtain the single ring closure product after stirring overnight.  Initial NMR 
studies of the single ring closure product clearly showed the presence of both vinylic 
protons of the methacrylate group, which indicated that the lactone ring had not closed 
first.  As shown in Figure 2.11.2, there are two competing 7-membered rings that could 
form in the RCM of tetraolefin 2.219.  We hoped that the more sterically accessible 
olefins (C-6 and C-7) would close preferentially (2.224) over the 7-membered ring 
between C-7 and C-13 (2.223).  2-D NMR analysis supported the assignment of ring 
closure between C-6 and C-7, indicated by the presence of signals between C-7 and C-5 
(HMBC, TOCSY), which would not be present in azepine 2.223.  We also did not 
observe a signal between C-7 and C-12, further supporting the presence of the 
pyrrolo[1,2-α]azepine ring system.   
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Figure 2.11.2  Possible ring closures and their key 2D-NMR correlations. 
 
 Encouraged by the results of the single ring closure, we then added an additional 
25 mol% catalyst and heated the reaction to 90 oC with continued stirring for 24 hours. 
By this method, we were able to obtain the product of tandem ring closure (2.225) in 26% 
isolated yield after purification via reverse phase chromatography.   
 With this result, we next studied the effect of the acid on the closure of the 
azepine ring, examining acids with a range of pKa values (see Table 2.11.3).  Without an 
acid additive, the reaction did not progress.  CSA, possessing a pKa value in the middle 
of the acids surveyed, was found to provide the greatest degree of conversion as 
measured by LC/MS (entry 5).  Doubling the amount of CSA to 2 equiv was found to 
greatly improve the efficiency of the reaction (entry 6), resulting in complete 
consumption of tetraene within 6 h and affording 65% isolated yield of pyrroloazepine 
2.224.    
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Table 2.11.3  Acid screen for tandem ring closing reaction. 
 
 With optimized conditions for closure of the azepine ring, we applied these 
conditions (Table 2.11.3, entry 6) to the tandem ring closure of tetraene 2.219, heating 
the reaction to 90 oC after complete conversion to 2.224.  While conversion to bis-ring 
closure product was observed by LC/MS (~20% conversion), the use of additional 
catalyst (2 x 10 mol%) and extended heating was required for full conversion of 2.224 to 
2.225.  A small selection of metathesis catalysts were screened with these optimized 
conditions (Hoveyda Grubbs II, Zhan 1B, Grubbs II, Schrock catalyst).  Grela catalyst 
and Hoveyda Grubbs II were found to be optimal and exhibited comparable activity.  
Thus, reaction of tetraene 2.219 in the presence of CSA (2 equiv) and Grela catalyst 
2.222 (3 x 10 mol%) afforded 2.225 in 52% isolated yield (Scheme 5).  Full 2-D NMR 
characterization of 2.225 supported our structural assignment of the tandem ring closure 
product. 
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Scheme 2.11.20  Bis ring-closing metathesis of epimeric tetraene. 
 
 As shown in Scheme 2.11.21, intermediate 2.225 was carried forward to unnatural 
analog 9a-epi-stemaphylline 2.226 through olefin reduction employing Pearlman’s 
catalyst,51 which also set the final C-14 stereocenter in 95% yield and 7:1 dr.   Reaction of 
2.226 in the presence of O3 led to the corresponding N-oxide 2.227 (53% yield).52 
 
 
Scheme 2.11.21  Synthesis of 9a-epi-stemaphylline and 9a-epi stemaphylline N-oxide. 
 
 With successful conditions for the tandem ring closing metathesis reaction, we 
turned our attention toward the synthesis of stemaphylline, subjecting pyrollidine tetraene 
2.216 to the optimized tandem ring closing metathesis reaction conditions.  Suprisingly, 
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the ring closure proceeded more slowly than expected, and upon isolation an inseparable 
mixture of products was obtained.  In consideration that olefin migration could be leading 
to epimerization, we tested the addition of 1,4-benzoquinone, reported to suppress 
undesirable olefin migration;53 however, a mixture of bis-ring closure products was still 
observed, wherein the C-12 carbon of the lactone was epimerized.   
 
 
 
Scheme 2.11.22  Attempted bis ring closing metathesis 
 
 To elucidate when the suspected epimerization was occuring,  the reaction was 
stopped after closure of the azepine ring in the presence of Hoveyda Grubbs II, CSA, and 
1,4-benzoquinone at room temperature. Isolation of mono-ring closure product 2.228 
demonstrated that a single product was formed and that closure of the -lactone was the 
problematic step.  Unfortunately, subjection of 2.228 to a variety of  acid additives and 
RCM catalysts was ineffective in suppressing the formation of the mixture of products.  
In an attempt to gain insight into the differences in reactivity between tetraene 2.216 and 
2.219  and azepeines 2.224 and 2.228, the four compounds were sketched and minimized 
using the MMFF force field to an energy gradient of <0.01 while preserving the 
stereochemistry. These calculations were performed using MOE (v2012.10; Chemical 
Computing Group; www.chemcomp.com).  
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orientation of the -lactone in 2.228 then allows for competing reaction pathways or 
epimerization of the C-12 stereocenter during the course of the reaction.   
 From this analysis, we began investigation of methods to expedite the closure of 
the -lactone in order to prevent the suspected epimerization.  Recently, Hoye and 
coworkers have developed a relay ring closing metathesis (RRCM) strategy54 to 
accelerate reactivity for difficult substrates and as a means to preload the ruthenium 
metathesis catalyst at a desired olefin to improve selectivity.  Incorporating dienes 
2.23055 and 2.23256 into intermediate 2.214, we arrived at RRCM substrate 2.233 in order 
to determine if directing the formation of  the ruthenium alkylidene would prove 
beneficial.  Reaction at room temperature revealed significant amounts of truncation 
products, presumably intermediates 2.216 and 2.228.  However, vigorous reflux and 
argon sparge led to rapid formation of the desired ring closing metathesis product 2.229 
with, excitingly, only minor epimerization (10:1).  Reduction with  Pearlman’s catalyst53 
afforded stemaphylline in 62% yield and with 4:1 selectivity at the C-12 stereocenter.  
Spectral and rotation data of the synthetic material was generally in agreement with that 
reported for the natural product 2.76, though complicated by the by the presence of a 4:1 
ratio of inseparable products.26 Further confirmation was acheived by conversion to 
stemaphylline N-oxide 2.77.  Attempts to form the N-oxide in the presence of O3 was 
ineffective; however formation with mCPBA in CH2Cl2 at 0 C afforded stemaphylline 
N-oxide 2.77 in 74% yield, isolated as a single isomer (Scheme 2.11.23).   
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Scheme 2.11.23  Relay RCM approach to stemaphylline and stemaphylline N-oxide. 
  
The synthetic 2.77 was in complete agreement with the spectral and rotation data 
reported for the natural product, thus completing the first total synthesis of both 2.76 and 
2.77.26  Furthermore, the observed fragmentation pattern of the synthetic material 
matched that reported by Mungkornasawakul and coworkers (Figure 2.11.4).  High 
resolution mass spectrometry (HRMS) fragmentation data of the reduced product clearly 
demonstrated the presence of the pyrrolo[1,2-α]azepine ring system and a fragment ion at 
m/z 180 ([M – C5H7O2]+), which corresponds to the loss of an α-methyl-γ-butyrolactone 
moiety often found in Stemona alkaloids.   
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Figure 2.11.4  High resolution mass spec fragment analysis of 2.76 
 
 In conclusion, we have completed the first total synthesis of both stemaphylline 
2.76 (19 steps) and stemaphylline N-oxide 2.77 (20 steps), via a tandem bis-RCM 
strategy, as well as unnatural 9a-epi-stemaphylline 2.226 and 9a-epi-stemaphylline N-
oxide 2.227.  The linear tetraene substrate leading to 2.226 and 2.227 was found by 
modelling to be pre-organized for the bis-tandem RCM, and smoothly afforded the 
desired unnatural products; however, the tetraene corresponding to natural 2.76 and 2.77 
was disorganized, leading to lower reactivity and ruthenium alklyidene-mediated 
epimerization. Thus, adopting a relay ring closing metathesis (RRCM) strategy enabled 
access to 2.76 and 2.77.   Biological evaluation of both natural and unnatural analogues is 
underway and will be reported in due course. 
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General Experimental 
All reagents were purchased from commercial suppliers and purified as needed according 
to the procedures of Armarego and Chai1.  Analytical thin-layer chromatography (TLC) 
was performed on 250 μm silica gel plates from Sorbent Technologies.  Visualization 
was accomplished via UV light, and/or the use of potassium permanganate and 
phosphomolybdic acid solutions followed by application of heat.  Chromatography was 
performed using Silica Gel 60 (230-400 mesh) from Sorbent Technologies or Silica 
RediSep Rf flash columns on a CombiFlash Rf automated flash chromatography system.  
All 1H and 13C NMR spectra were recorded on a Bruker AV-400 (400 MHz and 100 
MHz respectively).  All 1H and 13C chemical shifts are reported in ppm relative to 
residual solvent peaks as an internal standard set to δ 7.26 and δ 77.16 (CDCl3) and δ 
7.16 and δ 128.06 (C6D6).  Data are reported as follows:  chemical shift, multiplicity (s = 
singlet, d = doublet, t = triplet, q = quartet, br = broad, m = multiplet), coupling constant 
(Hz), integration.  Low resolution mass spectra (LCMS) were obtained on an Agilent 
1200 LCMS with electrospray ionization.  High resolution mass spectra (HRMS) were 
recorded on a Waters Qtof-API-US plus Acquity system with ES as the ion source.  
Crystals for x-ray structure determination were mounted on a cryoloop and maintained at 
100 K using a Bruker KryoFlex cryostat. Data were collected using a Bruker Microstar 
rotating-anode X-ray generator operated at 2.7 kW. Diffraction data were collected using 
Montel multi-layer confocal optics and a Bruker X8 kappa axis goniometer with a Bruker 
Proteum PT135 CCD area detector. Diffraction data scans were calculated using Cosmo 
software and the diffraction data integrated and scaled using Proteum2 software. 
Absorption correction was applied using SADABS (Sheldrick, 2006). The space group 
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was determined using XPREP (Sheldrick, 2006).  Diffraction data were phased and a 
molecular model was built using SIR2011 (Burla, et al., 2012). Refinement was 
performed using SHELXL (Sheldrick, 2006). Manual inspection of the refinement was 
done using COOT (Emsley & Cowtan, 2004) and PLATON (Spec, 2006). 
 
 
(3R)-1-((6S,7aS)-8,8-dimethyl-2,2-dioxidohexahydro-1H-3a,6-methanobenzo 
[c]isothiazol-1-yl)-3-methylhex-5-en-1-one (2.111) 
  
A solution of CuBr·DMS (1.46 eq) and LiCl (1.6 eq) in THF (0.5 M) at -78 oC was 
transferred to a solution of allylmagnesium bromide (1.2 eq) at -78 oC in THF via 
cannula.  TMS-Cl (1.5 eq) was added followed by a solution of (E)-1-((6S,7aS)-8,8-
dimethyl-2,2-dioxidohexahydro-1H-3a,6-methanobenzo[c]isothiazol-1-yl)but-2-en-1-one 
in THF (0.3 M).  The reaction continued stirring at -78 oC for 3 h.  The reaction was 
quenched by the addition of 9:1 NH4Cl/NH4OH, partitioned between ether and water, 
extracted with EtOAc (3x), dried over Na2SO4, and concentrated in vacuo.  Purification 
via flash chromatography (Hex:EtOAc 9:1) afforded the pure desired in 91% overall 
yield and 9:1 dr.    1H NMR (400 MHz, CDCl3) δ (ppm):  5.76 (ddt, J1 = 23.9, J2 = 10.6, 
J3 = 7.1 Hz, 1H); 5.03 (d, J1 = 6.2 Hz, 1H); 4.99 (s, 1H); 3.87 (t, J1 = 6.2 Hz, 1H); 3.45 
(q, J = 13.3 Hz, 2H); 2.75 (dd, J1 = 16.0 Hz, J2 = 6.3 Hz, 1H); 2.48 (dd, J1 = 16.3 Hz, J2 = 
7.5 Hz, 1H); 2.22 (sext, J = 6.8 Hz, 1H); 2.12-1.97 (m, 4H); 1.96-1.83 (m, 3H); 1.45-1.30 
(m, 2H); 1.15 (s, 3H); 0.98-0.94 (m, 6H).  13C NMR (100 MHz, CDCl3) δ (ppm):  171.60; 
136.64; 116.73; 65.38; 53.20; 48.44; 47.89; 44.81; 42.24; 41.07; 38.72; 33.00; 29.84; 
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26.62; 20.95; 20.04; 19.68. 
 
 
(3R,E)-7-((tert-butyldimethylsilyl)oxy)-1-((6S,7aS)-8,8-dimethyl-2,2-
dioxidohexahydro-1H-3a,6-methanobenzo[c]isothiazol-1-yl)-3-methylhept-5-en-1-
one 
 
To a solution of (3R)-1-((6S,7aS)-8,8-dimethyl-2,2-dioxidohexahydro-1H-3a,6-
methanobenzo[c]isothiazol-1-yl)-3-methylhex-5-en-1-one in DCM (0.25 M) was added 
(Z)-2,2,3,3,10,10,11,11-octamethyl-4,9-dioxa-3,10-disiladodec-6-ene (3.5 eq) and 
benzoquinone (0.1 eq).  Grubbs II (0.05 eq) was added and the reaction stirred at 40 oC 
overnight.  The reaction was cooled and concentrated under vacuum.  Purification via 
flash chromatography (Hex:EtOAc 9:1) afforded the pure desired in 88% yield.  1H NMR 
(400 MHz, CDCl3) δ (ppm):  5.65-5.50 (m, 2H); 4.12 (d, J = 4.5 Hz, 2H); 3.87 (t, J = 6.3 
Hz, 1H); 3.45 (q, J = 13.8 Hz, 2H); 2.74 (dd, J1 = 16.0 Hz, J2 = 6.0 Hz, 1H); 2.48 (dd, J1 
= 16.0 Hz, J2 = 7.6 Hz, 1H); 2.19 (sext, J = 6.8 Hz, 1H); 2.14-2.02 (m, 3H); 2.01-1.92 (m, 
1H); 1.92-1.83 (m, 3H); 1.58 (s, 1H); 1.45-1.29 (m, 2H); 1.14 (s, 3H0; 0.98-0.92 (m, 6H); 
0.89 (s, 9H); 0.06 (s, 6H). 
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(2R,3R,E)-2-allyl-7-((tert-butyldimethylsilyl)oxy)-1-((6S,7aS)-8,8-dimethyl-2,2-
dioxidohexahydro-1H-3a,6-methanobenzo[c]isothiazol-1-yl)-3-methylhept-5-en-1-
one (2.114) 
 
To a solution of (2R,3R,E)-2-allyl-7-((tert-butyldimethylsilyl)oxy)-3-methylhept-5-enal 
in THF (0.15 M) at -78 oC was added KHMDS (1.05 eq) dropwise.  The reaction was 
stirred at -78 oC for 1.5 h.  A solution of allyl iodide (3.0 eq) and HMPA (3.0 eq) in THF 
(1.5 M) was transferred to the reaction via cannula.  The reaction continued stirring at       
-78 oC for 4 h.  The reaction was quenched by the addition of brine, partitioned between 
Et2O and water, extracted with Et2O (3x), dried over Na2SO4, and concentrated.  
Purification via flash chromatography (Hex:EtOAc 9:1) afforded the pure desired in 60% 
yield.  1H NMR (400 MHz, CDCl3) δ (ppm):  5.87-5.73 (m, 1H); 5.64-5.53 (m, 1H); 
5.11-4.92 (m, 2H); 4.12 (d, J = 3.3 Hz, 1H); 3.90 (t, J = 6.4 Hz, 1H); 3.46 (q, J = 13.9 Hz, 
2H); 3.05-2.96 (m, 1H); 2.53-2.44 (m, 1H); 2.43-2.33 (m, 1H); 2.04 (d, J = 6.3 Hz, 1H); 
2.00-1.80 (m, 4H); 1.44-1.29 (m, 1H); 1.15 (s, 3H); 0.97-0.92 (m, 5H); 0.90 (s, 9H); 0.06 
(s, 6H).   
 
 
(2R,3R,E)-2-allyl-7-((tert-butyldimethylsilyl)oxy)-3-methylhept-5-enal (2.115) 
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To a solution of (2R,3R,E)-2-allyl-7-((tert-butyldimethylsilyl)oxy)-1-((6S,7aS)-8,8-
dimethyl-2,2-dioxidohexahydro-1H-3a,6-methanobenzo[c]isothiazol-1-yl)-3-methylhept-
5-en-1-one in 4:1 Et2O/THF (0.1 M) at 0 oC was added LAH (3.5 eq).  The reaction was 
stirred at 0 oC for 2 h.  The reaction was quenched by the addition of NH4Cl, extracted 
with EtOAc (3x), dried over Na2SO4, and concentrated under vacuum.  The crude product 
was then diluted in CH2Cl2 (0.1 M) and 4Å MS were added (0.5g/mmol) followed by 
NMO (1.48 eq).  After stirring at rt for 10 min, TPAP (0.1 eq) was added and the reaction 
continued stirring at rt for 1 h.  The reaction was filtered through Celite and concentrated 
in vacuo.  Purification via flash chromatography (Hex:EtOAc 9:1) afforded the pure 
desired aldehyde in 81% yield over 2 steps.  1H NMR (400 MHz, CDCl3) δ (ppm):  9.69 
(d, J = 2.6 Hz, 1H); 5.80-5.67 (m, 1H); 5.62-5.57 m, 2H); 5.11-4.99 (m, 2H); 4.13 (m, 
1H); 4.13 (d, J = 2.7 Hz, 1H); 2.52-2.42 (m, 1H); 2.39-2.31 (m, 1H); 2.28-2.16 (m, 2H); 
2.08-1.89 (m, 2H); 0.98-0.95 (m, 3H); 0.91 (s, 9H); 0.07 (s, 6H).   
 
 
(S,E)-N-((2R,3R,E)-2-allyl-7-((tert-butyldimethylsilyl)oxy)-3-methylhept-5-en-1-
ylidene)-2-methylpropane-2-sulfinamide (2.116) 
 
To a solution of (2R,3R,E)-2-allyl-7-((tert-butyldimethylsilyl)oxy)-3-methylhept-5-enal 
in THF (0.2 M) was added (S)-(-)-2-methyl-2-propanesulfinamide (1.0 eq) followed by 
Ti(OEt)4 (2.0 eq).  After stirring at rt overnight, the reaction was quenched by the 
addition of NaHCO3, extracted with EtOAc (5x), dried over Na2SO4, and concentrated 
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under vacuum.  Purification via flash chromatography (Hex:EtOAc 9:1) afforded the pure 
desired aldimine in 86% yield.   1H NMR (400 MHz, CDCl3) δ (ppm):  7.99 (d, J = 5.9 
Hz, 1H); 5.80-5.67 (m, 1H); 5.65-5.51 (m, 2H); 5.10-4.97 (m, 2H); 4.13 (d, J = 3.6 Hz, 
1H); 2.68-2.59 (m, 1H); 2.50-2.40 (m, 1H); 2.36-2.26 (m, 1H); 2.23-2.09 (m, 1H); 2.05-
1.83 (m, 2H); 1.21 (s, 9H); 0.90 (s, 9H); 0.06 (s, 6H).   
 
 
(S)-N-((3S,4R,5R,E)-4-allyl-9-((tert-butyldimethylsilyl)oxy)-1-(1,3-dioxan-2-yl)-5-
methylnon-7-en-3-yl)-2-methylpropane-2-sulfinamide (2.117) 
 
To a suspension of Mg powder (25.0 eq) in THF (1.0 M) was added an iodine crystal 
followed by 2-(2-bromoethyl)-1,3-dioxane (20.0 eq).  The Grignard reagent was allowed 
to form for 1 h at rt.  The Grignard was transferred via cannula to a solution of (S,E)-N-
((2R,3R,E)-2-allyl-7-((tert-butyldimethylsilyl)oxy)-3-methylhept-5-en-1-ylidene)-2-            
methylpropane-2-sulfinamide in THF (0.1 M) at -48 oC.  The reaction was allowed to 
slowly warm to rt and continued stirring overnight.  The reaction was quenched by the 
addition of sat aq NH4Cl followed by extraction with EtOAc (3x).  After drying over 
Na2SO4 and concentrating under vacuum, the addition product was purified via flash 
chromatography (Hex:EtOAc 0-60%) to afford the pure product in 75% yield.  1H NMR 
(400 MHz, CDCl3) δ (ppm):  6.02-5.82 (m, 1H); 5.64-5.49 (m, 2H); 5.09 (d, J = 17.2 Hz, 
1H); 5.03 (d, J = 10.1 Hz, 1H); 4.51 (t, J = 5.0 Hz, 1H); 4.14-4.06 (m, 4H); 3.74 (t, J = 
12.1 Hz, 2H); 3.59 (d, J = 9.5 Hz, 1H); 3.42-3.33 (m, 1H); 2.34-2.14 (m, 3H); 2.14-1.92 
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(m, 3H); 1.90-1.71 (m, 2H); 1.68-1.38 (m, 5H); 1.33 (d, J = 13.5 Hz, 1H); 1.19 (s, 9H); 
0.90 (s, 9H); 0.06 (s, 6H). 
 
 
(S)-N-((3S,4R,5R,E)-4-allyl-1-(1,3-dioxan-2-yl)-9-hydroxy-5-methylnon-7-en-3-yl)-2-
methylpropane-2-sulfinamide (2.123) 
 
To a solution of (S)-N-((3S,4R,5R,E)-4-allyl-9-((tert-butyldimethylsilyl)oxy)-1-(1,3-
dioxan-2-yl)-5-methylnon-7-en-3-yl)-2-methylpropane-2-sulfinamide in THF (0.1 M) at 
0 oC was added TBAF (2.0 eq).  The reaction was warmed to rt and continued stirring 
overnight.  The reaction was quenched by the addition of H2O, extracted with EtOAc, 
dried over Na2SO4, and concentrated in vacuo.  The reaction was purified via flash 
chromatography (DCM/MeOH 9:1) which afforded the product as a yellow oil in 81% 
yield.   1H NMR (400 MHz, CDCl3) δ (ppm):  5.91-5.79 (m, 1H); 5.70-5.56 (m, 2H); 5.08 
(dd, J1 = 17.0 Hz, J2 = 1.3 Hz, 1H); 5.02 (d, J = 10.1 Hz, 1H); 4.54 (t, J = 4.8 Hz, 1H); 
4.12-4.03 (m, 4H); 3.74 (t, J = 12.1, 2H); 3.43-3.34 (m, 1H); 3.24 (d, J = 9.1 Hz, 1H); 
2.30-2.12 (m, 3H); 2.05 (qt, J1 = 12.9 Hz, J2 = 5.0 Hz, 1H); 1.99-1.90 (m, 1H); 1.90-1.80 
(m, 1H); 1.79-1.70 (m, 2H); 1.70-1.61 (m, 2H); 1.55-1.48 (m, 1H); 1.46 (t, J = 5.9 Hz, 
1H); 1.32 (d, J = 13.4 Hz, 1H); 1.19 (s, 9H); 0.88 (d, J = 6.8 Hz, 3H). 
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(S)-N-((3S,4R)-1-(1,3-dioxan-2-yl)-4-((R)-1-((2S,3S)-3-(hydroxymethyl)oxiran-2-
yl)propan-2-yl)hept-6-en-3-yl)-2-methylpropane-2-sulfinamide (2.124) 
 
To a suspension of 4Å MS in CH2Cl2 at -20 oC was added (+)-DET (1.44 eq) and 
Ti(OiPr)4 followed by stirring at -20 oC for 10 min.  t-BuOOH (2.0 eq) was added and the 
reaction stirred for an additional 30 min.  A solution of (S)-N-((3S,4R,5R,E)-4-allyl-1-
(1,3-dioxan-2-yl)-9-hydroxy-5-methylnon-7-en-3-yl)-2-methylpropane-2-sulfinamide in 
CH2Cl2 (0.1 M) was added and the reaction stirred at -20 oC for 24 h.  The reaction was 
quenched with 30% aq NaOH/NaCl solution, filtered through Celite, and concentrated in 
vacuo.  Purification via flash chromatography (DCM/MeOH 9:1) afforded the pure 
desired epoxide in 95% yield.    1H NMR (400 MHz, CDCl3) δ (ppm):  5.84 (ddt, J1 = 7.0 
Hz, J2 = 10.0 Hz, J3 = 7.3 Hz, 1H); 5.09 (d, J = 17.4 Hz, 1H); 5.03 (d, J = 10.4 Hz, 1H); 
4.55 (t, J = 4.9 Hz, 1H); 4.07 (dd, J1 = 10.9 Hz, J2 = 4.9 Hz, 2H); 3.89 (ddd, J1 = 12.5 Hz, 
J2 = 5.4 Hz, J3 = 2.7 Hz, 1H); 3.74 (t, J = 12.3 Hz, 2H); 3.65 (ddd, J1 = 11.8 Hz, J2 = 7.3 
Hz, J3 = 4.3 Hz, 1H); 3.43-3.35 (m, 1H); 3.32-3.25 (m, 1H); 2.95 (ddd, J1 = 6.7 Hz, J2 = 
4.4 Hz, J3 = 2.2 Hz, 1H); 2.89-2.85 (m, 1H); 2.27-2.14 (m, 2H); 2.05 (qt, J1 = 12.6 Hz, J2 
= 5.1 Hz, 1H); 1.97-1.86 (m, 1H); 1.86-1.79 (m, 1H); 1.79-1.63 (m, 5H); 1.62-1.49 (m, 
1H); 1.46-1.28 (m, 2H); 1.20 (s, 9H); 1.01 (d, J = 6.8 Hz, 3H). 
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(S,E)-N-(6-chlorohexylidene)-2-methylpropane-2-sulfinamide (2.135) 
To a solution of 6-chlorohexanal (7.37 g, 54.79 mmol) in DCM (219 ml) at ambient 
temperature was added CuSO4 (20.11 g, 126.02 mmol) and (S)-2-methylpropane-2-
sulfinamide (7.64 g, 63.01 mmol) in a single batch.  The reaction was stirred for 12 h, at 
which point the starting material was fully consumed by TLC analysis (4:1 Hex/EtOAc, 
rf = 0.35).  The heterogeneous mixture was filtered through a silica pad and concentrated 
in vacuo to yield a viscous oil, which was purified by flash chromatography (4:1 
Hex/EtOAc) to afford the desired product as a clear oil (12.34 g, 94%).  [α]D20 = +157.9° 
(c = 1.5, MeOH). 1H NMR (400.1 MHz, CDCl3) δ (ppm): 8.05 (t, J = 4.5 Hz, 1H); 3.52 
(t, J = 6.5 Hz, 2H); 2.53 (m, 2H); 1.79 (m, 2H); 1.66 (m, 2H); 1.51 (m, 2H); 1.18 (s, 9H). 
13C NMR (100.6 MHz, CDCl3) δ (ppm): 169.26, 56.64, 44.82, 35.96, 32.37, 26.56, 24.78, 
22.42.  HRMS (TOF, ES+) C10H21NOSCl [M+H]+ calc 238.1032, found 238.1034. 
 
 
(S)-N-((S)-9-chloronon-1-en-4-yl)-2-methylpropane-2-sulfinamide (2.136) 
NaBr (380 g) was dissolved in 841 mL of deionized H2O.  To this fully dissolved 
saturated NaBr solution was added aldimine 2.135 (10.00g, 42.05 mmol) and indium 
powder (19.31 g, 168.2 mmol).  The mixture was stirred vigorously for 5 min, then allyl 
bromide (20.35 g, 168.2 mmol) was added in a single batch. Vigorous stirring was 
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continued for 9 h, at which point the starting material was consumed by TLC analysis 
(1:1 Hex/EtOAc, rf = 0.34).  The mixture was quenched with NaHCO3 and extracted x5 
with EtOAc.  The organic fractions were combined, washed with brine, dried over 
Na2SO4, and concentrated in vacuo to yield crude oil.  Purification by flash 
chromatography (1:1 Hex/ EtOAc) afforded the desired product as a clear oil (10.10 g, 
86%).  [α]D20 = +25.7° (c = 1.5, MeOH). 1H NMR (400.1 MHz, CDCl3) δ (ppm):  5.77 
(m, 1H);5.15 (m, 2H); 3.52 (t, J = 6.5Hz, 2H); 3.30 (sextet, J = 6.1 Hz, 1H); 3.21 (br d, J 
= 6.1 Hz, 1H); 2.35 (dp, J1 = 6.5 Hz, J2 = 10.4 Hz, 2H); 1.763 (quint., J = 6.5 Hz, 2H); 
1.53- 1.32 (m, 5H).  13C NMR (100.6 MHz, CDCl3) δ (ppm): 134.23, 119.14, 55.92, 
54.83, 45.08, 40.56, 34.91, 32.60, 26.88, 24.92, 22.79.  HRMS (TOF, ES+) 
C13H27NOSCl [M+H]+ calc. 280.1502, found 280.1504. 
 
 
(S)-1,2-diallylazepane (2.137) 
A 4N solution of HCl / dioxanes (14.92 ml) was cooled to 0°C and slowly added to a 
microwave vial containing sulfinamide 2.136 (2.0 g, 7.15 mmol).  Solution was then 
brought to ambient temperature and stirred for an additional 45 min, and concentrated in 
vacuo to afford the deprotected amine as the HCl salt in quantitative yield.   The amine 
was dissolved in DMF (35.9 mL), then K2CO3 (1.98 g, 14.34 mmol) and NaI (1.18 g, 
7.89 mmol) were added in a single batch.  The vial was sealed and submitted to 
microwave irradiation at 120°C for 15 min.  LC/MS analysis showed full consumption of 
starting material to the cyclized secondary amine.  Allyl bromide (0.954 g, 7.89 mmol) 
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was then added to the pale yellow solution at ambient temperature, and stirring was 
continued for 4 h.  Mixture was dissolved in 5% LiCl solution and extracted with Et2O (5 
x 40 mL).  Organic fractions were combined, washed with brine, dried over Na2SO4, and 
concentrated in vacuo to yield a pale yellow crude oil.  Purification by flash 
chromatography (1:1 Hex/EtOAc) afforded the desired product as a clear oil (0.82g, 
64%). [α]D20 = -5.0° (c = 0.9, MeOH). 1H NMR (400.1 MHz, CDCl3) δ (ppm): 5.82 (m, 
2H); 5.19-4.93 (m, 4H); 3.22 (m, 2H); 2.85 (m, 1H); 2.70 (m, 2H); 2.26 (m, 1H); 2.06 (m, 
1H); 1.75 (m, 1H); 1.66-1.38 (m, 7H).  13C NMR (100.6 MHz, CDCl3) δ (ppm):  137.98, 
137.51, 115.99, 115.66, 62.45, 55.71, 49.83, 39.34, 32.65, 28.88, 27.53, 25.78.  HRMS 
(TOF, ES+) C12H22N [M+H]+ calc. 180.1752, found 180.1751. 
 
 
(S)-octahydropyrido[1,2-α]azepine unsat-7 (2.138) 
To a solution of diene 2.137 (106 mg, 0.59 mmol) in toluene (11.8 mL) was added 
trifluoroacetic acid (71 mg, 0.62 mmol) and Grubbs II (49 mg, 0.06 mmol).  Solution was 
submitted to microwave irradiation for 1 h at 100°C.  The toluene was removed in vacuo, 
and the crude residue purified to afford the desired product as the TFA salt (94 mg, 60%). 
[α]D20 = +45.2° (c = 1.25, MeOH). 1H NMR (400.1 MHz, CDCl3) δ (ppm): 5.88 (m, 1H); 
5.64 (m, 1H); 3.94 (m, 1H); 3.57 (m, 2H); 3.18-3.04 (m, 2H); 2.73 (t, 1H); 2.25 (m, 1H); 
2.24-1.92 (m, 3H); 1.89-1.72 (m, 3H); 1.58 (m, 2H).  13C NMR (100.6 MHz, CDCl3) δ 
(ppm): 126.83, 120.24, 63.64, 55.70, 54.32, 31.93, 30.59, 27.21, 26.00, 21.96.  HRMS 
(TOF, ES+) C10H18N [M+H]+ calc. 152.1439, found 152.1440. 
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(S,E)-N-(4-chlorobutylidene)-2-methylpropane-2-sulfinamide (2.145) 
To a solution of 4-chlorobutanal in THF (0.1 M) was added (S)-(-)-2-methyl-2-
propanesulfinamide (1.0 eq) followed by Ti(OEt)4 (2.0 eq).  After stirring at rt overnight, 
the reaction was quenched by the addition of NaHCO3, extracted with EtOAc (5x), dried 
over Na2SO4, and concentrated under vacuum.  Purification via flash chromatography 
(Hex:EtOAc 9:1) afforded the pure desired aldimine in 86% yield.  1H NMR (400 MHz, 
CDCl3) δ (ppm):  8.11 (t, J = 4.0 Hz, 1H); 3.63 (td, J1 = 6.4 Hz, J2 = 1.9 Hz, 2H); 2.74-
2.68 (m, 2H); 2.18-2.10 (m, 2H); 1.20 (s, 9H). 
 
 
 
(R)-4-((tert-butyldiphenylsilyl)oxy)-2-methylbutan-1-ol (2.167) 
 
To a solution of LiCl (7.0 eq) and i-Pr2NH (2.1 eq) in THF was added n-BuLi (2.2 eq).  
The reaction was stirred at -78 oC for 10 min then warmed to 0 oC and stirred for 20 min.  
A solution of (1S,2S)-pseudoephedrinepropionamide (1.0 eq) in THF (0.1 M) was then 
added to the solution of LDA at -78 oC via cannula.  The reaction was stirred at -78 oC for 
30 min, 0 oC for 30 min, and rt for 30 min.  The reaction was then recooled to -78 oC and 
tert-butyl(2-iodoethoxy)diphenylsilane (2.0 eq) in THF (5.0 M) was added dropwise.  
The reaction stirred at -78 oC for 2 h followed by stirring at rt for 4 h.  The reaction was 
quenched with sat aq NH4Cl, extracted 3x with EtOAc, dried over Na2SO4, and 
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concentrated in vacuo.  Purification via flash chromatography (Hex:EtOAc 3:2) afforded 
the pure product in 83% yield.  To a solution of LDA (4.2 eq) in THF (0.2 M) at 0 oC was 
added BH3·NH3 complex.  After stirring at 0 oC for 15 min and rt for 15 min, a solution 
of (R)-4-((tert-butyldiphenylsilyl)oxy)-N-((1S,2S)-1-hydroxy-1-phenylpropan-2-yl)-N,2-
dimethylbutanamide (1.0 eq) in THF (0.2 M) was added followed by stirring at rt for 2 h.  
The reaction was quenched with sat aq NH4Cl, extracted with EtOAc (4x), dried over 
Na2SO4, and concentrated under vacuum.  Purification via flash chromatography 
(Hex:EtOAc 4:1) afforded the pure product in 93% yield.  1H NMR (400 MHz, CDCl3) δ 
(ppm):  7.68 (d, J = 7.1 Hz, 4H); 7.46-7.36 (m, 6H); 3.8-3.66 (m, 2H); 3.56-3.44 (m, 2H); 
2.41 (dd, J1 = 6.6 Hz, J2 = 5.8 Hz, 1H); 1.85 (sext, J = 6.5 Hz, 1H); 1.68-1.58 (m, 1H); 
1.54-1.45 (m, 1H); 1.06 (s, 9H); 0.90 (d, J = 6.8 Hz, 3H). 
 
 
(R)-4-((tert-butyldiphenylsilyl)oxy)-2-methylbutanal (2.168) 
To a solution of (R)-4-((tert-butyldiphenylsilyl)oxy)-2-methylbutan-1-ol (1.0 eq) in 
CH2Cl2 was added 4Å MS (0.5g/mmol) followed by NMO (1.48 eq).  The reaction stirred 
at rt for 10 min after which TPAP (0.1 eq) was added.  The reaction continued stirring at 
rt for 2h.  The reaction was then filtered through Celite and concentrated.  Purification via 
flash chromatography (Hex:EtOAc 9:1) afforded the pure product as a yellow oil in 71% 
yield.   1H NMR (400 MHz, CDCl3) δ (ppm):  9.68 (d, J = 1.5 Hz, 1H); 7.67-7.63 (m, 
4H); 7.46-7.35 (m, 6H); 3.77-3.65 (m, 2H); 2.58 (sext, J = 6.9 Hz, 1H); 2.06-1.96 (m, 
1H); 1.67-1.57 (m, 1H); 1.08 (d, J = 7.2 Hz, 3H); 1.04 (s, 9H). 
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(R,E)-ethyl 6-((tert-butyldiphenylsilyl)oxy)-4-methylhex-2-enoate (2.169) 
To a suspension of NaH (3.5 eq) in THF (0.75 M) at 0 oC was added triethyl 
phosphonoacetate (3.5 eq) followed by stirring at 0 oC for 10 min.  A solution of (R)-4-
((tert-butyldiphenylsilyl)oxy)-2-methylbutanal in THF (0.2 M) was added via cannula 
and the reaction stirred at 0 oC for 1 h.  The reaction was then quenched by the addition 
of sat aq NH4Cl, extracted with EtOAc x3, dried over Na2SO4, and concentrated under 
vacuum.  Purification via flash chromatography (Hex/EtOAc 9:1) afforded the pure α,β-
unsaturated ester in 81% yield. 1H NMR (400 MHz, CDCl3) δ (ppm):  7.65 (d, J = 7.6 
Hz, 4H); 7.45-7.35 (m, 6H); 6.86 (dd, J1 = 15.8 Hz, J2 = 8.0 Hz, 1H); 5.77 (d, J = 15.6 
Hz, 1H); 4.18 (q, J = 7.2 Hz, 2H); 3.66 (t, J = 6.1 Hz, 2H); 2.58 (sept, J = 7.0 Hz, 1H); 
1.69-1.55 (m, 2H); 1.29 (t, J = 7.1 Hz, 3H); 1.04 (s, 9H); 1.03 (d, J = 8.0 Hz, 3H). 
 
 
(R,E)-6-((tert-butyldiphenylsilyl)oxy)-4-methylhex-2-en-1-ol (2.170) 
To a solution of (R,E)-ethyl 6-((tert-butyldiphenylsilyl)oxy)-4-methylhex-2-enoate in 
CH2Cl2 (0.1 M) at -78 oC was added DIBAL-H (3.7 eq).  The reaction stirred at -78 oC 
for 1 h after which the reaction was quenched with Rochelle’s salt and warmed to rt.  
Extraction with EtOAc (3x), drying over Na2SO4, and concentration in vacuo gave the 
crude product.  Purification via flash chromatography (Hex/EtOAc 9:1-4:1) afforded the 
pure allylic alcohol in 94% yield.  1H NMR (400 MHz, CDCl3) δ (ppm):  7.69-7.64 (m, 
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4H); 7.46-7.35 (m, 6H); 5.60-5.47 (m, 2H); 4.06-4.00 (m, 2H); 3.67 (t, J = 6.4 Hz, 2H); 
2.39 (sept, J = 6.4 Hz, 1H); 1.64-1.49 (m, 2H); 1.06 (s, 9H); 0.98 (d, J = 6.8 Hz, 3H). 
 
 
(R,E)-((6-bromo-3-methylhex-4-en-1-yl)oxy)(tert-butyl)diphenylsilane (2.171) 
To a solution of (R,E)-6-((tert-butyldiphenylsilyl)oxy)-4-methylhex-2-en-1-ol in MeCN 
at rt was added Ph3P followed by CBr4.  The reaction stirred at rt for 1 h after the reaction 
was quenched with H2O, extracted with CH2Cl2, dried over Na2SO4, and concentrated 
under vacuum.  Purification via flash chromatography (Hex/EtOAc 95:5) afforded the 
pure allylic bromide in 97% yield.  1H NMR (400 MHz, CDCl3) δ (ppm):  7.69-7.64 (m, 
4H); 7.46-7.35 (m, 6H); 5.67-5.54 (m, 2H); 3.91-3.87 (m, 2H); 3.66 (t, J = 6.3 Hz, 2H); 
2.42 (sept, J = 7.0 Hz, 1H); 1.63-1.47 (m, 2H); 1.05 (s, 9H); 0.98 (d, J = 6.7 Hz, 3H). 
 
 
 
(S)-N-((3S,4S)-7-chloro-3-methylhept-1-en-4-yl)-2-methylpropane-2-sulfinamide 
(2.174) 
 
To a solution of (S,E)-N-(4-chlorobutylidene)-2-methylpropane-2-sulfinamide in sat aq 
NaBr was added indium powder (4.0 eq) followed by crotyl bromide (4.0 eq).  The 
reaction was vigorously stirred at rt for 24 h.  The reaction was quenched by the addition 
of sat aq NaHCO3, extracted with EtOAc (5x), dried over Na2SO4, and concentrated 
under vacuum.  Purification via flash chromatography (Hex/EtOAc 1:1) afforded the pure 
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product in 91% yield.  1H NMR (400 MHz, CDCl3) δ (ppm):  5.74-5.62 (m, 1H); 5.24-
5.12 (m, 2H); 3.54 (t, J = 6.2 Hz, 2H); 3.37 (d, J = 8.3 Hz, 1H); 3.20-3.10 (m, 1H); 2.74-
2.61 (m, 1H); 2.00-1.88 (m, 1H); 1.81-1.67 (m, 2H); 1.43-1.31 (m, 1H); 1.21 (s, 9H); 
1.06 (d, J = 6.9 Hz, 3H). 
 
 
(S)-N-((3S,4S)-7-chloro-3-isopropylhept-1-en-4-yl)-2-methylpropane-2-sulfinamide 
(2.175) 
 
To a solution of (S,E)-N-(4-chlorobutylidene)-2-methylpropane-2-sulfinamide in sat aq 
NaBr was added indium powder (4.0 eq) followed by (E)-1-bromo-4-methylpent-2-ene 
(4.0 eq).  The reaction was vigorously stirred at rt for 24 h.  The reaction was quenched 
by the addition of sat aq NaHCO3, extracted with EtOAc (5x), dried over Na2SO4, and 
concentrated under vacuum.  Purification via flash chromatography (Hex/EtOAc 1:1) 
afforded the pure product in 6% yield.    1H NMR (400 MHz, CDCl3) δ (ppm):  5.52 (dt, 
J1 = 17.0 Hz, J2 = 10.3 Hz, 1H); 5.29 (dd, J1 = 10.2 Hz, J2 = 2.4 Hz, 1H); 5.23 (dd, J1 = 
17.0 Hz, J2 = 2.3 Hz, 1H); 3.54 (t, J = 6.7 Hz, 2H); 2.75-2.67 (m, 1H); 2.24-2.10 (m, 1H); 
2.04-1.88 (m, 1H); 1.81-1.60 (m, 4H); 1.21 (s, 9H); 0.98 (d, J = 6.6 Hz, 3H); 0.87 (d, J = 
6.6 Hz, 3H).      
 
 
181 
 
 
(R)-benzyl 2-formylpyrrolidine-1-carboxylate (2.179) 
To a solution of oxalyl chloride (1.1 eq) in CH2Cl2 (1.0 M) at -78 oC was slowly added 
DMSO (2.2 eq).  After stirring at -78 oC for 30 min, a solution of Z-D-prolinol in CH2Cl2 
was added followed by stirring at -78 oC for an additional 1 h.  Et3N (5.0 eq) was added 
and the reaction was allowed to warm to rt. The reaction was quenched with NH4Cl, 
extracted with CH2Cl2, dried over Na2SO4, and concentrated in vacuo.  Purification via 
flash chromatography (Hex:EtOAc 1:1) afforded the desired product 99% yield.  1H 
NMR (400 MHz, CDCl3) δ (ppm):  9.54 (d, J = 41.9 Hz, 1H); 7.41-7.27 (m, 5H); 5.17 (d, 
J = 4.3 Hz, 1H); 5.13 (s, 1H); 4.25 (dt, J1 = 39.2 Hz, J2 = 6.3 Hz, 1H); 3.65-3.48 (m, 2H); 
2.20-1.97 (m, 2H); 1.97-1.78 (m, 2H). 
 
 
(R)-benzyl 2-((S)-1-hydroxyallyl)pyrrolidine-1-carboxylate 
To a solution of (R)-benzyl 2-formylpyrrolidine-1-carboxylate in THF (0.5 M) at 0 oC 
was added vinylmagnesium bromide (1.5 eq).  The reaction stirred at 0 oC for 1.5 h after 
which sat aq NH4Cl was added to quench the reaction.  Extraction with EtOAc (3x), 
drying over Na2SO4, and concentration in vacuo afforded the crude product.  Purification 
via flash chromatography (Hex/EtOAc 3:1) afforded the pure allylic alcohol in 95% 
yield.  1H NMR (400 MHz, CDCl3) δ (ppm):  7.39-7.27 (m, 5H); 5.88-5.74 (m, 1H); 5.32 
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(d, J = 17.4 Hz, 1H); 5.22-5.10 (m, 3H); 4.71-4.60 (m, 1H); 4.32-4.06 (m, 1H); 4.06-3.85 
(m, 1H); 3.65-3.51 (m, 1H); 3.44-3.25 (m, 1H); 1.96-1.68 (m, 4H). 
 
 
(R)-benzyl 2-((S)-1-((E)-but-2-en-1-yloxy)allyl)pyrrolidine-1-carboxylate (2.177) 
To a solution of (R)-benzyl 2-((S)-1-hydroxyallyl)pyrrolidine-1-carboxylate in THF at      
0 oC was added NaH (1.5 eq).  After warming to rt and stirring for 30 min, crotyl bromide 
(3.0 eq) was added and the reaction continued stirring overnight.  The reaction was 
quenched by the addition of sat aq NH4Cl, extracted with EtOAc (3x), dried over 
Na2SO4, and concentrated under vacuum.  Purification via flash chromatography afforded 
the pure product in 60% yield.  1H NMR (400 MHz, CDCl3) δ (ppm):  7.41-7.27 (m, 5H); 
5.81-5.40 (m, 3H); 5.35-5.03 (m, 4H); 4.40-3.62 (m, 4H); 3.60-3.36 (m, 1H); 3.36-3.23 
(m, 1H); 2.11-1.51 (m, 5H); 1.49-1.19 (m, 2H). 
 
 
(S)-3-hydroxy-1-((R)-4-isopropyl-2-thioxothiazolidin-3-yl)pent-4-en-1-one 
To a solution of (R)-1-(4-isopropyl-2-thioxothiazolidin-3-yl)ethanone (11.23 g, 55.21 
mmol, 1.0 eq) in CH2Cl2 (0.25 M) under argon at -48 °C was added TiCl4 (10.8 mL, 
98.27 mmol, 1.78 eq) dropwise followed by N,N-diisopropylethylamine (17.02 mL, 
97.72 mmol, 1.77 eq) dropwise.  After stirring at –48 °C for 2 h, the reaction mixture is 
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cooled to -78 °C and acrolein (3.80 mL, 55.21 mmol, 1.0 eq) is added dropwise.  The 
reaction stirred at -78 °C for 30 min.  The reaction is quenched by addition of pH 7 
phosphate buffer and warmed to room temperature.  The aqueous layer is extracted with 
CH2Cl2 and the combined organic extracts are dried over NaSO4 and concentrated in 
vacuo.  Purification via flash chromatography (Hex:EtOAc 4:1) affords the desired 
product as a yellow oil in 90%  overall yield and 5:1 dr.  The pure desired diastereomer 
can be isolated in 75% yield (10.74 g).  [α]20¦D = -358.3 (c = 1.02, CHCl3).  1H NMR 
(400 MHz, CDCl3) δ (ppm):  5.85 (ddd, J1 = 17.2 Hz, J¬2 = 10.5 Hz, J3 = 5.4 Hz, 1H); 
5.24 (d, J = 17.2 Hz, 1H); 5.11-5.04 (m, 2H); 4.63-4.56 (m, 1H); 3.56-3.44 (m, 2H); 3.25 
(dd, J1 = 17.5 Hz, J2 = 8.8 Hz, 1H); 3.12 (br, 1H); 2.98 (d, J = 11.6 Hz, 1H); 2.29 (oct, J 
= 6.7 Hz, 1H); 0.99 (d, J = 6.9 Hz, 3H); 0.91 (d, J = 6.9 Hz, 3H).  13C NMR (100 MHz, 
CDCl3) δ (ppm):  202.90; 172.04; 138.90; 115.00; 71.30; 68.52; 44.94; 30.67; 30.61; 
18.94; 17.66.  HRMS (TOF, ES+) C11H17NO2S2 [M+Na]+ calc. mass 282.0598, found 
282.0596. 
 
 
(S)-3-((tert-butyldiphenylsilyl)oxy)-1-((R)-4-isopropyl-2-thioxothiazolidin-3-yl)pent-
4-en-1-one (2.188) 
 
To a solution of (S)-3-hydroxy-1-((R)-4-isopropyl-2-thioxothiazolidin-3-yl)pent-4-en-1-
one (20.1 g, 77.49 mmol, 1.0 eq) in CH2Cl2 (0.2 M) at 0 ºC was added imidazole (5.54 g, 
81.36 mmol, 1.05 eq) followed by TBDPS-Cl (21.16 mL, 81.36 mmol, 1.05 eq).  The 
reaction was allowed to warm to rt and continue stirring overnight.  The reaction was 
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filtered through celite and concentrated under vacuum.  Purification via silica 
chromatography (Hex:EtOAc 4:1) afforded the desired product as a yellow oil in 95% 
yield (36.64 g).  [α]ଶ଴஽  = -139.7 (c = 0.69, CHCl3).  1H NMR (400 MHz, CDCl3) δ (ppm):  
7.70-7.65 (m, 4H); 7.45-7.33 (m, 6H); 5.90 (ddd, J1 = 17.0 Hz, J2 = 10.3 Hz, J3 = 6.5 Hz, 
1H); 5.03 (dt, J1 = 17.2 Hz, J2 = 1.4 Hz, 1H); 4.96 (dt, J1 = 10.3 Hz, J2 = 1.3 Hz, 1H); 
4.89-4.83 (m, 1H); 4.78-4.71 (m, 1H); 3.73 (dd, J1 = 17.0 Hz, J2 = 6.7 Hz, 1H); 3.35 (dd, 
J1 = 11.4 Hz, J2 = 8.0 Hz, 1H), 3.27 (dd, J1 = 17.0 Hz, J2 = 5.8 Hz, 1H), 2.94 (dd, J1 = 
11.4 Hz, J2 = 1.0 Hz, 1H); 2.29 (oct, J = 6.7 Hz, 1H); 1.03 (s, 9H); 1.00 (d, J = 6.7 Hz, 
3H); 0.90 (d, J = 7.0 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ (ppm):  202.76; 170.94; 
139.80; 136.07; 136.01; 134.14; 133.85; 129.69; 127.58; 127.54; 115.31; 71.64; 71.56; 
46.27; 30.84; 30.58; 27.11; 19.44; 19.20; 17.78.  HRMS (TOF, ES+) C27H35NO2S2Si 
[M+H]+ calc. mass 498.1957, found 498.1960. 
 
 
(S)-3-((tert-butyldiphenylsilyl)oxy)pent-4-en-1-ol (2.189) 
To a solution of (S)-3-((tert-butyldiphenylsilyl)oxy)-1-((R)-4-isopropyl-2-
thioxothiazolidin-3-yl)pent-4-en-1-one (15.45 g, 31.04 mmol, 1.0 eq) in THF (0.1 M) 
under argon at 0 °C is added methanol (5.0 mL, 124 mmol, 4.0 eq) followed by 2.0 M 
LiBH4 solution in THF (46.5 mL, 93.11 mmol, 3.0 eq) dropwise.  The reaction was 
allowed to stir for 45 min at 0 °C.  The reaction was quenched with NH4Cl solution, 
extracted 3x with EtOAc, dried over Na2SO4, and concentrated under vacuum.  
Purification via flash chromatography (Hex:EtOAc 4:1) afforded the desired product as a 
clear, colorless oil in 93% yield (9.83 g).  [α]20¦D = 0.7 (c = 0.70, CHCl3).  1H NMR 
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(400 MHz, CDCl3) δ (ppm):  7.75-7.66 (m, 4H); 7.48-7.34 (m, 6H); 5.86 (ddd, J1 = 16.9 
Hz, J¬2 = 10.5 Hz, J3 = 6.2 Hz, 1H); 5.06 (dt, J1 = 17.2 Hz, J2 = 1.4 Hz, 1H); 5.01 (dt, J1 
= 10.4 Hz, J2 = 1.3 Hz, 1H); 4.44 (m, 1H); 3.75 (m, 1H); 3.65 (m, 1H); 1.92 (br, 1H); 
1.81 (m, 1H); 1.70 (m, 1H); 1.10 (s, 9H).   13C NMR (100 MHz, CDCl3) δ (ppm):  
140.18; 136.12; 136.03; 133.91; 133.74; 129.94; 129.82; 127.77; 127.60; 114.99; 73.35; 
59.56; 39.45; 27.16; 19.43.  HRMS (TOF, ES+) C21H28O2Si [M+H]+ calc. mass 
341.1937, found 341.1935. 
 
OTBDPS
H
O
 
(S)-3-((tert-butyldiphenylsilyl)oxy)pent-4-enal (2.190) 
To a flame-dried flask equipped with a stir bar, under argon, was added CH2Cl2 (71 mL) 
followed by (COCl)2 (3.12 mL, 35.66 mmol, 1.2 eq).  The reaction was cooled to -78 oC 
and DMSO (4.64 mL, 65.38 mmol, 2.2 eq) was added dropwise.  After stirring at -78 oC 
for 30 min, a solution of (S)-3-((tert-butyldiphenylsilyl)oxy)pent-4-en-1-ol (10.12 g, 
29.72 mmol, 1.0 eq) in CH2Cl2 (0.25 M) was added dropwise.  The reaction was allowed 
to stir at -78 oC for 30 min after which NEt¬3 (5.0 eq) was added followed by warming 
to rt.  The reaction was quenched with NH4Cl, extracted with CH2Cl2, dried over 
Na2SO4, and concentrated in vacuo.  Purification via flash chromatography (Hex:EtOAc 
4:1) afforded the desired product as a clear, colorless oil in 98% yield (9.86 g).  [α]20¦D = 
6.7 (c = 0.73, CHCl3).  1H NMR (400 MHz, CDCl3) δ (ppm):  9.71 (t, J = 2.6 Hz, 1H); 
7.72-7.65 (m, 4H); 7.48-7.35 (m, 6H); 5.91 (ddd, J¬1 = 17.0 Hz, J2¬ = 10.4 Hz, J3 = 5.9 
Hz); 5.15 (dt, J1 = 17.1 Hz, J2 = 1.3 Hz, 1H); 5.07 (dt, J1 = 10.5 Hz, J2 = 1.3 Hz, 1H); 
4.67 (m, 1H); 2.53-2.48 (m, 2H); 1.09 (s, 9H).  13C NMR (100 MHz, CDCl3) δ (ppm):  
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201.57; 139.30; 136.00; 133.61; 133.50; 130.07; 129.90; 127.86; 127.68; 115.60; 70.36; 
50.84; 27.07; 19.41.  HRMS (TOF, ES+) C21H26O2Si [M+H]+ calc. mass 339.1780, 
found 339.1777. 
 
 
(S,E)-ethyl 5-((tert-butyldiphenylsilyl)oxy)hepta-2,6-dienoate 
To a suspension of dried LiCl (1.40 g, 33.11 mmol, 1.2 eq) in MeCN (0.1 M) in a flame-
dried flask under argon was added DBU (4.21 mL, 27.59 mmol, 1.0 eq), triethyl 
phosphonoacetate (6.77 mL, 33.11 mmol, 1.2 eq), and (S)-3-((tert-
butyldiphenylsilyl)oxy)pent-4-enal (9.34 g, 27.59 mmol, 1.0 eq).  The reaction stirred at 
rt for 2 h.  The reaction is quenched by the addition of pH 7 buffer followed by extraction 
with EtOAc.  The organic extracts were dried over Na2SO4 and concentrated under 
vacuum.  Purification via flash chromatography (Hex:EtOAc 4:1) afforded the desired 
product as a clear, colorless oil in 90% yield (10.14 g).  [α]20¦D = 53.9 (c = 0.87, 
CHCl3).  1H NMR (400 MHz, CDCl3) δ (ppm):  7.75-7.66 (m, 4H); 7.48-7.35 (m, 6H); 
6.91 (dt, J1 = 7.5 Hz, J2 = 15.7 Hz, 1H); 5.84 (ddd, J1 = 16.9 Hz, J2 = 10.4 Hz, J3 = 6.2 
Hz, 1H); 5.76 (d, J = 15.7 Hz, 1H); 5.14-5.02 (m, 2H); 4.32 (q, J = 5.9 Hz, 1H); 4.20 (q, J 
= 7.1 Hz, 2H); 2.39-2.33 (m, 2H); 1.30 (t, J = 7.1 Hz, 3H); 1.12 (s, 9H).  13C NMR (100 
MHz, CDCl3) δ (ppm):  166.30; 144.66; 139.66; 136.00; 135.97; 134.01; 133.79; 129.85; 
129.73; 127.69; 127.55; 123.79; 115.30; 73.57; 60.16; 40.63; 27.08; 19.40; 14.34.  
HRMS (TOF, ES+) C25H32O3Si [M+H]+ calc. mass 409.2199, found 409.2202. 
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(S,E)-5-((tert-butyldiphenylsilyl)oxy)hepta-2,6-dienoic acid (2.191) 
To a solution of (S,E)-ethyl 5-((tert-butyldiphenylsilyl)oxy)hepta-2,6-dienoate (9.76 g, 
23.89 mmol, 1.0 eq) in 3:1 THF/H2O (0.2 M) under argon was added LiOH (5.72 g, 
238.88 mmol, 10.0 eq).  The resulting solution was heated to 55 oC for 18 hrs.  The 
reaction was cooled to rt and acidified to pH 2 by slow addition of HCl.  The solution 
was then extracted with EtOAc, dried over Na2SO4, and concentrated in vacuo.  
Purification via flash chromatography (Hex:EtOAc 1:1) afforded the desired product as a 
clear, colorless oil in 89% yield (8.09 g).  [α]20¦D = 58.1 (c = 1.04, CHCl3).  1H NMR 
(400 MHz, CDCl3) δ (ppm):  7.74-7.63 (m, 4H); 7.49-7.34 (m, 6H); 7.00 (dt, J1 = 7.3 
Hz, J2 = 15.7 Hz, 1H); 5.82 (ddd, J1 = 16.8 Hz, J2 = 10.3 Hz, J3 = 6.2 Hz, 1H); 5.74 (d, J 
= 15.7 Hz, 1H); 5.14-5.03 (m, 2H); 4.36-4.29 (m, 1H); 2.36 (t, J = 6.4 Hz, 2H); 1.10 (s, 
9H).  13C NMR (100 MHz, CDCl3) δ (ppm):  172.00; 147.84; 139.59; 136.07; 136.03; 
134.01; 133.79; 129.97; 129.81; 127.80; 127.63; 123.19; 115.51; 73.22; 40.70; 27.13; 
19.44.  HRMS (TOF, ES+) C23H28O3Si [M+Na]+ calc. mass 403.1705, found 
403.1708. 
 
 
(R)-3-((S,E)-5-((tert-butyldiphenylsilyl)oxy)hepta-2,6-dienoyl)-4-phenyloxazolidin-2-
one (2.192) 
 
To a solution of (S,E)-5-((tert-butyldiphenylsilyl)oxy)hepta-2,6-dienoic acid (7.23 g, 
19.00 mmol, 1.0 eq), in THF (0.1 M), under argon at -78 oC, was added NEt3 (3.18 mL, 
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22.79 mmol, 1.2 eq) followed by dropwise addition of pivaloyl chloride (2.62 mL, 21.28 
mmol, 1.12 eq).  The reaction was allowed to stir at -78 oC for 15 min followed by 
stirring at 0 oC for 15 min.  In a separate flame-dried flask under argon at -78 oC was 
added (R)-(−)-4-Phenyl-2-oxazolidinone (3.10 g, 19.00 mmol, 1.0 eq) followed by THF 
(0.1 M).  n-BuLi (7.98 mL, 19.90 mmol, 1.05 eq) was added dropwise followed by 
continued stirring at -78 oC for 30 min.  The solution of mixed anhydride was cooled 
back down to – 78 oC and the oxazolidinone was added via cannula.  After stirring at -78 
oC for 20 min, the reaction warmed to rt and continued stirring for 1 h.  The reaction was 
quenched by addition of saturated NH4Cl, extracted with EtOAc, dried over Na2SO4, 
and concentrated.  Purification via flash chromatography (Hex:EtOAc 4:1) afforded the 
desired product as a clear, colorless oil in 95% yield (9.49 g).  [α]20¦D = -8.6 (c = 0.90, 
CHCl3).  1H NMR (400 MHz, CDCl3) δ (ppm):  7.68-7.59 (m, 4H); 7.44-7.28 (m, 11H); 
7.20 (d, J = 15.5 Hz, 1H); 7.03 (m, 1H); 5.77 (ddd, J1 = 16.90 Hz, J2 = 10.3 Hz, J3 = 6.1 
Hz, 1H); 5.47 (dd, J1 = 8.6 Hz, J2 = 3.8 Hz, 1H); 5.09-4.98 (m, 2H); 4.69 (t, J = 8.7 Hz, 
1H); 4.32-4.24 (m, 2H); 2.44-2.31 (m, 2H); 1.05 (s, 9H).  13C NMR (100 MHz, CDCl3) 
δ (ppm):  164.24; 153.75; 147.67; 139.61; 139.31; 136.04; 134.03; 133.80; 129.88; 
129.74; 129.32; 128.79; 127.75; 127.59; 126.04; 122.50; 115.41; 73.25; 70.07; 57.85; 
40.98; 27.13; 19.42.  HRMS (TOF, ES+) C32H35NO4Si [M+Na]+ calc. mass 526.2414, 
found 526.2416. 
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(R)-3-((3R,5S)-5-((tert-butyldiphenylsilyl)oxy)-3-methylhept-6-enoyl)-4-
phenyloxazolidin-2-one 
 
To a solution of copper iodide dimethyl sulfide complex (2.47 g, 10.40 mmol, 2.0 eq) in 
THF (0.23 M) under argon at -78 oC was slowly added MeLi (7.2 mL, 10.14 mmol, 1.95 
eq).  The reaction stirred at rt for 30 min.  TMS-I (1.44 mL, 10.14 mmol, 1.95 eq) was 
added followed by stirring at -78 oC for an additional 5 min.  A solution of (R)-3-((S,E)-
5-((tert-butyldiphenylsilyl)oxy)hepta-2,6-dienoyl)-4-phenyloxazolidin-2-one (2.73 g, 
5.20 mmol,1.0 eq) in THF (0.15 M) was cooled to -78 oC and transferred to the cuprate 
solution via cannula.  After stirring at -78 oC overnight, NEt3 (7.75 mL) was added and 
the reaction stirred for an additional hour.  The reaction was quenched by the addition of 
pH 10 ammonia buffer, extracted with EtOAc, dried over Na2SO4, and concentrated.  
Purification via flash chromatography (Hex:EtOAc 4:1) afforded the desired product as a 
clear, colorless oil in 90% yield (2.53 g) and 17:1 d.r.  [α]20¦D = -20.0 (c = 0.98, CHCl3).   
1H NMR (400MHz, CDCl3) d 7.67-7.63 (m, 4H), 7.41-7.29 (m, 11H), 5.73 (ddd, J = 
17.1, 10.4, 7.1 Hz, 1H), 5.40 (dd, J = 8.6, 3.6 Hz, 1H), 4.94-4.87 (m, 2H), 4.65 (t, J = 8.8 
Hz, 1H), 4.26 (dd, J = 8.9, 3.6 Hz, 1H), 4.13-4.08 (m, 1H), 2.82-2.67 (m, 2H), 2.01-1.92 
(m, 1H), 1.52-1.46 (m, 1H), 1.41-1.35 (m, 1H), 1.04 (s, 9H), 0.63 (d, J = 6.6 Hz, 3H); 
13C NMR (100 MHz, CDCl3)  171.8, 153.6, 140.8, 139.1, 136.04, 135.99, 134.2, 
134.1, 129.5, 129.4, 129.1, 128.6, 127.5, 127.3, 125.8, 114.6, 73.0, 69.8, 57.6, 44.6, 42.6, 
27.1, 26.0, 19.7, 19.3.  HRMS (TOF, ES+) C33H39NO4Si [M+Na]+ calc. mass 
564.2546, found 564.2546. 
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(R)-3-((2R,3R,5S)-2-allyl-5-((tert-butyldiphenylsilyl)oxy)-3-methylhept-6-enoyl)-4-
phenyloxazolidin-2-one (2.193) 
  
To a solution of (R)-3-((3R,5S)-5-((tert-butyldiphenylsilyl)oxy)-3-methylhept-6-enoyl)-
4-phenyloxazolidin-2-one (3.1 g, 5.72 mmol, 1.0 eq) in THF (0.1 M) under argon at -78 
oC under argon was added 1.0 M LiHMDS (6.3 mL, 6.29 mmol, 1.1 eq).  The reaction 
continued stirring for 2 h at -78 oC.  In a separate flask a solution of allyl iodide (1.57 
mL, 17.16 mmol, 3.0 eq) and HMPA (3.0 mL, 17.16 mmol, 3.0 eq) in THF (0.5 M) was 
prepared and transferred to the enolate solution at -78 oC.  The reaction was warmed to -
45 oC and continued stirring overnight.  The reaction was quenched by the addition of 
saturated NH4Cl, extracted with EtOAc, dried over Na2SO4, and concentrated.  
Purification via flash chromatography (Hex:EtOAc 4:1) afforded the desired product as a 
clear, colorless oil in 87% yield (2.89 g) and 15:1 d.r.  [α]20¦D = -29.6 (c = 0.63, CHCl3).   
1H NMR (400 MHz, CDCl3) δ 7.70-7.65 (m, 4H), 7.46-7.31 (m, 9 H), 7.27-25 (m, 2H), 
5.75 (ddd, J = 17.2, 10.3, 7.3 Hz, 1H), 5.53-5.43 (m, 1H), 5.35 (dd,  J = 8.6, 3.4 Hz, 1H), 
5.00-4.92 (m, 2H), 4.77-4.72 (m, 2H), 4.55 (t, J = 8.8 Hz, 1H), 4.22 (dd, J = 8.9, 3.5 Hz, 
1H), 4.15-4.10 (m, 1H), 3.82-3.77 (m, 1H), 2.29-2.21 (m, 1H), 2.13-2.09 (m, 1H), 1.72-
1.66 (m, 2H), 1.33-1.27 (m, 1H), 1.08 (s, 9H), 0.66 (d, J  = 6.6. Hz, 3H).  13C NMR (100 
MHz, CDCl3)  174.5, 153.3, 140.1, 139.0, 135.8, 135.8, 134.8, 134.2, 133.9, 129.5, 
129.4, 128.8, 128.4, 127.4, 127.3, 125.9, 116.7, 115.2, 73.3, 69.3, 57.7, 47.3, 40.8, 32.9, 
30.9, 26.9, 19.1, 17.2.  HRMS (TOF, ES+) C36H43NO4Si [M+H]+ calc. mass 582.3040, 
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found 582.3035.    
 
  
(2R,3R,5S)-2-allyl-5-((tert-butyldiphenylsilyl)oxy)-3-methylhept-6-enoic acid 
To a solution of (R)-3-((2R,3R,5S)-2-allyl-5-((tert-butyldiphenylsilyl)oxy)-3-methylhept-
6-enoyl)-4-phenyloxazolidin-2-one (4.74 g, 8.14 mmol, 1.0 eq) in 3:1 THF/H2O (0.2 M) 
under argon at 0 oC was added 30% H2O2 (3.65 mL, 32.15 mmol, 3.95 eq) followed by 
LiOH (390 mg, 16.28 mmol, 2.02 eq).  The reaction was warmed to rt and continued 
stirring overnight.  The reaction was quenched with saturated NaHSO4 and NH4Cl, 
extracted with EtOAc, dried over Na2SO4, and concentrated in vacuo.  Purification via 
flash chromatography (Hex:EtOAc 4:1) afforded the desired product as a clear, colorless 
oil in 96% yield (3.42 g).  [α]20¦D = 19.8 (c = 0.75, CHCl3).  1H NMR (400MHz, 
CDCl3) d 7.75-7.70 (m, 4H), 7.47-7.38 (m, 6H), 5.86-5.68 (m, 2H), 5.10-4.98 (m, 4H), 
4.24-4.19 (m, 1H), 2.38-2.29 (m, 2H), 2.17-2.13 (m, 1H), 1.74-1.66 (m, 2H), 1.46-1.39 
(m, 1H), 1.12 (s, 9H), 0.72 (d, J = 6.7 Hz, 3H); 13C NMR (100 MHz, CDCl3)  180.8, 
140.2, 136.0, 135.9, 135.5, 134.2, 134.0, 129.6, 129.5, 127.5, 127.4, 116.7, 115.2, 73.3, 
50.4, 42.3, 33.5, 31.0, 27.0, 19.2, 16.5.  HRMS (TOF, ES+) C27H36O3Si [M+H]+ calc. 
mass 437.2512, found 437.2514. 
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TBDPSO
OH
 
(2R,3R,5S)-2-allyl-5-((tert-butyldiphenylsilyl)oxy)-3-methylhept-6-en-1-ol  (2.194) 
To a solution of (2R,3R,5S)-2-allyl-5-((tert-butyldiphenylsilyl)oxy)-3-methylhept-6-
enoic acid (1.87 g, 4.27 mmol, 1.0 eq) in 4:1 THF/Et2O (0.1 M) under argon at 0 oC was 
added LiAlH4 (594 mg, 14.96 mmol, 3.5 eq).  The reaction was allowed to warm to rt 
and continue stirring for 7 h.  The reaction was cooled to 0 oC and quenched with H2O.  
The reaction was then warmed to rt and diluted with Et2O.  Rochelle’s Salt and 1.0 M 
NaOH were added followed by stirring for 30 min.  The reaction was then filtered 
through Celite, extracted with EtOAc, dried over Na2SO4, and concentrated.  
Purification via flash chromatography (Hex:EtOAc 4:1) afforded the desired product as a 
clear, colorless oil in 84% yield (1.51 g).  [α]20¦D = 35.6 (c = 0.59, CHCl3).  1H NMR 
(400MHz, CDCl3) d 7.70-7.65 (m, 4H), 7.45-7.34 (m, 6H), 5.83-5.69 (m, 2H), 5.04-4.95 
(m, 4H), 4.16-4.11 (m, 1H), 3.47 (dd, J = 5.8, 2.1 Hz, 2H), 2.03-1.91 (m, 2H), 1.59-1.49 
(m, 2H), 1.43-1.39 (m, 1H), 1.34-1.27 (m, 1H), 1.23 (bs, 1H), 1.07 (s, 9H), 0.59 (d, J = 
6.9 Hz, 3H); 13C NMR (100 MHz, CDCl3)  140.5, 137.9, 135.95, 135.90, 134.4, 
134.1, 115.8, 114.9, 73.7, 63.3, 45.7, 41.7, 33.3, 29.0, 27.0, 19.2, 16.2.  HRMS (TOF, 
ES+) C27H38O2Si [M+H]+ calc. mass 423.2719, found 423.2723. 
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(2R,3R,5S)-2-allyl-5-((tert-butyldiphenylsilyl)oxy)-3-methylhept-6-enal 
To a solution of (2R,3R,5S)-2-allyl-5-((tert-butyldiphenylsilyl)oxy)-3-methylhept-6-en-1-
ol (1.35 g, 3.18 mmol, 1.0 eq) in CH2Cl2 (0.1 M) under argon was added 4Å molecular 
sieves (0.5g/mmol) followed by NMO (551.8 mg, 4.71 mmol, 1.48 eq).  The reaction was 
stirred at rt for 10 min after which TPAP (112 mg, 0.32 mmol, 0.1 eq) was added.  The 
reaction continued to stir at rt for 5 h.  The reaction was filtered through Celite and 
concentrated in vacuo.  Purification via flash chromatography (Hex:EtOAc 4:1) afforded 
the desired product as a clear, colorless oil in 85% yield (1.14 g).  [α]20¦D = 11.2 (c = 
0.55, CHCl3).  1H NMR (400MHz, CDCl3) δ 9.52 (d, J = 2.6 Hz,1H), 7.68-7.63 (m, 4H), 
7.44-7.33 (m, 6H), 5.76 (ddd, J =  17.3, 10.3, 7.0 Hz, 1H), 5.70-5.60 (m, 1H), 5.02-4.95 
(m, 4H), 4.18-4.13 (m, 1H), 2.37-2.31 (m, 1H), 2.20-2.15 (m, 1H), 2.07-2.01 (m, 1H), 
1.82-1.79 (m, 1H), 1.59-1.53 (m, 1H), 1.42-1.35 (m, 1H), 1.06 (s, 9H), 0.66 (d, J = 6.9 
Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 204.9, 140.1, 136.0, 135.9, 135.7, 134.2, 134.0, 
120.7, 129.6, 127.5, 127.4, 116.7, 115.4, 73.3, 56.3, 41.9, 30.4, 29.3, 27.0, 19.2, 16.5.  
HRMS (TOF, ES+) C27H36O2Si [M+Na]+ calc. mass 443.2382, found 443.2383. 
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(R,E)-N-((2R,3R,5S)-2-allyl-5-((tert-butyldiphenylsilyl)oxy)-3-methylhept-6-en-1-
ylidene)-2-methylpropane-2-sulfinamide (2.195) 
 
To a solution of (2R,3R,5S)-2-allyl-5-((tert-butyldiphenylsilyl)oxy)-3-methylhept-6-enal 
(897 mg, 2.13 mmol, 1.0 eq) in THF (0.2 M) under argon was added Ti(OEt)4 (1.11 mL, 
5.33 mmol, 2.5 eq) followed by (S)-2-methylpropane-2-sulfinamide (284 mg, 2.34 mmol, 
1.1 eq).  The reaction was allowed to stir at 40 oC overnight.  The reaction was quenched 
by the addition of saturated NaHCO3, extracted with EtOAc, dried over sodium sulfate, 
and concentrated under vacuum.  Purification via flash chromatography (Hex:EtOAc 4:1) 
afforded the desired product as a clear, colorless oil in 92% yield (1.03 g).  [α]ଶ଴஽  = -88.6 
(c = 0.76, CHCl3).  1H NMR (400MHz, CDCl3) δ 7.83 (d, J = 6.2 Hz, 1H); 7.70-7.62 (m, 
4H); 7.45-7.32 (m, 6H); 5.75 (ddd, J1 = 17.2 Hz, J2 = 10.2 Hz, J3 = 7.0 Hz, 1H); 5.64 
(dddd, J1 = 17.0 Hz, J2 = 13.9 Hz, J3 = 10.2 Hz, J4 = 7.0 Hz, 1H); 5.04-4.96 (m, 2H); 
4.96-4.88 (m, 2H); 4.16 (q, J = 7.2 Hz, 1H); 2.48-2.40 (m, 1H); 2.38-2.27 (m, 1H); 2.18-
2.08 (m, 1H); 1.83-1.72 (m, 1H); 1.57 (ddd, J1 = 13.2 Hz, J2 = 8.4 Hz, J3 = 4.8 Hz, 1H); 
1.39 (ddd, J1 = 14.1, J2 = 9.3 Hz, J3 = 5.3 Hz, 1H); 1.17 (s, 9H); 1.06 (s, 9H); 0.65 (d, J = 
6.9 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 171.65; 140.49; 136.14; 136.07; 134.33; 
134.21; 129.81; 129.66; 127.68; 127.51; 116.89; 115.25; 73.42; 56.60; 50.06; 42.68; 
34.00; 31.40; 27.18; 22.65; 19.39; 16.09. HRMS (TOF, ES+) C31H45NO2SSi [M+Na]+ 
calc. mass 546.2838, found 546.2841. 
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N-((3S,4R,5R,7S)-4-allyl-7-((tert-butyldiphenylsilyl)oxy)-5-methylnona-1,8-dien-3-
yl)pivalamide (2.181) 
 
To a solution of (S,E)-N-((2R,3R,5S)-2-allyl-5-((tert-butyldiphenylsilyl)oxy)-3-
methylhept-6-en-1-ylidene)-2-methylpropane-2-sulfinamide in CH2Cl2 (0.1 M) at -48 oC 
was added vinyl Grignard (1.0 M, 10.0 eq) dropwise.  The reaction stirred at -48 oC for 7 
h and was then allowed to warm to rt and continue stirring overnight.  The reaction was 
quenched by the addition of sat aq NH4Cl, extracted with CH2Cl2 (3x), dried over 
Na2SO4, and concentrated under vacuum.  Purification via flash 
chromatography(Hex/EtOAc 1:1) afforded the pure product in 65% overall yield and 
37% isolated yield of the desired diastereomer.   1H NMR (400MHz, CDCl3) δ (ppm):  
7.70-7.62 (m, 4H); 7.45-7.31 (m, 6H); 5.80-5.66 (m, 2H); 5.53 (ddd, J1 = 17.2 Hz, J2 = 
10.1 Hz, J3 = 8.3 Hz, 1H); 5.20 (d, J = 16.0 Hz, 1H); 5.17 (d, J = 9.1 Hz, 1H); 5.06 (d, J 
= 18.5 Hz, 1H); 5.03 (d, J = 10.5 Hz, 1H); 4.97 (d, J = 10.6 Hz, 1H); 4.93 (d, J = 17.4 Hz, 
1H); 4.05 (ddd, J1 = 10.7 Hz, J2 = 7.3 Hz, J3 = 4.1 Hz, 1H); 3.83 (td, J1 = 7.3 Hz, J2 = 2.3 
Hz, 1H); 2.10-1.92 (m, 2H); 1.66-1.57 (m, 1H); 1.57-1.48 (m, 1H); 1.41-1.33 (m, 1H); 
1.28-1.18 (m, 2H); 1.16 (s, 9H); 1.06 (s, 9H); 0.59 (d, J = 7.0 Hz, 3H). 
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(2R,3R,5S)-2-allyl-5-((tert-butyldiphenylsilyl)oxy)-N-((R)-2-hydroxy-1-phenylethyl)-
3-methylhept-6-enamide (2.196) 
 
To a solution of Weinreb salt (301 mg, 3.09 mmol, 3.0 eq) in THF (0.5 M) under argon at 
0 oC, was added AlMe3 (1.55 mL, 3.09 mmol, 3.0 eq) dropwise. The reaction stirred at 0 
oC for 15 min then warmed to rt and stirred for an additional 15 min. The reaction was 
recooled to 0 oC and a solution of (R)-3-((2R,3R,5S)-2-allyl-5-((tert-
butyldiphenylsilyl)oxy)-3-methylhept-6-enoyl)-4- phenyloxazolidin-2-one (600 mg, 1.03 
mmol, 1.0 eq) in THF (0.1 M) was added. The reaction was warmed to 50 oC and stirred 
overnight. The product was partitioned between water and EtOAc, extracted with EtOAc 
(3x), dried over Na2SO4, and concentrated in vacuo. Purification via flash 
chromatography (Hex/EtOAc 1:1) did not afford the desired Weinreb amide, however the 
product of ring opening of the oxazolidinone (15) was isolated in 59% yield (338 mg).  
Crystals of (2R,3R,5S)-2-allyl-5-((tert-butyldiphenylsilyl)oxy)-N-((R)-2-hydroxy-1-
phenylethyl)-3-methylhept-6-enamide (15) were obtained as thin, colorless needles. Due 
to significant positional disorder in the structure, diffraction quality was poor at high 
angles requiring the use of a rotating-anode to obtain sufficient completeness for 
determination of the absolute structure. The molecule crystallized in the orthorhombic 
space group P212121 with 2 molecules in the asymmetric unit. The absolute 
configuration was determined with a Flack parameter of -0.0032, with an e.s.d. of 0.0383.  
[α]20¦D = 4.3 (c = 0.43, CHCl3).  1H NMR (400MHz, CDCl3) δ (ppm): 7.72-7.62 (m, 
4H); 7.44-7.27 (m, 9H); 7.25-7.19 (m, 2H); 5.94 (d, J = 6.7 Hz, 1H); 5.80 (ddd, J1 = 17.3 
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Hz, J2 = 10.4 Hz, J3 = 7.1 Hz, 1H); 5.67-5.55 (m, 1H); 5.05-4.88 (m, 5H); 4.16 (m, 1H); 
3.83-3.72 (m, 2H); 2.82 (br, 1H); 2.33-2.22 (m, 1H); 2.17-2.08 (m, 1H); 1.86 (ddd, J1 = 
10.6 Hz, J2 = 6.5 Hz, J3 = 4.2 Hz, 1H); 1.71-1.60 (m, 2H); 1.37 (ddd, J1 = 14.0 Hz, J2 = 
10.5 Hz, J3 = 4.7 Hz, 1H); 1.08 (s, 9H); 0.70 (d, J = 6.6 Hz, 3H).   13C NMR (100 MHz, 
CDCl3)  174.70; 140.40; 139.05; 136.12; 136.08; 136.05; 134.41; 134.09; 129.79; 
129.69; 128.86; 127.92; 127.67; 127.51; 126.92; 116.80; 115.44; 77.36; 73.51;  66.70; 
55.97; 52.89; 42.74; 34.45;  31.69; 27.15; 19.37; 16.88..  HRMS (TOF, ES+) 
C35H45NO3Si [M+Na]+ calc. mass 578.3066, found 578.3065. 
 
 
(2R,3R,5S)-2-allyl-5-((tert-butyldiphenylsilyl)oxy)-N-methoxy-N,3-dimethylhept-6-
enamide 
 
To a solution of (2R,3R,5S)-2-allyl-5-((tert-butyldiphenylsilyl)oxy)-3-methylhept-6-enoic 
acid in DMF (0.15 M) at 0 oC was added HATU (2.0 eq) followed by Weinreb salt (2.0 
eq) and N-methylmorpholine (NMM) (2.0 eq).  The reaction was stirred at 0 oC for 18 h.  
The reaction as then diluted with EtOAc, quenched with NH4Cl, extracted with EtOAc 
(3x), washed with 5% LiCl (1x), dried over Na2SO4, and concentrated under vacuum.  
Purification via flash chromatography (Hex/EtOAc 10-20%) afforded the pure Weinreb 
amide in 85% yield.  1H NMR (400MHz, CDCl3) δ (ppm):  7.71-7.63 (m, 4H); 7.45-7.31 
(m, 6H); 5.75 (ddd, J1 = 17.3 Hz, J2 = 10.3 Hz, J3 = 7.2 Hz, 1H); 5.66 (qt, J1 = 10.1 Hz, 
J2 = 7.0 Hz, 1H); 5.06-4.89 (m, 4H); 4.18-4.08 (m, 1H); 3.56 (s, 3H); 3.11 (s, 3H); 2.69-
2.56 (m, 1H); 2.36-2.25 (m, 1H); 2.17-2.07 (m, 1H); 1.75-1.56 (m, 2H); 1.32-1.22 (m, 
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1H); 1.06 (s, 9H); 0.60 (d, J = 6.6 Hz, 3H). 
 
TBDPSO O
 
(4R,5R,7S)-4-allyl-7-((tert-butyldiphenylsilyl)oxy)-5-methylnona-1,8-dien-3-one 
(2.198) 
 
To a solution of (2R,3R,5S)-2-allyl-5-((tert-butyldiphenylsilyl)oxy)-N-methoxy-N,3-
dimethylhept-6-enamide in THF (0.1 M) at 50 oC was added vinylmagnesium bromide 
(2.0 eq).  The reaction stirred at 50 oC for 15 min and was then quenched by the addition 
of sat aq NH4Cl., extracted with EtOAc (3x), dried over Na2SO4, and concentrated.  
Purification via flash chromatography (Hex/EtOAc 9:1) afforded the pure product in 77% 
yield.  1H NMR (400MHz, CDCl3) δ (ppm):  7.73-7.64 (m, 4H); 7.47-7.33 (m, 6H); 6.31 
(dd,   J1 = 17.4 Hz, J2 = 10.5 Hz, 1H); 6.12 (dd, J1 = 17.4 Hz, J2 = 1.3 Hz, 1H); 5.75 (ddd, 
J1 = 17.3 Hz, J2 = 10.4 Hz, J3 = 7.1 Hz, 1H); 5.67 (dd, J1 = 10.4 Hz, J2 = 1.3 Hz, 1H); 
5.62 (qt, J1 = 13.8 Hz, J2 = 6.9 Hz, 1H); 5.03-4.91 (m, 4H); 4.16-4.08 (m, 1H); 2.62 (ddd, 
J1 = 10.0 Hz, J2 = 5.9 Hz, J3 = 4.2 Hz, 1H); 2.40-2.30 (m, 1H); 2.14-2.05 (m, 1H); 1.76-
1.65 (m, 1H); 1.58 (ddd, J1 = 12.9 Hz, J2 = 9.3 Hz, J3 = 3.3 Hz, 1H); 1.33-1.23 (m, 1H); 
1.09 (s, 9H); 0.62 (d, J = 6.7 Hz, 3H). 
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(R,E)-N-((4R,5R,7S)-4-allyl-7-((tert-butyldiphenylsilyl)oxy)-5-methylnona-1,8-dien-
3-ylidene)-2-methylpropane-2-sulfinamide 
 
To a solution of ketone in THF (0.15 M) in a microwave vial was added (R)-2-
methylpropane-2-sulfinamide (1.0 eq) and Ti(OEt)4 (2.0 eq).  The reaction was heated in 
the microwave at 120 oC for 2 h, then quenched by the addition of sat aq NaHCO3, 
extracted with EtOAc (3x), dried over Na2SO4, and concentrated in vacuo.  Purification 
via flash chromatography (Hex/EtOAc 4:1) afforded the pure ketamine in 24% yield.  1H 
NMR (400MHz, CDCl3) δ (ppm):  7.70-7.61 (m, 4H); 7.45-7.31 (m, 6H); 5.78-5.53 (m, 
3H); 5.00-4.86 (m, 6H); 4.14-4.04 (m, 1H); 2.71-2.60 (m, 1H); 2.38-2.24 (m, 1H); 2.19-
2.07 (m, 1H); 1.74-1.55 (m, 3H); 1.24 (s, 9H); 1.05 (s, 9H); 0.62 (d, J = 6.7 Hz, 3H). 
 
(R)-N-((3S,4R,5R,7S)-4-allyl-7-((tert-butyldiphenylsilyl)oxy)-5-methylnon-8-en-3-yl)-
2-methylpropane-2-sulfinamide (2.199) 
 
To a solution of (R,E)-N-((4R,5R,7S)-4-allyl-7-((tert-butyldiphenylsilyl)oxy)-5-
methylnona-1,8-dien-3-ylidene)-2-methylpropane-2-sulfinamide in THF (0.1 M) at          
-78 oC was added L-selectride (3.0 eq) dropwise.  The reaction was allowed to warm to rt 
and continue stirring for 3 h.  The reaction was quenched by the addition of sat aq NH4Cl, 
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extracted with EtOAc (3x), dried over Na2SO4, and concentrated under vacuum.  
Purification via flash chromatography (Hex/EtOAc 1:1) afforded the reduced product in 
99% yield.  1H NMR (400MHz, CDCl3) δ (ppm):  7.70-7.62 (m, 4H); 7.45-7.32 (m, 6H); 
5.79 (ddd, J1 = 16.9 Hz, J2 = 11.0 Hz, J3 = 6.9 Hz, 1H); 5.72-5.60 (m, 1H); 5.05 (s, 1H); 
5.01 (d, J = 7.3 Hz, 1H); 4.98 (s, 1H); 4.94 (d, J = 4.8 Hz, 1H); 4.08 (ddd, J1 = 10.8 Hz, 
J2 = 6.9 Hz, J3 = 4.2 Hz, 1H); 3.17-3.09 (m, 1H); 2.82 (d, J = 8.1 Hz, 1H); 2.03-1.86 (m, 
2H); 1.68-1.58 (m, 2H); 1.57-1.43 (m, 4H); 1.22 (s, 9H); 1.06 (s, 9H); 0.90 (t, J = 7.2 Hz, 
3H); 0.55 (d, J = 6.6 Hz, 3H). 
 
 
(R)-N-((3S,4R,5R,7S)-4-allyl-7-hydroxy-5-methylnona-1,8-dien-3-yl)-2-
methylpropane-2-sulfinamide (2.200) 
 
To a solution of N-((3S,4R,5R,7S)-4-allyl-7-((tert-butyldiphenylsilyl)oxy)-5-methylnona-
1,8-dien-3-yl)pivalamide in THF (0.1 M) at 0 oC was added TBAF (2.0 eq).  The reaction 
warmed to rt and continued stirring overnight.  The reaction was quenched by the 
addition of H2O, extracted with EtOAc (3x), dried over Na2SO4, and concentrated.  
Purification via flash chromatography (DCM/MeOH 95:5) afforded the pure allylic 
alcohol in 91% yield.  1H NMR (400MHz, CDCl3) δ (ppm):  5.89-5.72 (m, 2H); 5.65 
(ddd, J1 = 17.3 Hz, J2 = 10.2 Hz, J3 = 8.2 Hz, 1H); 5.28-5.18 (m, 3H); 5.16-5.05 (m, 3H); 
4.13 (q, J = 6.7 Hz, 1H); 3.97-3.91 (m, 1H); 3.55 (d, J = 2.2 Hz, 1H); 2.32-2.23 (m, 1H); 
2.20-2.10 (m, 1H); 1.90-1.80 (m, 1H); 1.65-1.50 (m, 3H); 1.45-1.37 (m, 1H); 1.19 (s, 
201 
 
9H); 1.02 (d, J = 6.9 Hz, 3H). 
 
OHTBDPSO
 
(3R,4R,5R,7S)-4-allyl-7-((tert-butyldiphenylsilyl)oxy)-5-methylnona-1,8-dien-3-ol 
(2.204) 
 
To a solution of (2R,3R,5S)-2-allyl-5-((tert-butyldiphenylsilyl)oxy)-3-methylhept-6-enal 
in THF at -78 oC was added vinylmagnesium bromide (1.1 eq).  The reaction continued 
stirring at -78 oC overnight.  The reaction was quenched by the addition of sat aq NH4Cl, 
extracted with EtOAc (3x), dried over Na2SO4, and concentrated in vacuo.  Purification 
via flash chromatography (Hex/EtOAc 50-100%) afforded the pure allylic alcohol in 87% 
yield and 7:1 dr.  1H NMR (400MHz, CDCl3) δ (ppm):  7.71-7.63 (m, 4H); 7.45-7.32 (m, 
6H); 5.84-5.69 (m, 3H); 5.21-5.07 (m, 2H); 5.04-4.91 (m, 4H); 4.15-4.07 (m, 2H); 2.17-
2.08 (m, 1H); 2.07-1.97 (m, 1H); 1.70-1.48 (m, 3H); 1.39-1.28 (m, 2H); 1.06 (s, 9H); 
0.62 (d, J = 6.7 Hz, 3H). 
  
 
2-((3S,4R,5R,7S)-4-allyl-7-((tert-butyldiphenylsilyl)oxy)-5-methylnona-1,8-dien-3-
yl)isoindoline-1,3-dione (2.206) 
 
To a solution of (3R,4R,5R,7S)-4-allyl-7-((tert-butyldiphenylsilyl)oxy)-5-methylnona-
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1,8-dien-3-ol in THF (0.2 M) at 0 oC was added Ph3P (1.05 eq) and phthalimide (1.05 
eq).  DEAD (1.05 eq) was added dropwise and the reaction was warmed to rt and stirred 
overnight.  The reaction was partitioned between H2O and EtOAc, extracted with EtOAc 
(3x), dried over Na2SO4, and concentrated in vacuo.  Purification via flash 
chromatography (Hex/EtOAc 10-90%) afforded the pure product in up to 26% isolated 
yield and 7:1 dr.   1H NMR (400MHz, CDCl3) δ (ppm):  7.82-7.77 (m, 2H); 7.72-7.65 (m, 
2H); 7.62-7.54 (m, 4H); 7.43-7.27 (m, 6H); 6.23-6.12 (m, 1H); 5.80-5.68 (m, 1H); 5.43 
(ddd, J1 = 17.7 Hz, J2 = 10.3 Hz, J3 = 8.0 Hz, 1H); 5.26 (d, J = 17.1 Hz, 1H); 5.15 (d, J = 
10.0 Hz, 1H); 4.97-4.90 (m, 2H); 4.60-4.47 (m, 2H); 4.28 (dd, J1 = 10.3 Hz, J2 = 1.4 Hz, 
1H); 3.89-3.82 (m, 1H); 2.44-2.36 (m, 1H); 2.13-2.04 (m, 1H); 2.02-1.92 (m, 1H); 1.50-
1.41 (m, 1H); 1.33-1.20 (m, 2H); 0.98 (s, 9H); 0.53 (d, J = 6.3 Hz, 3H). 
 
 
(((3S,5R,6R,E)-6-allyl-9-azido-5-methylnona-1,7-dien-3-yl)oxy)(tert-butyl) 
diphenylsilane (2.207) 
 
To a solution of (3R,4R,5R,7S)-4-allyl-7-((tert-butyldiphenylsilyl)oxy)-5-methylnona-
1,8-dien-3-ol in toluene (0.1 M) at 0 oC was added Ph3P (1.05 eq) and DPPA (1.05 eq).  
DEAD (1.05 eq) was added dropwise and the reaction was heated to 50 oC and stirred 
overnight.  The reaction was partitioned between H2O and EtOAc, extracted with EtOAc 
(3x), dried over Na2SO4, and concentrated under vacuum.  Purification via flash 
chromatography (Hex/EtOAc 10-90%) afforded the pure terminal allylic azide in 85% 
yield.  1H NMR (400MHz, CDCl3) δ (ppm):  7.74-7.65 (m, 4H); 7.48-7.34 (m, 6H); 5.80 
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(ddd, J1 = 17.1 Hz, J2 = 10.3 Hz, J3 = 7.0 Hz, 1H); 5.70-5.57 (m, 1H); 5.43 (dd, J1 = 15.3 
Hz, J2 = 8.5 Hz, 1H); 5.35-5.26 (m, 1H); 5.00-4.91 (m, 4H); 4.15 (q, J = 6.9 Hz, 1H); 
3.64 (d, J = 6.4 Hz, 2H); 2.10-1.99 (m, 2H); 1.99-1.90 (m, 1H); 1.62-1.52 (m, 1H); 1.47 
(ddd, J1 = 13.3 Hz, J2 = 8.2 Hz, J3 = 4.8 Hz, 1H); 1.40-1.31 (m, 1H); 1.09 (s, 9H); 0.61 
(d, J = 6.9 Hz, 3H).  
 
 
(3R,4R,5R,7S)-4-allyl-7-((tert-butyldiphenylsilyl)oxy)-1-(1,3-dioxan-2-yl)-5-
methylnon-8-en-3-ol (2.208) 
 
To a solution of (2R,3R,5S)-2-allyl-5-((tert-butyldiphenylsilyl)oxy)-3-methylhept-6-enal 
in THF at -78 oC was added (2-(1,3-dioxan-2-yl)ethyl)magnesium bromide (1.1 eq).  The 
reaction continued stirring at -78 oC overnight.  The reaction was quenched by the 
addition of sat aq NH4Cl, extracted with EtOAc (3x), dried over Na2SO4, and 
concentrated in vacuo.  Purification via flash chromatography (Hex/EtOAc 50-100%) 
afforded the pure alcohol in 85% yield and 7:1 dr.  1H NMR (400MHz, CDCl3) δ (ppm):  
7.71-7.63 (m, 4H); 7.45-7.32 (m, 6H); 5.85-5.70 (m, 2H); 5.03-4.86 (m, 4H); 4.53 (t, J = 
4.8 Hz, 1H); 4.16-4.06 (m, 4H); 3.75 (t, J = 11.1 Hz, 2H); 3.60-3.54 (m, 1H); 2.19-2.05 
(m, 2H); 2.04-1.96 (m, 1H); 1.73-1.64 (m, 2H); 1.56-1.46 (m, 3H); 1.43-1.29 (m, 3H); 
1.23-1.16 (m, 1H); 1.06 (s, 9H); 0.60 (d, J = 6.9 Hz, 3H). 
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(((3S,5R,6R)-6-((S)-1-azido-3-(1,3-dioxan-2-yl)propyl)-5-methylnona-1,8-dien-3-
yl)oxy)(tert-butyl)diphenylsilane (2.209) 
 
To a solution of (3R,4R,5R,7S)-4-allyl-7-((tert-butyldiphenylsilyl)oxy)-1-(1,3-dioxan-2-
yl)-5-methylnon-8-en-3-ol in toluene (0.1 M) at 0 oC was added Ph3P (1.05 eq) and 
DPPA (1.05 eq).  DEAD (1.05 eq) was added dropwise and the reaction was heated to    
70 oC and stirred overnight.  The reaction was partitioned between H2O and EtOAc, 
extracted with EtOAc (3x), dried over Na2SO4, and concentrated under vacuum.  
Purification via flash chromatography (Hex/EtOAc 10-90%) afforded the pure terminal 
allylic azide in 65% yield.  1H NMR (400MHz, CDCl3) δ (ppm):  7.71-7.63 (m, 4H); 
7.45-7.32 (m, 6H); 5.75 (ddd, J1 = 17.2 Hz, J2 = 10.2 Hz, J3 = 7.3 Hz, 1H); 5.63 (qt, J1 = 
10.2 Hz, J2 = 6.4 Hz, 1H); 5.03-4.84 (m, 4H); 4.43 (t, J = 5.3 Hz, 1H); 4.12-4.03 (m, 3H); 
3.76-3.66 (m, 2H); 2.72-2.49 (m, 2H); 2.14-1.94 (m, 4H); 1.61-1.50 (m, 4H); 1.48-1.37 
(m, 1H); 1.36-1.27 (m, 1H); 1.05 (s, 9H); 0.71 (d, J = 6.9 Hz, 3H). 
 
 
(3S,5R,6R)-6-((S)-1-azido-3-(1,3-dioxan-2-yl)propyl)-5-methylnona-1,8-dien-3-ol 
To a solution of (((3S,5R,6R)-6-((S)-1-azido-3-(1,3-dioxan-2-yl)propyl)-5-methylnona-
1,8-dien-3-yl)oxy)(tert-butyl)diphenylsilane in THF (0.1 M) at 0 oC was added TBAF 
(2.0 eq).  The reaction warmed to rt and continued stirring overnight.  The reaction was 
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quenched by the addition of H2O, extracted with EtOAc (3x), dried over Na2SO4, and 
concentrated.  Purification via flash chromatography (DCM/MeOH 95:5) afforded the 
pure allylic alcohol in 93% yield.  1H NMR (400MHz, CDCl3) δ (ppm):  5.83 (ddd, J1 = 
17.1 Hz, J2 = 10.5 Hz, J3 = 6.0 Hz, 1H); 5.74 (qt, J1 = 6.4 Hz, J2 = 12.8 Hz, 1H); 5.31-
5.14 (m, 2H); 5.13-4.92 (m, 3H); 4.49 (t, J1 = 5.4 Hz, 1H); 4.12-4.02 (m, 3H); 3.73 (td, J1 
= 12.3 Hz, J2 = 2.4 Hz, 2H); 2.85-2.62 (m, 2H); 2.41-2.22 (m, 1H); 2.18-1.99 (m, 3H); 
1.84-1.53 (m, 4H); 1.45 (ddd, J1 = 14.3 Hz, J2 = 8.8 Hz, J3 = 5.5 Hz, 1H); 1.36-1.29 (m, 
1H); 1.00 (d, J1 = 6.9 Hz, 3H). 
 
 
(3S,5R,6R)-6-((S)-1-azido-3-(1,3-dioxan-2-yl)propyl)-5-methylnona-1,8-dien-3-yl 
methacrylate (2.210) 
 
To a solution of (3S,5R,6R)-6-((S)-1-azido-3-(1,3-dioxan-2-yl)propyl)-5-methylnona-1,8-
dien-3-ol in CH2Cl2 at 0 oC was added Et3N (3.0 eq), DMAP (1.0 eq), and methacrylic 
anhydride (2.2 eq).  The reaction warmed to rt and continued stirring for 3.5 h.  The 
reaction was quenched by the addition of H2O, extracted with EtOAc (3x), dried over 
Na2SO4, and concentrated.  Purification via flash chromatography (DCM/MeOH 95:5) 
afforded the pure compound in 76% yield.  1H NMR (400MHz, CDCl3) δ (ppm):  6.11 (s, 
1H); 5.78 (ddd, J1 = 17.1 Hz, J2 = 10.5 Hz, J3 = 6.3 Hz, 1H); 5.70 (qt, J1 = 6.6 Hz, J2 = 
9.9, 1H); 5.57-5.53 (m, 1H); 5.26-5.10 (m, 4H); 5.05-4.91 (m, 2H); 4.49 (t, J = 5.2 Hz, 
1H); 4.12-4.05 (m, 2H); 3.81-3.68 (m, 2H); 2.75 (d, J = 6.6 Hz, 1H); 2.34-2.22 (m, 1H); 
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2.15-1.99 (m, 3H); 1.94 (s, 3H); 1.73-1.58 (m, 4H); 1.36-1.29 (m, 1H); 1.02 (d, J = 7.2 
Hz, 3H). 
  
 
(R)-N-((3S,4R,5R,7S)-4-allyl-7-((tert-butyldiphenylsilyl)oxy)-1-(1,3-dioxan-2-yl)-5-
methylnon-8-en-3-yl)-2-methylpropane-2-sulfinamide, (2.213) 
To a solution of (R)-N-((2R,3R,5S)-2-allyl-5-((tert-butyldiphenylsilyl)oxy)-3-methylhept-
6-en-1-ylidene)-2-methylpropane-2-sulfinamide (723 mg, 1.38 mmol, 1.0 eq) in CH2Cl2 
(0.1 M) under argon at -45 oC was added (2-(1,3-dioxan-2-yl)ethyl)magnesium bromide 
(27.6 mL, 1.0 M in THF, 20.0 equiv) dropwise via cannula.  The reaction was allowed to 
warm to room temperature and continue stirring for 24 h.  The reaction was quenched 
with NH4Cl, extracted with EtOAc, dried over sodium sulfate, and concentrated.  
Purification via flash chromatography (Hex:EtOAc 50-100%) afforded the desired 
product as a clear, colorless oil in 86% yield and 10:1 dr.  The pure desired diastereomer 
can be isolated in 78% yield (689 mg).  [α]ଶ଴஽  = -9.7 (c = 0.38, CHCl3).  1H NMR 
(400MHz, CDCl3) δ 7.70-7.61 (m, 4H); 7.45-7.31 (m, 6H); 5.84-5.69 (m, 2H); 5.09-4.92 
(m, 4H); 4.44 (t, J = 4.6 Hz, 1H); 4.08 (dd, J1 = 11.0 Hz, J2 = 5.2 Hz, 3H); 3.78-3.68 (m, 
2H); 3.41 (d, J = 6.0 Hz, 1H); 3.31-3.23 (m, 1H); 2.13-1.97 (m, 2H); 1.71-1.63 (m, 1H); 
1.63-1.48 (m, 5H); 1.48-1.39 (m, 2H); 1.36-1.29 (m, 1H); 1.29-1.20 (m, 2H); 1.16 (s, 
9H); 1.06 (s, 9H); 0.61 (d, J = 6.7 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 140.60; 
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139.36; 136.11; 136.07; 134.51; 134.29; 129.75; 129.62; 127.66; 127.50; 116.37; 115.36; 
102.22; 73.92; 67.00; 66.98; 57.94; 55.97; 46.91; 40.99; 31.74; 31.25; 28.80; 27.80; 
27.18; 25.92; 22.98; 19.35; 18.22.  HRMS (TOF, ES+) C37H57NO4SSi [M+H]+ calc. 
mass 640.3852, found 640.3856. 
 
 
(R)-N-((3R,4R,5R,7S)-4-allyl-1-(1,3-dioxan-2-yl)-7-hydroxy-5-methylnon-8-en-3-yl)-
2-methylpropane-2-sulfinamide 
To a solution of (R)-N-((3S,4R,5R,7S)-4-allyl-7-((tert-butyldiphenylsilyl)oxy)-1-(1,3-
dioxan-2-yl)-5-methylnon-8-en-3-yl)-2-methylpropane-2-sulfinamide (930 mg, 1.45 
mmol, 1.0 eq) in THF (0.1 M) under argon at 0 oC was added 1.0 M TBAF (5.0 mL, 5.08 
mmol, 3.5 eq).  The reaction was warmed to rt and continued stirring overnight.  The 
reaction was quenched by the addition of saturated NH4Cl, extracted with EtOAc, dried 
over sodium sulfate, and concentrated in vacuo.  Purification via flash chromatography 
(EtOAc 100%) afforded the desired product as a clear, colorless oil in 97% yield (565 
mg).  [α]ଶ଴஽  = -45.8 (c = 1.01, CHCl3).  1H NMR (400MHz, CDCl3) δ 5.89-5.76 (m, 2H); 
5.23 (d, J = 17.2 Hz, 1H); 5.14-5.06 (m, 2H); 5.04 (d, J = 10.2 Hz, 1H); 4.48 (t, J = 3.9 
Hz, 1H); 4.16 (q, J = 6.6 Hz, 1H); 4.07 (dd, J1 = 11.0, J2 = 5.0, 2H); 3.78-3.68 (m, 2H); 
3.52 (d, J = 6.6 Hz, 1H); 3.39-3.31 (m, 1H); 2.25-2.18 (m, 2H); 2.05 (qt, J1 = 13.1 Hz, J2 
= 5.1 Hz, 1H); 1.94 (br, 1H); 1.84-1.73 (m, 1H); 1.70-1.49 (m, 6H); 1.42 (ddd, J1 = 14.3 
208 
 
Hz, J2 = 9.3 Hz, J3 = 5.9 Hz, 1H); 1.36-1.29 (m, 1H); 1.18 (s, 9H); 1.02  (d, J = 6.8 Hz, 
3H).  13C NMR (100 MHz, CDCl3) δ 141.13; 139.18; 116.54; 115.49; 102.16; 72.29; 
67.00; 58.31; 56.10; 46.87; 40.58; 31.83; 31.74; 29.93; 28.71; 25.89; 22.99; 19.17.  
HRMS (TOF, ES+) C21H39NO4S [M+H]+ calc. mass 402.2678, found 402.2681. 
 
O HN
O
O
S
OO
 
(3S,5R,6R)-6-((R)-1-((R)-1,1-dimethylethylsulfinamido)-3-(1,3-dioxan-2-yl)propyl)-5-
methylnona-1,8-dien-3-yl methacrylate (2.218) 
To a solution of (R)-N-((3R,4R,5R,7S)-4-allyl-1-(1,3-dioxan-2-yl)-7-hydroxy-5-
methylnon-8-en-3-yl)-2-methylpropane-2-sulfinamide (490 mg, 1.22 mmol, 1.0 eq) in 
CH2Cl2 (0.1 M) under argon at 0 oC was added NEt3 (0.43 mL, 3.05 mmol, 2.5 eq) and 
DMAP (15 mg, 0.12 mmol, 0.1 eq).  Methacrylic anhydride (0.4 mL, 2.68 mmol, 2.2 eq) 
was added dropwise and the reaction was warmed to rt and continued stirring for 3.5 
hours.  The reaction was quenched by the addition of saturated NH4Cl, extracted with 
EtOAc, dried over sodium sulfate, and concentrated in vacuo.  Purification via flash 
chromatography (EtOAc 50-100%) afforded the desired product as a clear, colorless oil 
in 82% yield (467 mg).  [α]ଶ଴஽  = -32.8 (c = 1.05, CHCl3).  1H NMR (400MHz, CDCl3) δ 
6.10 (s, 1H); 5.87-5.73 (m, 2H); 5.55 (s, 1H); 5.36-5.25 (m, 2H); 5.20 (d, J = 10.5 Hz, 
1H); 5.10 (dd, J1 = 17.3 Hz, J2 = 1.6 Hz, 1H); 5.04 (dd, J1 = 10.2 Hz, J2 = 1.4 Hz, 1H); 
4.48 (t, J = 4.3 Hz, 1H); 4.08 (dd, J1 = 10.7 Hz, J2 = 5.0 Hz, 2H); 3.78-3.69 (m, 2H); 3.51 
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(d, J = 5.9 Hz, 1H); 3.41-3.33 (m, 1H); 2.24-2.16 (m, 2H); 2.05 (qt, J1 = 13.2 Hz, J2 = 5.0 
Hz, 1H); 1.93 (s, 3H); 1.83-1.48 (m, 9H); 1.36-1.29 (m, 1H); 1.18 (s, 9H); 1.04 (d, J = 
6.8 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ  166.68; 139.07; 136.73; 136.38; 125.52; 
117.76; 116.72; 102.12; 74.49; 67.02; 66.99; 57.59; 56.04; 46.44; 37.49; 31.72; 31.36; 
29.74; 28.43; 25.91; 23.00; 18.45; 18.38.  HRMS (TOF, ES+) C37H57NO4SSi [M+Na]+ 
calc. mass 470.2940, found 470.2943. 
 
 
(3S,5R,6R)-6-((R)-1-allylpyrrolidin-2-yl)-5-methylnona-1,8-dien-3-yl methacrylate, 
(2.219) 
To a vial containing (3S,5R,6R)-6-((R)-1-((R)-1,1-dimethylethylsulfinamido)-3-(1,3-
dioxan-2-yl)propyl)-5-methylnona-1,8-dien-3-yl methacrylate (440 mg, 0.94 mmol, 1.0 
eq), was added 95:5 TFA/H2O (0.2 M).  The reaction was allowed to stir at rt for 5 min, 
followed by dilution in 5 mL of toluene.  The resulting crude imine was concentrated in 
vacuo and resuspended in 5 mL toluene and concentrated.  The crude imine was then 
dissolved in DCE (0.1 M) followed by addition of PS-BH(OAc)3 (2.0 g, 4.7 mmol, 5.0 
eq).  The reaction mixture was rotated at rt for 2 h.  The crude pyrrolidine was then 
filtered through celite eluting with DCM and MeOH.  The solution was concentrated and 
dissolved in DMF (0.2 M).  K2CO3 (260 mg, 1.88 mmol, 2.0 eq) and allyl iodide (0.086 
mL, 0.94 mmol, 1.0 eq) were added and the reaction was stirred at rt for 2 h, after which 
an additional 0.5 eq of allyl iodide (0.043 mL) was added.  After stirring at rt for an 
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additional hour, the reaction was filtered through celite eluting with DCM and MeOH, 
concentrated in vacuo, and purified by reverse phase chromatography (10-90% 
H2O/MeCN) to afford the pure product in 46% isolated yield (143 mg).  [α]ଶ଴஽  = 80.5 (c = 
0.49, CHCl3).  1H NMR (400MHz, C6D6) δ  6.20 (s, 1H); 5.93-5.73 (m, 3H); 5.68-5.60 
(m, 1H); 5.29 (d, J = 17.2 Hz, 1H); 5.22 (t, J = 1.6 Hz, 1H); 5.14 (dd, J1 = 17.2 Hz, J2 = 
1.1 Hz, 1H); 5.07-4.96 (m, 4H); 3.34-3.26 (m, 1H); 3.07-2.99 (m, 1H); 2.60 (dd, J1 = 
14.0, J2 = 7.6 Hz, 1H); 2.42-2.35 (m, 1H); 2.18-1.96 (m, 4H); 1.87 (s, 3H); 1.83 (ddd, J1 
= 12.1 Hz, J2 = 8.8 Hz, J3 = 3.3 Hz, 1H); 1.68-1.58 (m, 1H); 1.58-1.38 (m, 5H); 1.04 (d, J 
= 7.0 Hz, 3H).  13C NMR (100 MHz, C6D6) δ  166.20; 139.56; 137.39; 137.30; 137.06; 
124.93; 117.27; 115.92; 115.22; 74.85; 66.25; 58.43; 54.23; 45.57; 38.46; 33.84; 29.04; 
27.53; 23.34; 20.06; 18.50.  HRMS (TOF, ES+) C21H34NO2 [M+H]+ calc. mass 
332.2590, found 332.2589. 
 
(3S,5R)-5-((9R,9aR)-2,3,5,8,9,9a-hexahydro-1H-pyrrolo[1,2-a]azepin-9-yl)hex-1-en-
3-yl methacrylate, (2.224) 
To a solution of (3S,5R,6R)-6-((R)-1-allylpyrrolidin-2-yl)-5-methylnona-1,8-dien-3-yl 
methacrylate (27 mg, 0.081 mmol, 1.0 eq) in toluene (0.005 M) under argon was added 
CSA (37.6 mg, 0.162 mmol, 2.0 eq) and Grela catalyst (5.5 mg, 0.0081 mmol, 0.1 eq).  
The reaction continued stirring for 6 h at rt before being concentrated in vacuo.  The 
reaction was purified via reverse phase chromatography (MeCN/H2O 10-90%) to afford 
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the pure product of single ring closure in 65% yield (16.0 mg).  [α]ଶ଴஽  = 11.9 (c = 0.26, 
CHCl3).  1H NMR (400MHz, CDCl3) δ  6.10 (s, 1H); 5.91-5.81 (m, 1H); 5.81-5.69 (m, 
2H); 5.55 (s, 1H); 5.34-5.25 (m, 2H); 5.21 (d, J = 10.3 Hz, 1H); 3.41 (dd, J1 = 15.2 Hz, J2 
= 6.6 Hz, 1H); 3.09 (t, J = 8.2 Hz, 1H); 2.87 (d, J = 15.2 Hz, 1H); 2.40-2.24 (m, 4H); 
2.05-1.87 (m, 2H); 1.94 (s, 3H); 1.82-1.50 (m, 5H); 1.46-1.31 (m, 2H); 1.00 (d, J = 6.7 
Hz, 3H).  13C NMR (100 MHz, C6D6) δ  166.70; 136.82; 136.27; 132.07; 128.84; 125.44; 
118.02; 74.93; 71.23; 57.81; 54.09; 49.77;  35.71; 32.27; 31.66; 26.00; 21.54; 19.17; 
18.45.  HRMS (TOF, ES+) C19H30NO2 [M+H]+ calc. mass 304.2277, found 304.2278. 
 
 
(S)-5-((R)-2-((9R,9aR)-2,3,5,8,9,9a-hexahydro-1H-pyrrolo[1,2-a]azepin-9-yl)propyl)-
3-methylfuran-2(5H)-one, (2.225) 
To a solution of (3S,5R,6R)-6-((R)-1-allylpyrrolidin-2-yl)-5-methylnona-1,8-dien-3-yl 
methacrylate (27.5 mg, 0.083 mmol, 1.0 eq) in toluene (0.005 M) under argon was added 
CSA (38.5 mg, 0.166 mmol, 2.0 eq) followed by stirring for 10 min at rt.  Grela catalyst 
(5.6 mg, 0.0083 mmol, 0.1 eq) was added and the reaction was allowed to stir at rt for 7.5 
h.  An additional 10 mol% catalyst (5.6 mg) was added and the reaction continued 
stirring for 15 h at 90 oC.  An additional 10 mol% catalyst (5.6 mg) was then added and 
the reaction continued stirring for an additional 8 h.  The reaction was then concentrated 
in vacuo and purified via reverse phase chromatography (MeCN/H2O 10-90%) to afford 
the pure product of bis-ring closure in 52% yield (11.9 mg).  [α]ଶ଴஽  = 76.9 (c = 0.20, 
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CHCl3).  1H NMR (500MHz, CDCl3) δ (ppm):  7.05 (s, 1H); 5.83-5.75 (m, 1H); 5.73-
5.65 (m, 1H); 4.90 (m, 1H); 3.45 (dd, J1 = 15.5 Hz, J2 = 6.0 Hz, 1H); 3.08 (t, J = 8.3 Hz, 
1H); 2.86 (d, J = 15.5 Hz, 1H); 2.42 (dd, J1 = 12.8 Hz, J2 = 4.3 Hz, 1H); 2.34-2.23 (m, 
2H); 2.04-1.95 (m, 1H); 1.92 (s, 3H); 1.93-1.85 (m, 1H); 1.83-1.63 (m, 4H); 1.61-1.53 
(m, 1H); 1.52-1.46 (m, 1H); 1.45-1.39 (m, 1H); 1.05 (d, J = 6.8 Hz, 3H).  13C NMR (125 
MHz, CDCl3) δ (ppm):  174.23; 148.60; 130.93; 130.20; 129.14; 80.76; 70.46; 57.75; 
54.79; 50.30; 35.82; 32.61; 32.49; 25.71; 21.87; 19.87; 10.85.  HRMS (TOF, ES+) 
C17H26NO2 [M+H]+ calc. mass 276.1964, found 276.1964. 
 
 
(3R,5S)-3-methyl-5-((R)-2-((9R,9aR)-octahydro-1H-pyrrolo[1,2-a]azepin-9-
yl)propyl)dihydrofuran-2(3H)-one (9a-epi-stemaphylline), (2.226) 
To a solution of (S)-5-((R)-2-((9R,9aR)-2,3,5,8,9,9a-hexahydro-1H-pyrrolo[1,2-a]azepin-
9-yl)propyl)-3-methylfuran-2(5H)-one (18.1 mg, 0.066 mmol, 1.0 eq) in THF (0.025 M) 
at rt was added Pd(OH)2/C (4.5 mg, 0.25 eq).  The reaction was then bubbled with 
hydrogen gas for 3 min, placed under an atmosphere of hydrogen (via balloon) and 
stirred at rt for 12 h.  The reaction was then filtered through a pad of Celite and 
concentrated.  Purification via reverse phase chromatography (MeCN/H2O 10-90%) 
afforded the pure product in 95% yield (17.5 mg).  [α]ଶ଴஽  = 27.7 (c = 0.68, CHCl3).  1H 
NMR (500MHz, CDCl3) δ (ppm):  4.39-4.32 (m, 1H); 3.12-3.05 (m, 1H); 3.04-2.97 (m, 
1H); 2.70-2.60 (m, 1H); 2.51 (ddd, J1 = 12.5 Hz, J2 = 8.4 Hz, J3 = 5.3 Hz, 1H); 2.47-2.38 
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(m, 1H); 2.37-2.27 (m, 1H); 2.26-2.16 (m, 1H); 2.08-1.96 (m, 1H); 1.86-1.75 (m, 2H); 
1.73-1.51 (m, 9H); 1.45-1.31 (m, 3H); 1.27 (d, J = 7.1 Hz, 3H); 1.00 (d, J = 6.6 Hz, 3H).  
13C NMR (125 MHz, CDCl3) δ (ppm):  179.51; 78.33; 70.33; 58.53; 54.78; 51.85; 37.80; 
36.86; 35.98; 32.34; 28.24; 25.28; 22.29; 19.67; 15.22.  HRMS (TOF, ES+) C17H29NO2 
[M+H]+ calc. mass 280.2277, found 280.2275. 
 
 
(9R,9aR)-9-((R)-1-((2S,4R)-4-methyl-5-oxotetrahydrofuran-2-yl)propan-2-
yl)decahydropyrrolo[1,2-a]azepine 4-oxide (9a-epi-stemaphylline-N-oxide), (2.227) 
To a solution of 9a-epi-stemaphylline (16.3 mg, 0.058 mmol, 1.0 eq) in DCM (0.005 M), 
was bubbled ozone for 3 min.  Upon completion, the reaction was concentrated and 
purified via reverse phase chromatography (MeCN/H2O 10-90%) to afford the pure N-
oxide in 53% yield (9.1 mg).  [α]ଶ଴஽  = 18.1 (c = 0.33, CHCl3).  1H NMR (600MHz, 
CDCl3) δ (ppm):  4.40-4.33 (m, 1H); 3.69-3.62 (m, 1H); 3.61-3.54 (m, 1H); 3.53-3.46 (m, 
1H); 3.26-3.15 (m, 2H); 2.71-2.63 (m, 1H); 5.56-2.45 (m, 3H); 2.43-2.35 (m, 1H); 2.21 
(ddd, J1 = 5.4 Hz, J2 = 11.4 Hz, J3 = 23.4 Hz, 1H); 2.15-2.10 (m, 1H); 2.09-2.00 (m, 1H); 
1.94-1.79 (m, 3H); 1.75-1.65 (m, 3H); 1.64-1.57 (m, 1H); 1.46-1.33 (m, 3H); 1.30-1.22 
(m, 1H); 1.27 (d, J = 7.2 Hz, 3H); 1.05 (d, J = 6.3 Hz, 3H).  13C NMR (125 MHz, 
CDCl3) δ (ppm):  179.29; 81.12; 77.77; 72.24; 66.26; 42.96; 37.74; 36.65; 35.98; 31.92; 
28.68; 25.47; 24.47; 21.73; 20.06; 19.16; 15.15.  HRMS (TOF, ES+) C17H30NO3 [M+H]+ 
calc. mass 296.2226, found 296.2226. 
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(S)-N-((2R,3R,5S)-2-allyl-5-((tert-butyldiphenylsilyl)oxy)-3-methylhept-6-en-1-
ylidene)-2-methylpropane-2-sulfinamide, (2.212) 
To a solution of (2R,3R,5S)-2-allyl-5-((tert-butyldiphenylsilyl)oxy)-3-methylhept-6-enal 
(990 mg, 2.35 mmol, 1.0 eq) in THF under argon was added Ti(OEt)4 (1.23 mL, 5.88 
mmol, 2.5 eq) followed by (S)-2-methylpropane-2-sulfinamide (313 mg, 2.59 mmol, 1.1 
eq).  The reaction was allowed to stir at 40 oC overnight.  The reaction was quenched by 
the addition of saturated NaHCO3, extracted with EtOAc, dried over sodium sulfate, and 
concentrated under vacuum.  Purification via flash chromatography (Hex:EtOAc 4:1) 
afforded the desired product as a clear, colorless oil in 92% yield (1.13 g).  [α]ଶ଴஽  = 108.8 
(c = 0.76, CHCl3).  1H NMR (400MHz, CDCl3) δ 7.87 (d, J = 6.0 Hz, 1H); 7.68-7.62 (m, 
4H); 7.45-7.32 (m, 6H); 5.73 (ddd, J1 = 17.4 Hz, J2 = 10.4 Hz, J3 = 7.3 Hz, 1H); 5.64 
(dddd, J1 = 17.0 Hz, J2 = 13.7 Hz, J3 = 10.2 Hz, J4 = 6.8 Hz, 1H); 5.03-4.93 (m, 3H); 4.89 
(d, J = 17.2 Hz, 1H); 4.17-4.09 (m, 1H); 2.50-2.42 (m, 1H); 2.38-2.28 (m, 1H); 2.19-2.09 
(m, 1H); 1.82-1.72 (m, 1H); 1.55 (ddd, J1 = 13.3 Hz, J2 = 8.7 Hz, J3 = 4.4 Hz, 1H); 1.44-
1.35 (m, 1H); 1.17 (s, 9H); 1.05 (s, 9H); 0.66 (d, J = 6.9 Hz, 3H).  13C NMR (100 MHz, 
CDCl3) δ 171.50; 140.42; 136.13; 136.06; 134.30; 134.19; 129.81; 129.67; 127.70; 
127.51; 116.82; 115.45; 73.50; 56.78; 50.24; 42.78; 33.78; 31.42; 27.17; 22.64; 19.39; 
16.07. HRMS (TOF, ES+) C31H45NO2SSi [M+H]+ calc. mass 524.3019, found 524.3018. 
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(S)-N-((3S,4R,5R,7S)-4-allyl-7-((tert-butyldiphenylsilyl)oxy)-1-(1,3-dioxan-2-yl)-5-
methylnon-8-en-3-yl)-2-methylpropane-2-sulfinamide, (2.214) 
To a solution of (S)-N-((2R,3R,5S)-2-allyl-5-((tert-butyldiphenylsilyl)oxy)-3-methylhept-
6-en-1-ylidene)-2-methylpropane-2-sulfinamide (867 mg, 1.66 mmol, 1.0 eq) in CH2Cl2 
(0.1 M) under argon at -45 oC was added (2-(1,3-dioxan-2-yl)ethyl)magnesium bromide 
(16.5 mL, 1.0 M in THF, 10.0 equiv) dropwise.  The reaction was allowed to warm to 
room temperature and continue stirring for 24 h.  The reaction was quenched with NH4Cl, 
extracted with EtOAc, dried over sodium sulfate, and concentrated.  Purification via flash 
chromatography (Hex:EtOAc 50-100%) afforded the desired product as a clear, colorless 
oil in 95% yield and 1.2:1 dr.  The pure desired diastereomer can be isolated in 51% yield 
(542 mg).  [α]ଶ଴஽  = 35.9 (c = 1.68, CHCl3).  1H NMR (400MHz, CDCl3) δ 7.70-7.62 (m, 
4H); 7.44-7.31 (m, 6H); 5.93-5.82 (m, 1H); 5.77 (ddd, J1 = 17.5 Hz, J2 = 10.5 Hz, J3 = 7.3 
Hz, 1H); 5.08-4.90 (m, 4H); 4.46 (t, J = 4.6 Hz, 1H); 4.11-4.03 (m, 3H); 3.77-3.66 (m, 
2H); 3.56 (d, J = 9.3 Hz, 1H); 3.27-3.19 (m, 1H); 2.13-1.97 (m, 3H); 1.81-1.62 (m, 4H); 
1.54-1.42 (m, 2H); 1.40-1.28 (m, 3H); 1.27-1.20 (m, 1H); 1.17 (s, 9H); 1.05 (s, 9H); 0.57 
(d, J = 6.6 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 140.59; 140.36; 136.06; 136.01; 
134.38; 134.25; 129.66; 129.53; 127.59; 127.42; 115.78; 115.25; 102.33; 102.03; 73.95; 
66.93; 66.89; 59.70; 56.07; 48.76; 43.11; 35.23; 32.35; 30.94; 27.10; 26.08; 25.91; 25.83; 
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23.97; 22.89; 19.29; 17.78. HRMS (TOF, ES+) C37H57NO4SSi [M+Na]+ calc. mass 
640.3852, found 640.3856. 
 
 
(S)-N-((3S,4R,5R,7S)-4-allyl-1-(1,3-dioxan-2-yl)-7-hydroxy-5-methylnon-8-en-3-yl)-
2-methylpropane-2-sulfinamide  
To a solution of (S)-N-((3S,4R,5R,7S)-4-allyl-7-((tert-butyldiphenylsilyl)oxy)-1-(1,3-
dioxan-2-yl)-5-methylnon-8-en-3-yl)-2-methylpropane-2-sulfinamide (595 mg, 0.93 
mmol, 1.0 eq) in THF (0.1 M) under argon at 0 oC was added TBAF (3.25 mL, 3.25 
mmol, 3.5 eq).  The reaction was warmed to rt and continued stirring overnight.  The 
reaction was quenched by the addition of saturated NH4Cl, extracted with EtOAc, dried 
over sodium sulfate, and concentrated in vacuo.  Purification via flash chromatography 
(EtOAc 100%) afforded the desired product as a clear, colorless oil in 97% yield (362 
mg).  [α]ଶ଴஽  = 28.4 (c = 0.80, CHCl3).  1H NMR (400MHz, CDCl3) δ 5.95-5.81 (m, 2H); 
5.25 (d, J = 17.3 Hz, 1H); 5.15-5.07 (m, 2H); 5.04 (d, J = 10.1 Hz, 1H); 4.50 (t, J = 4.8 
Hz, 1H); 4.33-4.25 (m, 1H); 4.09 (dd, J1 = 11.0 Hz, J2 = 5.1 Hz, 2H); 3.80-3.70 (m, 3H); 
3.34 (tt, J1 = 9.5 Hz, J2 = 3.1 Hz, 1H); 2.31-2.13 (m, 2H); 2.13-1.99 (m, 2H); 1.97-1.88 
(m, 1H); 1.82 (ddd, J1 = 13.6 Hz, J2 = 6.7 Hz, J3 = 4.3 Hz, 1H); 1.78-1.67 (m, 2H); 1.66-
1.50 (m, 4H); 1.49-1.37 (m, 2H); 1.36-1.30 (m, 1H); 1.20 (s, 9H); 0.97 (d, J = 6.9 Hz, 
3H).  13C NMR (100 MHz, CDCl3) δ 141.24; 139.73; 116.26; 114.99; 102.19; 72.02; 
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67.05; 59.21; 56.30; 48.09; 41.23; 32.48; 32.28; 30.43; 27.34; 25.93; 23.03; 19.34.  
HRMS (TOF, ES+) C21H40NO4S [M+H]+ calc. mass 402.2678, found 402.2681. 
 
O HN
O
O
S
OO
 
(3S,5R,6R)-6-((S)-1-((S)-1,1-dimethylethylsulfinamido)-3-(1,3-dioxan-2-yl)propyl)-5-
methylnona-1,8-dien-3-yl methacrylate, (2.215) 
To a solution of (S)-N-((3S,4R,5R,7S)-4-allyl-1-(1,3-dioxan-2-yl)-7-hydroxy-5-
methylnon-8-en-3-yl)-2-methylpropane-2-sulfinamide (563 mg, 1.4 mmol, 1.0 eq) in 
CH2Cl2 (0.1 M) under argon at 0 oC was added NEt3 (0.49 mL,. 3.5 mmol, 2.5 eq) and 
DMAP (85.5 mg, 0.70 mmol, 0.5 eq).  Methacrylic anhydride (0.46 mL, 3.08 mmol, 2.2 
eq) was added dropwise and the reaction was warmed to rt and continued stirring for 3.5 
hours.  The reaction was quenched by the addition of saturated NH4Cl, extracted with 
EtOAc, dried over sodium sulfate, and concentrated in vacuo.  Purification via flash 
chromatography (EtOAc 50-100%) afforded the desired product as a clear, colorless oil 
in 73% yield (483 mg).  [α]ଶ଴஽  = 36.6 (c = 0.80, CHCl3).  1H NMR (400MHz, CDCl3) δ 
6.11 (s, 1H); 5.97-5.84 (m, 1H); 5.78 (ddd, J1 = 17.4 Hz, J2 = 10.4 Hz, J3 = 7.0, 1H); 5.55 
(t, J = 1.7 Hz, 1H); 5.35-5.25 (m, 2H); 5.20 (d, J = 10.4 Hz, 1H); 5.11 (d, J = 17.3 Hz, 
1H); 5.04 (d, J = 10.0 Hz, 1H); 4.51 (t, J = 5.0 Hz, 1H); 4.09 (dd, J1 = 10.7 Hz, J2 = 5.0 
Hz, 2H); 3.79-3.69 (m, 2H); 3.56 (d, J = 9.6 Hz, 1H); 3.35 (tt, J1 = 9.6 Hz, J2 = 2.7 Hz, 
1H); 2.27-2.14 (m, 2H); 2.07 (qt, J1 = 13.4 Hz, J2 = 5.0 Hz, 1H); 2.02-1.92 (m, 1H); 1.94 
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(s, 3H); 1.89-1.82 (m, 1H); 1.80-1.71 (m, 1H); 1.65-1.46 (m, 6H); 1.46-1.39 (m, 1H); 
1.37-1.30 (m, 1H); 1.19 (s, 9H); 1.00 (d, J = 6.3 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 
166.53; 139.74; 136.61; 136.34; 125.36; 117.58; 116.12; 101.92; 74.68; 66.89; 66.86; 
59.35; 56.11; 48.69; 39.26; 32.40; 32.24; 31.55; 26.41; 25.77; 22.83; 18.32; 17.81.  
HRMS (TOF, ES+) C25H44NO5S [M+H]+ calc. mass 470.2940, found 470.2943. 
 
 
(3S,5R,6R)-6-((S)-1-allylpyrrolidin-2-yl)-5-methylnona-1,8-dien-3-yl methacrylate, 
(2.216) 
To a vial containing (3S,5R,6R)-6-((S)-1-((S)-1,1-dimethylethylsulfinamido)-3-(1,3-
dioxan-2-yl)propyl)-5-methylnona-1,8-dien-3-yl methacrylate (287 mg, 0.61 mmol, 1.0 
eq), was added 95:5 TFA/H2O (0.2 M).  The reaction was allowed to stir at rt for 5 min, 
followed by dilution in 5 mL of toluene.  The resulting crude imine was concentrated in 
vacuo and resuspended in 5 mL toluene and concentrated.  The crude imine was then 
dissolved in DCE (0.1 M) followed by addition of PS-BH(OAc)3 (1.32 g, 3.05 mmol, 5.0 
eq).  The reaction mixture was rotated at rt for 2 h.  The crude pyrrolidine was then 
filtered through celite eluting with DCM and MeOH.  The solution was concentrated and 
dissolved in DMF (0.2 M).  K2CO3 (253 mg, 1.83 mmol, 3.0 eq) and allyl iodide (0.056 
mL, 0.61 mmol, 1.0 eq) were added and the reaction was stirred at rt for 2 h, after which 
an additional 0.5 eq of allyl iodide (0.028 mL) was added.  After stirring at rt for an 
additional hour, the reaction was filtered through celite eluting with DCM and MeOH, 
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concentrated in vacuo, and purified by reverse phase chromatography (10-90% 
H2O/MeCN) to afford the pure product in 47% isolated yield (97 mg).  [α]ଶ଴஽  = -36.2 (c = 
0.48, CHCl3).  1H NMR (400MHz, C6D6) δ  6.20-6.17 (m, 1H); 5.96-5.80 (m, 2H); 5.80-
5.71 (m, 1H); 5.67 (q,   J = 7 Hz, 1H); 5.28 (dt, J1 = 17.0 Hz, J2 = 1.4 Hz, 1H); 5.23-5.15 
(m, 2H); 5.08-4.96 (m, 4H); 5.07-4.96 (m, 4H); 3.52-3.44 (m, 1H); 3.06-2.99 (m, 1H); 
2.65 (dd, J1 = 13.6, J2 = 7.7 Hz, 1H); 2.57-2.49 (m, 1H); 2.30 (td, J1 = 8.7 Hz, J2 = 2.6 
Hz, 1H); 1.98-1.89 (m, 2H); 1.87 (s, 3H); 1.85-1.74 (m, 1H); 1.74-1.64 (m, 3H); 1.56-
1.34 (m, 5H); 0.83 (d, J = 6.7 Hz, 3H).  13C NMR (100 MHz, C6D6) δ  166.26; 139.79; 
137.32; 137.22; 125.01; 116.93; 116.02; 115.20; 73.79; 63.41; 57.41; 53.70; 43.23; 
40.25; 31.61; 30.38; 26.88; 23.95; 18.48; 16.67.  HRMS (TOF, ES+) C21H34NO2 [M+H]+ 
calc. mass 332.2590, found 332.2588. 
 
(3S,5R)-5-((9R,9aS)-2,3,5,8,9,9a-hexahydro-1H-pyrrolo[1,2-a]azepin-9-yl)hex-1-en-
3-yl methacrylate, (2.228) 
To a solution of (3S,5R,6R)-6-((S)-1-allylpyrrolidin-2-yl)-5-methylnona-1,8-dien-3-yl 
methacrylate (10 mg, 0.03 mmol, 1.0 eq) in toluene (0.005 M) under argon was added 
CSA (14 mg, 0.06 mmol, 2.0 eq) and benzoquinone (0.8 mg, 0.0075 mmol, 0.25 eq).  
After stirring at rt for 10 min, Hoveyda Grubbs II catalyst (1.9 mg, 0.003 mmol, 10 
mol%) was added and the reaction continued stirring for 15 h at rt.  An additional 10 mol 
% catalyst (1.9 mg) was added followed by stirring at rt for an additional 8.5 h.  After 
220 
 
addition of 10 mol% catalyst (1.9 mg) and stirring for 15 additional h the reaction was 
concentrated in vacuo.  The reaction was purified via reverse phase chromatography 
(MeCN/H2O 10-90%) followed by additional purification via flash chromatography 
(DCM/MeOH/NH4OH 94.9:5:0.1) to afford the product of a single ring closure in 48% 
yield (4.4 mg).  [α]ଶ଴஽  = -38.1 (c = 0.89, CHCl3).  1H NMR (400MHz, CDCl3) δ  6.11 (s, 
1H); 5.94-5.85 (m, 2H); 5.73-5.68 (m, 1H); 5.59-5.53 (m, 2H); 5.17 (d, J = 17.3 Hz, 1H); 
5.07 (d, J = 9.8 Hz, 1H); 3.38-3.2 (m, 1H); 3.12-3.06 (m, 1H); 2.69 (dd, J1 = 13.1 Hz, J2 
= 7.5 Hz, 1H); 2.58 (dd, J1 = 14.0 Hz, J2 = 8.9 Hz, 1H); 2.53-2.46 (m, 1H); 2.16-2.08 (m, 
1H); 1.95 (s, 3H); 1.93-1.87 (m, 1H); 1.85 (dt, J1 = 13.1 Hz, J2 = 2.5 Hz, 1H); 1.79-1.71 
(m, 1H); 1.70-1.58 (m, 4H); 1.55-1.47 (m, 1H); 1.42-1.34 (m, 1H); 1.01 (d, J = 6.6 Hz, 
3H).  13C NMR (100 MHz, C6D6) δ 166.94; 136.88; 136.59; 133.58; 131.31; 125.39; 
116.51; 73.83; 65.25; 56.93; 54.21; 43.65;  41.66; 36.55; 25.51; 24.40; 22.60; 21.75; 
18.49.  HRMS (TOF, ES+) C19H30NO2 [M+H]+ calc. mass 304.2277, found 304.2275. 
 
 
(E)-(3S,5R,6R)-6-((S)-1-((S)-1,1-dimethylethylsulfinamido)-3-(1,3-dioxan-2-
yl)propyl)-5-methylnona-1,8-dien-3-yl 4-(allyloxy)-2-methylbut-2-enoate, (2.231) 
To a solution of triethylamine (0.347 mL, 3.43 mmol, 5.0 eq) in CH2Cl2 (0.1 M) under 
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argon was added DMAP (84 mg, 0.686 mmol, 1.0 eq), 2-methyl-6-nitrobenzoic 
anhydride (MNBA) (590 mg, 1.715 mmol, 2.5 eq) and carboxylic acid 30 (268 mg, 1.715 
mmol, 2.5 eq) at room temperature. After stirring for 10 min, (S)-N-((3S,4R,5R,7S)-4-
allyl-1-(1,3-dioxan-2-yl)-7-hydroxy-5-methylnon-8-en-3-yl)-2-methylpropane-2-
sulfinamide (275.6 mg, 0.686 mmol, 1.0 eq) was added. The mixture was refluxed with 
stirring for 3 h. The mixture was cooled down to 0 °C, and a saturated aqueous solution 
of NH4Cl was added. The aqueous layer was extracted with CH2Cl2 and the combined 
organic layer was washed with sat. NaHCO3 and dried over MgSO4. Concentration under 
vacuum gave the crude product, and purification by silica gel column chromatography 
(1:1 Hex/EtOAc) afforded the desired product as a colorless oil in 98% yield (361 mg).  
[α]ଶ଴஽  = 60.5 (c = 0.58, CHCl3)  1H NMR (400MHz, CDCl3) δ 6.83 (td, J1 = 5.9 Hz, J2 = 
1.3 Hz, 1H); 5.98-5.84 (m, 2H); 5.76 (ddd, J1 = 17.3 Hz, J2 = 10.4 Hz, J3 = 7.1 Hz, 1H); 
5.35-5.24 (m, 3H); 5.20 (t, J = 10.3 Hz, 2H); 5.10 (d, J = 17.3 Hz, 1H); 5.03 (d, J = 10.0 
Hz, 1H); 4.51 (t, J = 4.9 Hz, 1H); 4.16 (d, J = 5.9 Hz, 2H); 4.08 (dd, J1 = 10.9 Hz, J2 = 
4.9 Hz, 2H); 4.01 (d, J = 5.7 Hz, 2H); 3.74 (t, J = 12.3 Hz, 2H); 3.56 (d, J = 9.5 Hz, 1H); 
3.34 (t, J = 10.0 Hz, 1H); 2.27-2.13 (m, 2H); 2.06 (qt, J1 = 12.6 Hz, J2 = 4.9 Hz, 1H); 
2.00-1.92 (m, 1H); 1.83 (s, 3H); 1.80-1.70 (m, 1H); 1.68 (s, 1H); 1.63-1.38 (m, 5H); 1.33 
(d, J = 13.6 Hz, 1H); 1.18 (s, 9H); 0.99 (d, J = 6.4 Hz, 3H).  13C NMR (100 MHz, CDCl3) 
δ 166.71; 139.90; 138.18; 136.45; 134.48; 129.61; 117.81; 117.67; 116.22; 102.06; 
74.92; 71.83; 67.03; 67.00; 66.93; 59.53; 56.25; 48.83; 39.39; 32.51; 32.38; 31.71; 26.48; 
25.89; 22.95; 17.91; 12.97.  HRMS (TOF, ES+) C29H50NO6S [M+H]+ calc. mass 
540.3359, found 540.3354. 
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(E)-(3S,5R,6R)-6-((S)-1-((Z)-4-(allyloxy)but-2-en-1-yl)pyrrolidin-2-yl)-5-
methylnona-1,8-dien-3-yl 4-(allyloxy)-2-methylbut-2-enoate, (2.233) 
To a vial containing (E)-(3S,5R,6R)-6-((S)-1-((S)-1,1-dimethylethylsulfinamido)-3-(1,3-
dioxan-2-yl)propyl)-5-methylnona-1,8-dien-3-yl 4-(allyloxy)-2-methylbut-2-enoate 
(276.4 mg, 0.512 mmol, 1.0 eq), was added 95:5 TFA/H2O (0.2 M).  The reaction was 
allowed to stir at rt for 5 min, followed by dilution in 5 mL of toluene.  The resulting 
crude imine was concentrated in vacuo and resuspended in 5 mL toluene and 
concentrated.  The crude imine was then dissolved in DCE (0.1 M) followed by addition 
of PS-BH(OAc)3 (1.11 g, 2.56 mmol, 5.0 eq).  The reaction mixture was rotated at rt for 2 
h.  The crude pyrrolidine was then filtered through celite eluting with DCM and MeOH.  
The solution was concentrated and dissolved in DMF (0.2 M).  K2CO3 (212 mg, 1.54 
mmol, 3.0 eq) and allylic bromide 32 (118 mg, 0.61 mmol, 1.1 eq) were added and the 
reaction was stirred at rt for 2 h, after which, the reaction was filtered through celite 
eluting with DCM and MeOH, concentrated in vacuo, and purified by reverse phase 
chromatography (10-90% H2O/MeCN) to afford the pure product in 40% isolated yield 
(97 mg).  [α]ଶ଴஽  = -36.2 (c = 0.48, CHCl3).    [α]ଶ଴஽  = -42.7 (c = 1.26, CDCl3).  1H NMR 
(400MHz, CDCl3) δ 6.83 (td, J1 = 5.9 Hz, J2 = 1.3 Hz, 1H); 5.96-5.88 (m, 2H); 5.76 (ddd, 
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J1 = 17.2 Hz, J2 = 10.5 Hz, J3 = 6.7 Hz, 1H); 5.73-5.62 (m, 3H); 5.34 (q, J = 6.9 Hz, 1H); 
5.32-5.20 (m, 4H); 5.20-5.15 (m, 2H); 4.96 (d, J = 17.0 Hz, 1H); 4.91 (d, J = 10.0 Hz, 
1H); 4.17 (dd, J1 = 5.9 Hz, J2 = 1.0 Hz, 2H); 4.12 (dd, J1 = 12.2 Hz, J2 = 6.0 Hz, 1H); 
4.06 (dd, J1 = 12.0 Hz, J2 = 5.4 Hz, 1H); 4.01 (dt, J1 = 5.7 Hz, J2 = 1.3 Hz, 2H); 3.99-3.97 
(m, 2H); 3.37 (dd, J1 = 13.7 Hz, J2 = 4.6 Hz, 1H); 3.07-3.00 (m, 1H); 2.79 (dd, J1 = 13.8 
Hz, J2 = 7.2 Hz, 1H); 2.42-2.30 (m, 2H); 2.06-1.96 (m, 1H); 1.92 (dt, J1 = 14.1 Hz, J2 = 
9.0 Hz, 1H); 1.84 (s, 3H); 1.74-1.53 (m, 9H); 0.86 (d, J = 6.9 Hz). 13C NMR (100 MHz, 
CDCl3) δ 166.74; 139.37; 138.07; 136.69; 135.00; 134.47; 131.04; 129.59; 128.22; 
117.73; 117.21; 117.17; 115.21; 74.18; 71.90; 71.31; 67.00; 66.05; 63.92; 53.71; 50.92; 
43.10; 39.98; 31.19; 30.10; 26.56; 23.55; 16.47; 12.99.  HRMS (TOF, ES+) C29H46NO4 
[M+H]+ calc. mass 472.3427, found 472.3429. 
 
 
(S)-5-((R)-2-((9R,9aS)-2,3,5,8,9,9a-hexahydro-1H-pyrrolo[1,2-a]azepin-9-yl)propyl)-
3-methylfuran-2(5H)-one, (2.229) 
 (E)-(3S,5R,6R)-6-((S)-1-((Z)-4-(allyloxy)but-2-en-1-yl)pyrrolidin-2-yl)-5-methylnona-
1,8-dien-3-yl 4-(allyloxy)-2-methylbut-2-enoate (90 mg, 0.19 mmol, 1.0 eq) was placed 
under argon and dissolved in toluene (0.02 M).  CSA (88.7 mg, 0.38 mmol, 2.0 equiv) 
was added and the solution was stirred for 10 min at rt.  In a two neck flask equipped 
with a reflux condenser a solution of Hoveyda Grubbs II catalyst (23.8 mg, 0.038 mmol, 
0.2 eq) was dissolved in toluene (0.007 M relative to tetraene 33) and heated to vigorous 
reflux.  After the solution was brought to reflux the reaction mixture was sparged with 
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argon through the second neck of the flask.  The solution of tetraene 33 and CSA in 
toluene was then added dropwise via syringe over 10 min.  After 20 minutes of 
additional heating under argon sparge the reaction mixture was concentrated in vacuo and 
purified by reverse phase chromatography (10-90% H2O/MeCN) to afford the pure 
product in 37% isolated yield (19.3 mg) and with minimal epimerization (10:1).   [α]ଶ଴஽  = 
-13.0 (c = 1.26, CHCl3)  1H NMR (400MHz, CDCl3) δ 6.14 (m, 1H); 5.72-5.67 (m, 1H); 
5.49-5.44 (m, 1H); 4.47-4.42 (m, 1H); 4.47-4.42 (m, 1H); 3.20 (dd, J1 = 16.7 Hz, J2 = 6.2 
Hz, 1H); 2.98 (d, J = 16.7 Hz, 1H); 2.81 (td, J1 = 8.2 Hz, J2 = 3.5 Hz, 1H); 2.54-5.48 (m, 
1H); 229-2.18 (m, 2H); 1.75-1.70 (m, 1H); 1.70-1.59 (m, 6H); 1.58-1.52 (m, 1H); 1.52-
1.44 (m, 2H); 1.44-1.38 (m, 1H); 1.14 (ddd, J1 = 14.0 Hz, J2 = 8.8 Hz, J3 = 7.5 Hz, 1H); 
0.81 (d, J = 6.9 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 173.31; 148.25; 131.15; 129.69; 
128.35; 127.98; 80.16; 67.21; 54.79; 54.74; 52.43; 46.81; 39.02; 32.33; 28.10; 27.44; 
23.03; 19.70; 10.64.  HRMS (TOF, ES+) C37H57NO4SSi [M+Na]+ calc. mass 470.2940, 
found 470.2943. 
 
 
(3R,5S)-3-methyl-5-((R)-2-((9R,9aS)-octahydro-1H-pyrrolo[1,2-a]azepin-9-
yl)propyl)dihydrofuran-2(3H)-one (stemaphylline), (2.76) 
To a solution of (S)-5-((R)-2-((9R,9aS)-2,3,5,8,9,9a-hexahydro-1H-pyrrolo[1,2-a]azepin-
9-yl)propyl)-3-methylfuran-2(5H)-one (17.9 mg, 0.065 mmol, 1.0 eq) in THF (0.025 M) 
at rt was added Pd(OH)2/C (5.4 mg, 0.16 eq).  The reaction was then bubbled with 
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hydrogen gas for 3 minutes, placed under an atmosphere of hydrogen (via balloon) and 
stirred at rt for 12 h.  An additional portion of Pd(OH)2 (5.4 mg, 0.16 eq) was added and 
the reaction was again bubbled with hydrogen gas for 3 min, placed under an atmosphere 
of hydrogen (via balloon) and stirred at rt for 8 h. The reaction was then filtered through a 
pad of Celite and concentrated in vacuo.  Purification via reverse phase chromatography 
(MeCN/H2O 10-90%) afforded the pure product in 62% yield (11.3 mg).   [α]ଶ଴஽  = -36.2 
(c = 0.70, CHCl3).  1H NMR (600MHz, CDCl3) δ (ppm):  4.46-4.40 (m, 1H); 3.08-2.91 
(m, 3H); 2.72-2.54 (m, 3H); 2.54-2.48 (m, 1H); 2.00-1.94 (m, 1H); 1.84-1.77 (m, 2H); 
1.77-1.68 (m, 3H); 1.68-1.55 (m, 5H); 1.53-1.43 (m, 3H); 1.38-1.30 (m, 1H); 1.26 (d, J = 
7.0 Hz, 3H); 0.98 (d, J = 6.8 Hz, 3H).  13C NMR (125 MHz, CDCl3) δ (ppm):  179.65; 
78.08; 64.87; 53.94; 52.22; 46.12; 39.59; 37.81; 35.80; 33.01; 28.15; 28.07; 27.73; 26.15; 
23.73; 18.94; 14.99.  HRMS (TOF, ES+) C17H29NO2 [M+H]+ calc. mass 280.2277, 
found 280.2279. 
 
 
(9R,9aR)-9-((R)-1-((2S,4R)-4-methyl-5-oxotetrahydrofuran-2-yl)propan-2-
yl)decahydropyrrolo[1,2-a]azepine 4-oxide (stemaphylline-N-oxide), (2.77) 
To a solution of stemaphylline (7.0 mg, 0.025 mmol, 1.0 eq) in CH2Cl2 (0.02 M) at 0 C 
under argon was added mCPBA (6.8 mg, 0.028 mmol, 1.1 eq).  The reaction stirred at 0 
C for 30 min, then concentrated in vacuo, and purified via reverse phase 
chromatography (MeCN/H2O 10-90%) to afford the pure product in 74% yield (5.5 mg).   
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[α]ଶ଴஽  = -42.3 (c = 0.22, CHCl3).  1H NMR (600MHz, CDCl3) δ (ppm):  4.71-4.65 (m, 
1H); 3.70-3.60 (m, 1H); 3.60-3.53 (m, 2H); 3.40-3.35 (m, 2H); 2.70-2.62 (m, 2H); 2.60-
2.54 (m, 1H); 2.41-2.30 (m, 1H); 2.30-2.20 (m, 1H); 2.12-2.04 (m 1H); 2.00-1.88 (m, 
2H); 1.87-1.80 (m, 1H); 1.80-1.71 (m, 2H); 1.70-1.64 (m, 2H); 1.62-1.50 (m, 3H); 1.44 
(q, J = 12.2 Hz, 1H); 1.25 (d, J = 7.0 Hz, 3H); 0.90 (d, J = 7.2 Hz, 3H).  13C NMR (125 
MHz, CDCl3) δ (ppm):  179.94; 81.85; 76.73; 71.31; 67.48; 40.84; 38.05; 35.97; 35.42; 
35.18; 25.66; 25.36; 25.32; 20.95; 19.62; 17.53; 15.21.  HRMS (TOF, ES+) C17H30NO3 
[M+H]+ calc. mass 296.2226, found 296.2225. 
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CHAPTER 3 
   
DISCOVERY OF NOVEL SELECTIVE PAR4 ANTAGONISTS 
  
3.1  Introduction to Platelet Biology 
The platelet is a circulating disc-shaped cell, responsible for initiation of the 
hemostatic mechanisms that repair injury to the vascular endothelium.  Circulating 
platelets do not normally encounter the connective tissue matrix that lies beneath vascular 
endothelial cells.  Once a break within the integrity of this vascular lining occurs, 
platelets are exposed to, and interact with, collagen fibrils. Platelet interactions with 
collagen not only provide a surface for platelet adhesion, but also serve as a strong 
stimulus for platelet activation. This results in signaling pathways that induce platelets to 
change their shape, spreading along the collagen fibrils, and to secrete thromboxane A2 
and ADP into the circulation. The released thromboxane A2 and ADP stimulate 
neighboring platelets, causing them to become activated in turn and to secrete additional 
thromboxane A2 and ADP.  Platelet activation also causes release of α granules and 
dense granules, which contain numerous compounds which are involved in clotting and 
other functions.   
Activated platelets not only secrete these substances, they also directly bind to the 
circulating coagulation protein fibrinogen via the abundant platelet integrin glycoprotein 
(GP) IIb/IIIa.1,2  Fibrinogen can simultaneously bind two GPIIb/IIIa receptors and can 
therefore function as a link between two platelets.  This platelet-fibrinogen-platelet 
connection initiates the process of platelet aggregation.1  Since each platelet has 40,000 to 
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 Thrombin is an essential protein in the clotting cascade.  It activates a number of 
coagulation factors, cleaves fibrinogen to fibrin, and regulates critical elements involved 
in coagulation through stimulation of a family of membrane-bound, G-protein coupled 
protease activated receptors (PARs) found on the surface of platelets.  Thrombin is the 
most potent activator of platelets, and it works via PAR1 and PAR4, two subtypes of this 
family.  Thrombin is generated at the site of injury via cleavage of prothrombin by other 
activated clotting factors, and it is the key activating factor of platelets, resulting in 
generation of a platelet plug.  Thrombin is also involved in increased endothelial cell 
permeability and blood-brain barrier breakdown after injury.5   
Thrombin works by cleavage of the amino terminal peptide of one arm of the 
extracellular portion of PAR, resulting in generation of a new “tethered ligand” which 
binds to the second extracellular portion of PAR and induces activation of the 
intracellular G-proteins, leading to the aforementioned downstream effects on platelet 
activity. Thrombin activates PAR1 and PAR4 in a progressive manner, with PAR1 
activated at low thrombin concentrations (EC50 = 100 pM) and PAR4 recruited at higher 
thrombin concentrations (EC50 = 5 nM).6  Because of PAR4’s low affinity for thrombin, 
it is activated locally at the site of the clot as more thrombin accumulates.  PAR1 is 
ubiquitously expressed, and PAR1 signaling is involved not only in coagulation, but also 
inflammation, pain, healing, and cancer metastasis,7 while the expression of PAR4 is 
much more restricted, mainly to platelets and in certain brain areas and vascular beds 
after stress (Figue 3.1.2).8-11 
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 Platelets play a critical role in thrombosis, which is necessary for normal response 
to injury but also a major cause of mortality and morbidity.  Medical management of 
acute coronary syndrome and cerebrovascular injury is centered on anti-platelet 
therapies.13-15  The clinical importance of platelet activation in the pathophysiology of 
coronary disease is reflected by the benefits of aspirin, clopidogrel, and glycoprotein 
(GP) IIb/IIIa inhibitors in patients with ischemic stroke.15  The reduction in rates of MI, 
stroke, and sudden death with marketed oral antiplatelet drugs used singly or in 
combinations has been significant,16 but the large proportion of events that are not 
prevented is still our leading cause of death and disability.   
All of the drugs on the market that inhibit thrombosis – those that act on the 
clotting cascade, such as heparin, warfarin, and direct thrombin inhibitors (i.e. 
bivalirudin), and those that inhibit platelet activation, such as clopidogrel, GPIIb/IIIa 
inhibitors, and aspirin – carry risks associated with excessive bleeding and do not fully 
attenuate platelet activation.  This can lead to delayed onset of action and long-lived 
effects, which is linked to adverse bleeding events. Vorapaxar, a thrombin receptor 
antagonist (TRA) that targets PAR1, was recently shown in Phase III clinical trials to 
increase clinically significant bleeding including intracranial hemorrhage.17,18  
PARs are also widely expressed in the CNS.8,9  PAR4-/- mice are protected from 
thrombosis and cerebral ischemia/reperfusion injury19 and have prolonged tail bleeding 
times but no clinically apparent bleeding disorder.20  After a stroke, PAR4 expression 
increases in the penumbra, the area of brain tissue surrounding the site of the stroke 
which is at risk for further damage.21  These data suggest that PAR4 may be involved in 
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mediation of cerebrovascular injury after stroke, making it an attractive target for anti-
platelet therapy as well as prevention of further morbidity after a stroke. 
 Platelet activation by thrombin leads to a second, much larger burst of thrombin 
generation through the intrinsic pathway.22-24  Using a reconstituted thrombin generation 
assay with purified platelets and select coagulation factors, it has been shown that 
activation of PAR1 and PAR4 by their activating peptides (AP) contributes to the 
maintenance and amplification of thrombin generation.25  Since PAR1 is the high-affinity 
thrombin receptor, it is activated earlier in the process than PAR4, the low-affinity 
thrombin receptor. This is illustrated dramatically in Fig. 3.2.1, which shows that 
antagonism of PAR1 signaling by RWJ-56110 (RWJ) dramatically inhibits thrombin 
generation on the platelet surface when stimulated by the collagen receptor agonist 
convulxin (CVX), while inhibiting PAR4 with its antagonist YD-3 much less 
prominently affects peak thrombin generation.  
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signaling desensitizes over time, while PAR4 signaling persists.28,29  Our data and that of 
others points to PAR4 as an important mediator of thrombosis.20,30,31  Recently, it has 
been demonstrated that PAR4 signaling can resensitize PAR1 signaling, which will lead 
to amplified platelet activation in the presence of high concentrations of thrombin.32  Our 
theory is that the early engagement of PAR1 by low levels of thrombin plays a critical 
role in initial hemostasis, but as levels of thrombin build at a site of injury (or in 
hypercoaguable states), PAR4 becomes engaged, resulting in strong signaling eventually 
leading to thrombosis.  In order to test these hypotheses, we proposed to target PAR4 as a 
novel target for anti-platelet/anti-thrombotic therapeutics. The only published PAR4 
antagonist is YD-3, and it is much too hydrophobic to be used in in vivo studies (Figue 
3.2.3). 
 
 
Figure 3.2.3  Known PAR4 selective antagonists. 
 
 The most difficult aspect of developing new pharmaceuticals in this field is 
maintaining balance between preventing pathologic thrombosis and avoiding excessive 
bleeding.  For example, recent clinical trials showed incremental efficacy of factor Xa 
inhibitors in acute coronary syndrome,33,34 though the APPRAISE-2 trial with apixaban 
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was terminated early due to excessive bleeding.  Bleeding risk also exists for direct 
thrombin inhibitors currently on the market.  Thrombin receptor antagonists (TRAs) have 
been eagerly anticipated in cardiovascular medicine; vorapaxar is a TRA in two Phase III 
clinical trials, TRA•CER35 and TIMI-50. The TRA•CER trial in patients with acute 
coronary syndrome was discontinued early due to intracranial bleeding,17 and the TIMI-
50 secondary prevention trial in patients who had already experienced a heart attack or 
ischemic stroke, or had known peripheral vascular disease, was halted in patients who 
had previously experienced a stroke due to excessive bleeding without significant 
benefit.18   
Our preliminary data provide further evidence that PAR1 is critically involved in 
platelet-dependent thrombin generation needed for primary hemostasis,12 and that  PAR4 
is not involved in the amplification of thrombin generation (Fig. 3.2.2).  The fact that 
PAR4 is the low-affinity thrombin receptor that is only activated once a significant 
amount of thrombin has been generated suggests that its inhibition will not be detrimental 
to primary hemostasis.  However, at the start of our study, no PAR4 antagonists existed 
with the physiochemical properties to study the physiological effect of inhibition of 
PAR4 in vivo.   
 Due to the lack of tool compounds, the field’s understanding of the role of PAR4 
in physiological environments is limited.  There are no probes available to study the role 
of PAR4 in thrombosis, ischemic stroke, and neurodegeneration in vivo. The PAR4 
antagonist YD-3 was first described in 200036 with little further characterization or 
optimization (Figure 3.2.3).37  YD-3 has poor physiochemical properties and virtually no 
solubility in acceptable vehicles; therefore, it is not suitable for in vivo studies.  An 
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optimized, in vivo tool compound would allow us to determine basic pharmacological 
information about PAR4 including receptor density, mechanism of action for PAR4 
antagonists and agonists, and effects on in vivo models of thrombosis.  Such a compound 
would enable researchers to delineate the role of PAR4 in multiple systems and 
therapeutic areas. 
 To generate inhibitors of PAR4, we aimed to improve on YD-3, a known potent 
PAR4 inhibitor, by optimizing solubility, potency, and selectivity to provide a probe 
compound for critical physiological testing of PAR4 in thrombosis and hemostasis.   
 
3.3  Synthetic Efforts Towards Novel PAR4-Selective Antagonists 
 A shortened synthetic route of YD-3 allowed our lab to independently test the 
potency of YD-3 mediated inhibition of PAR4 on human platelets. We were able to 
repeat published work confirming that YD-3 inhibits PAR4 mediated platelet 
aggregation.36,37  However, this synthesis also resulted in the generation of an inactive 
isomer of YD-3, which comprised 75% of the final yield (Scheme 3.3.1).  
 
 
Scheme 3.3.1  Shortened synthesis of YD-3. 
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The inhibitory concentration-response curve (CRC) data suggest that SEY-3 has 
slightly decreased potency compared to YD-3, which is attributable to elimination of the 
nitrogen in the 2 position of the indazole ring.  IC50 values for YD-3 and SEY-3 were 25 
nM and 76 nM, respectively (Fig. 5B,D).  Selectivity of YD-3 and SEY-3 was shown by 
comparing inhibition of PAR1 by both antagonists.  YD-3 was approximately 100-fold 
selective for PAR4 verses PAR1 (IC50 of 2.4 μM, Fig. 3.3.2 A,B), while SEY-3 was 17-
fold selective for PAR4 (PAR1 IC50 of 1.3 μM, Fig. 3.3.2 C,D). 
 The primary endogenous agonist of PAR1 and PAR4 is thrombin; therefore, we 
tested the ability of PAR1 and PAR4 antagonism, alone or in combination, to inhibit 
response from a concentration of thrombin that will typically activate both receptors.  
Measuring P-selectin expression, which is a marker for platelet α granule release, we 
found that neither antagonist alone was able to significantly inhibit thrombin-mediated 
platelet activation, but dual antagonism of PAR1 and PAR4 significantly reduced 
thrombin-mediated platelet α granule release (Fig. 3.3.3).  
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Figure 3.3.4  Selected examples from exploration of SAR around SEY-3. 
 
 Using a high-throughput calcium mobilization assay with YD-3 as a control, we 
determined the analogues that were effective at inhibiting the response from a 
submaximal concentration of PAR4 activating peptide (PAR4-AP) at 10 μM.   Similar to 
the SAR reported previously that led to the discovery YD-3, this SAR was very shallow, 
with few analogues displaying activity comparable to that of YD-3.  From 3 rounds of 
synthesis we produced 38 compounds, of which compounds SEY-3 (also known as 1), 3, 
5, VU0469152, VU046154, VU0469155, VU0469907, VU0476680, VU0476683, 
VU0476684, VU0476686, and VU0476689 were capable of inhibiting PAR4 mediated 
platelet calcium mobilization to less than 50% of the maximum response, indicating that 
indole was a suitable replacement for the indazole core.   Of note, the corresponding 
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carboxylic acid of the terminal ethyl ester, compound 2, was inactive, as were other ester 
replacements including 6 and VU0469133 (Figure 3.3.4).  Of the compounds tested, only 
SEY-3 (1), 3, and 5 were able to fully antagonize a maximal PAR4-AP response.  Other 
‘hits’ from the screening process did not fully antagonize the PAR4 mediated GPIIbIIIa 
activation even at 10 μM concentration.   
The addition of chlorine in the 3-position of YD-3 was previously shown to give 
modest improvement in the potency of YD-3 for PAR4.  Because of the lack of a 
terminal ester, we attempted to improve upon the most potent partial antagonist – 
VU0469155, a 3-pyridyl-4-methoxy derivative – by adding a chlorine in the 3-position of 
the benzyl group, resulting in VU0476689. There was a modest improvement in the 
potency against PAR4, but not enough to warrant further investigation (Figure 3.3.5). 
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Figure 3.3.5  CRC data for VU0469155 derivatives. Platelets were treated with indicated 
concentrations of compound for 5 minutes prior to stimulation with 200 μM PAR4-AP. 
GPIIbIIIa activation was measured via flow cytometric analysis of PAC-1 binding. Data 
is presented as mean±SEM (n=2). 
 
 We measured potency of full antagonists against both PAR1 and PAR4 mediated 
GPIIbIIIa activation (via PAC-1 binding) and P-selectin expression (anti-CD62p binding) 
using flow cytometry.  We did not observe any notable functional selectivity between the 
molecules’ ability to inhibit GPIIbIIIa activation and P-selectin expression. SEY-3 
(Figure 3.3.6 D) was less potent than YD-3 (Figure 3.3.6 B) at inhibiting PAR4 mediated 
responses, demonstrating IC50 values for PAR4 mediated GPIIbIIIa activation of 66 ± 1 
nM vs 26 ± 1 nM, respectively.  Both 3 and 5 were significantly less potent than either 
YD-3 or SEY-3, with IC50 for PAR4 mediated GPIIbIIIa activation of 1.0 ± 1.1 μM and 
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170  ± 1 nM respectively (Figure 3.3.6 F and H).  However, YD-3 also inhibited PAR1-
AP mediated GPIIbIIIa activation by 55% at 10 μM, a previously undocumented 
observation (Figure 3.3.6 A).  Interestingly, SEY-3 reduced maximum PAR1-AP 
GPIIbIIIa response by 38% (Figure 3.3.6 C), and compounds 3 and 5 inhibited PAR1 by 
31% (Figure 3.3.6 E) and 56% (Figure 3.3.6 F), respectively.  Together, these data 
suggest that addition of nitrogen into the indole core may contribute to off-target effects 
against PAR1, as seen with YD-3, and that an indole can serve as a potent, highly 
selective PAR4 inhibitor with only modest loss of potency compared to YD-3.  
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Figure 3.3.6  Selected SEY-3 analogue PAR1 and PAR4 CRC data. SEY-3 (1), 3, and 5 
were compared with YD-3 potency against PAR1 and PAR4 mediated GPIIbIIIa 
activation and P-selectin expression. Platelets were treated with compound or DMSO 
control for 5 minutes prior to stimulation with 20 μM PAR1-AP (left panels) or 200 μM 
PAR4-AP (right panels) for 10 minutes. GPIIbIIIa activation (black circles) and P-
selectin expression (gray squares) in PAR activated platelets by flow cytometry.  
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 The PAR4 partial antagonists VU0469152, VU046154, VU0469155, 
VU0469907, VU0476680, VU0476683, VU0476684, VU0476686, and VU0476689 
displayed a similar magnitude of inhibition against PAR1 mediated platelet activation as 
did YD-3, SEY-3 (1), 3, and 5 (Figure 3.3.7); however, because these compounds also 
did not fully antagonize PAR4 mediated platelet responses even at 10 μM, this additional 
loss of selectivity was felt to indicate that they were poor lead compounds. 
 
 
Figure 3.3.7  Compounds displayed varying degrees of off-target PAR1 inhibitory 
activity. Platelets were treated with 10 μM indicated antagonist for 5 minutes, followed 
by challenge with 20 μM PAR1-AP. Flow cytometric analysis of PAC-1 binding was 
used to determine GPIIbIIIa activation. Data presented as mean±SEM (n=2). 
                                                                                                                                                                        
 Inhibition of the PAR4-AP response does not completely describe the potency of 
any PAR4 antagonist.  Compounds should elicit an inhibitory effect against thrombin, 
either alone or in combination with a PAR1 antagonist, such as RWJ-56110.40  Against a 
high dose of thrombin, where both PAR1 and PAR4 are engaged,31 PAR4 antagonists 
alone cannot significantly inhibit thrombin mediated GPIIbIIIa activation.  We tested the 
ability of YD-3, SEY-3 (1), 3, and 5 to inhibit thrombin mediated GPIIbIIIa activation at 
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concentrations where they were selective for PAR4 (Figure 3.3.8).  10 μM RWJ-56110 
alone was able to modestly inhibit thrombin mediated GPIIbIIIa activation, and when 
used in combination with either YD-3 or SEY-3 was able to reduce thrombin mediated 
signaling by 43 ± 10% and 37 ± 6%, respectively, further demonstrating that the indole 
scaffold provides comparable PAR4 efficacy to the parent indazole core of YD-3 (Figure 
3.3.8).  Neither 3 (14 ± 2% reduction) nor 5 (17 ± 2% reduction), when added in 
conjunction with RWJ-56110, was able to meaningfully inhibit thrombin mediated 
platelet GPIIbIIIa activation.  These data suggest that even slight loss of antagonist 
potency against PAR4-AP response translates into dramatic reductions in potency against 
thrombin-mediated response. 
 
 
Figure 3.3.8  Dual PAR1/PAR4 inhibition significantly inhibits thrombin-mediated 
platelet activation. Platelets were treated with PAR1 antagonist RWJ-56110 or PAR4 full 
antagonist, either alone or in combination, prior to stimulation with 10 nM thrombin for 
10 minutes. GPIIbIIIa activation was measured. Data reported as mean±SEM (n=3). 
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 The activities of the full antagonists YD-3, SEY-3, 3, and 5 were assessed via a 
classical measurement of platelet activity, a platelet aggregation assay.  Using YD-3 as a 
control, SEY-3 (1) and 5 were able to significantly inhibit PAR4 but not PAR1 mediated 
platelet aggregation in healthy subjects (Figure 3.3.9).  Compound 3 also inhibited PAR4 
mediated platelet aggregation versus PAR1 mediated platelet aggregation, though non-
significantly (p=0.054). 
 
 
Figure 3.3.9  Full PAR4 antagonists selectively inhibit PAR4 and not PAR1 mediated 
platelet aggregation. Platelets were treated with YD-3, SEY-3, 3, or 5 for 10 minutes 
prior to stimulation with either 20 μM PAR4-AP (white bars) or 200 μM PAR4-AP 
(black bars). Data reported as percent light transmittance, where 100% represents fully-
aggregated platelets. Unpaired two-tailed t-test vs DMSO-treated agonist control. Data 
displayed as mean ± SEM (n=3 or more). Means are significantly different where 
indicated. ***p<0.0001. *p<0.05. 
 
 To examine the putative mechanism of action of the most potent antagonists, YD-
3 and SEY-3, we used PAR4-AP mediated P-selectin expression to generate twelve-point 
CRCs in the presence of increasing concentrations of antagonist. YD-3 was previously 
described as a competitive antagonist by platelet aggregation studies. We confirmed this 
finding by P-selectin expression. Figure 3.3.10 shows parallel rightward shifts in the 
250 
 
PAR4 CRC in response to increasing concentrations of compound, indicative of a 
competitive mechanism of action for both YD-3 (Figure 3.3.10 A) and SEY-3 (Figure 
3.3.10 B). 
 
 
Figure 3.3.10  YD-3 and SEY-3 act as competitive antagonists against PAR4. Platelets 
were treated with indicated concentrations of YD-3 (A) or SEY-3 (B) for 5 minutes prior 
to stimulation with a full PAR4-AP. P-selectin was measured via flow cytometry. Data 
represented as mean±SEM (n=3). 
 
 
 These data indicate that indoles are a suitable scaffold for selective inhibitory 
activity against PAR4 mediated platelet activation and thus can serve as a novel scaffold 
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from which to build future anti-platelet therapeutics. Given the large number of 
commercially available derivatives of indoles, bromides, aryl boronic acids, and boronic 
esters, the synthetic routes presented are capable of rapidly generating numerous 
compounds. The use of a high throughput purified platelet calcium mobilization assay 
allows for rapid identification of molecules with inhibitory activity towards PAR4.  SEY-
3 retains antagonist activity against responses to both PAR4-AP and thrombin nearly 
equal to that of YD-3, and as such was the most potent novel compound developed 
during SAR exploration around YD-3.  The other scaffolds 3 (2-pyridine) and 5 
(azaindole) retained selectivity for PAR4 versus PAR1, but sacrificed potency against 
PAR4 activating peptide and, most importantly, thrombin.  Both YD-3 and, to a lesser 
extent, SEY-3 displayed weak off-target effects against PAR1. The inability of 
compounds SEY-3, 3, and 5 to inhibit PAR4 mediated platelet aggregation in all 
volunteers may be reflective of the loss of potency of these compounds for PAR4. 
 Thrombin mediated GPIIbIIIa activation was not abolished even when both 
antagonists were added prior to stimulation.  One possible explanation is that thrombin 
binds GPIb receptors, which may contribute to signaling.41  Furthermore, thrombin 
activated PARs create tethered ligands which are essentially irreversible agonists, such 
that any orthosteric molecule must be either irreversible or have such high affinity that 
the displacement of the tethered ligand is possible.  Single digit nanomolar or 
subnanomolar potency seems to be required for effective antagonism against thrombin 
mediated PAR4 signaling.  Alternatively, one could envision that negative allosteric 
modulators may prove to be a better approach to inhibit thrombin activated PARs.  
Though we have identified indole as a favorable scaffold for future production of PAR4 
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antagonists, there is considerable room for improvement in the development of 
antagonists of PAR4 and, as such, efforts are underway to discover higher potency 
compounds. 
  
3.4  Discovery of Novel, Selective PAR4 Antagonists 
 Due to the shallow SAR of SEY-3, we screened approximately 500 compounds 
hand-picked from the VU screening library, based on a similarity search to SEY-3, in an 
attempt to discover previously unexplored SAR around the indole scaffold.  We 
identified six new scaffolds that displayed potent PAR4 inhibition (>50% at 10 μM) 
(Figure 3.4.1). 
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Figure 3.4.1  Novel PAR4 antagonists. 
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 Full CRC data and selectivity studies on one of these compounds, VU0099704, 
revealed a selective PAR4 antagonist with an IC50 = 124 nM that was 81 fold selective 
for PAR4 over PAR1 (PAR1 IC50 = >10 μM) (Figure 3.4.2). 
 
 
 
 
Figure 3.4.2  CRC data of VU0099704 at PAR1 and PAR4. 
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 In summary, we have discovered a lead compound in a novel series of potent, 
selective PAR4 antagonists.  This simple compound allows for a great deal of further 
derivatization which can lead to the discovery of even more potent compounds.  
Generation of analogues around VU0099704 is in progress in our lab.  
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 VU0099704 
 
1H NMR (400 MHz, CDCl3) δ (ppm):  8.58 (d, J = 2.1 Hz, 1H); 8.17 (dd, J1 = 9.1 Hz, J2 
= 2.2 Hz, 1H); 7.55-7.49 (m, 2H); 7.48-7.36 (m, 4H); 4.90 (s, 2H); 3.97 (s, 3H).  13C 
NMR (100 MHz, CDCl3) δ (ppm):  142.11; 140.07; 137.73; 133.03; 130.00; 129.14; 
127.52; 126.06; 119.46; 118.42; 117.61; 109.37; 55.08; 30.80.  HRMS (TOF, ES+) 
C16H14N2O3 [M+Na]+ calc. mass 283.1083, found 283.1081. 
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